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Abstract 
Occupational asthma (OA) accounts for up to 15% of all adult-onset asthma. Though OA is 
preventable it is under-recognised in the UK. Fractional exhaled nitric oxide (FENO) is a non-invasive 
measure of eosinophilic airway inflammation used in asthma management, but its use in 
occupational settings is debated. In order to understand asthma risk and the role of airway 
inflammation in allergen-exposed workers, this thesis examined two hypotheses: firstly, that risk of 
respiratory symptoms and asthma increases with allergen exposure; and secondly, that airway 
inflammation relates to asthma risk in exposed populations.  
 
A systematic review of asthma risk in woodworkers explores existing evidence for associations 
between allergen exposure and asthma. Three cross-sectional studies, including 773 workers, 
examine allergen exposure and asthma, airway inflammation, and lung function in the wood, 
foundry, and laboratory animal industries. 
 
Symptoms were prevalent but did not clearly relate to allergen exposure. In woodworkers, atopy 
was the strongest modifier of asthma risk. Airway inflammation was common in foundry workers 
and related to increasing isocyanate exposure. Laboratory animal workers with more than three 
years’ exposure had more airway inflammation and poorer spirometry. There was little overlap 
between airway inflammation and airflow obstruction in symptomatic workers. Airway inflammation 
significantly increased the risk of work-related symptoms and asthma among symptomatic workers. 
However, no clear relationship between allergen exposure and airway inflammation was found.  
 
In OA, FENO could be useful in a number of ways: in health surveillance; in asthma diagnosis; and as a 
measure of allergen exposure. Longitudinal studies are needed to explore how airway inflammation 
relates to future asthma risk, and to understand how workplace allergen exposures modify airway 
inflammation in workers at risk of OA.   
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Introduction 
 The global burden of asthma 
Asthma is a chronic allergic disease of the small and medium-sized airways. Its prevalence in 
northern European countries has been increasing over the past decades, and incidence in the UK is 
among the highest in the world with one in 12 adults and up to one in five children affected (1). 
Asthma is a treatable condition, yet deaths due to asthma attacks remain unacceptably common. In 
2014 the National Review of Asthma Deaths (NRAD) issued a report criticising asthma care in the UK 
and highlighted the importance of recognising and modifying disease risk factors to avoid 
preventable deaths (2). As well as being life-threatening, asthma has a huge impact on patient 
morbidity. Globally, an estimated 15 million disability-adjusted life years (DALYs) are lost per year 
due to asthma (3). 
 
Asthma is characterised by intermittent symptoms including wheeze, cough, chest tightness, or 
dyspnoea. These symptoms occur in the presence of variable airflow obstruction and demonstrate 
reversibility, with an improvement in airflow following the administration of bronchodilators (4). 
Variable airflow obstruction is a defining feature of asthma and symptoms may vary significantly 
from day to day. The clinical picture of asthma is heterogeneous and varies between individuals in its 
symptom predominance, associated biomarkers, treatment response, severity and prognosis. As a 
result, it is increasingly recognised as a spectrum of disease with distinct disease phenotypes and 
endotypes (5). This recognition has prompted the development of a number of targeted asthma 
therapies and specific asthma biomarkers that are increasingly used in the monitoring and treatment 
of the disease.  
 
Asthma contributes £1 billion per year to NHS costs (6). However, both economic and health costs 
may impact elsewhere and often go unrecognised. A diagnosis of asthma presents a number of 
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potential economic issues to the individual. Many adults with asthma are of working age. 
Productivity when at work may be affected if ill-health or medication use impairs individual ability to 
perform duties at work. Poor health may lead to unemployment or early retirement, in turn leading 
to loss of earnings, an inability to contribute to general taxation, and dependence on state subsidies. 
Around 50% of the economic costs of asthma fall outside direct costs to health services, including 
loss of individual earnings, reduced national taxation, and loss of productivity at work (7). Efforts to 
reduce asthma incidence and severity in working-age adults have benefits not only in morbidity and 
mortality reduction, but also in significant improvements in productivity and unemployment (8). 
Thus, working age asthmatics may suffer disproportionately in social, financial and personal terms. 
Therefore, underscoring and understanding the intersection between asthma, work, and the 
individual is fundamental to improving outcomes for such people.  
 Occupational asthma: an opportunity to improve asthma outcomes  
Occupational asthma (OA) is typified by the development of asthma symptoms following exposures 
to an allergen in the workplace. The British Occupational Health and Research Foundation (BOHRF) 
defines OA as ‘asthma induced by exposure in the working environment to airborne dusts, vapours, 
or fumes, in workers with or without pre-existing asthma’ (9). OA may be sensitiser or irritant-
induced; the former characterised by symptoms following a latent period of exposure to a sensitising 
agent, the latter following an intense exposure to an irritant dust, vapour, gas or fume at work (also 
known as acute irritant induced asthma or AIIA) or from low-dose exposure to irritants such as 
cleaning agents (10). Population estimates indicate that 10-25% of all adult-onset asthma is 
occupational, and there are approximately 3000 new cases annually in the UK (11-13). The incidence 
of OA may be underestimated by a factor of up to 50%: many reporting schemes rely on physician-
diagnosed cases but population-based studies suggest the incidence is much higher (9). A further 
25% of workers with non-occupational asthma may have work-exacerbated disease (work-
exacerbated asthma or WEA). Unique to OA is the prospect of cure, but only if the disease is 
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identified early and the patient moved away from the offending exposure (11). Therefore, the 
recognition and prevention of OA and WEA presents a huge opportunity to reduce the associated 
morbidity and mortality not only of these conditions, but also of adult asthma as a whole.  
1.2.1 The burden of OA in the UK 
A diagnosis of occupational asthma is particularly damaging as, by definition, it impacts employment 
as well as health. Ongoing exposure to respiratory sensitisers exacerbates OA and is associated with 
a poorer prognosis (14). Early detection and removal from exposure to the known cause represents 
the best health outcome for patients. However, many workers with OA are unable to be relocated to 
a non-exposed environment: their employer may be too small to accommodate relocation; there 
may be no alternative roles available in which to move; or individuals may be self-employed (9). 
Evidence from the UK suggests that employment outcomes after a diagnosis of OA are poor; one 
third of patients are unemployed 6 years after diagnosis, suffering an associated loss of income (9). 
The majority of people are dependent on their job for financial stability, and they may provide 
additional support for their spouse, children, or other dependents. A diagnosis of OA therefore 
introduces a direct conflict between health and wealth, and many individuals continue to be 
exposed in the workplace, through choice or necessity, sacrificing their health to a loss of earnings 
(15). The personal impact of an OA diagnosis can be devastating. In addition to developing 
potentially debilitating asthma, individuals report increased work-related stress, personal and 
professional relationship breakdown, job, income or property loss, and a loss of role in society (9, 
16). 
 
Furthermore, OA presents a significant economic burden to society through loss of earnings, tax 
revenue, sickness absence, and treatment costs to the National Health Service (NHS) (17). The 
economic burden of OA in Britain is unfairly distributed. The average worker with OA can expect to 
lose between 3.5 and 4.5 workdays per year, and in 2003 the cost of all cases of diagnosed OA was 
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estimated at £100 million. These costs are met mostly by the individual or the state, with employers 
incurring only 4% of the total (17). As a result, employers have little economic incentive to prevent 
OA among their workforce, despite health surveillance being a mandatory requirement where risk of 
OA cannot be reduced to levels as low as reasonably practicable and evidence that employers may 
lose out financially from OA due to associated productivity loss. This contrasts to practice in other 
countries such as Finland and Canada, where employers have a responsibility to contribute to 
insurance schemes that allow workers who develop occupational diseases to be retrained in 
alternative employment (18). 
1.2.2 Occupational asthma – mechanisms for disease and trends in exposure 
The pathophysiological mechanisms for OA are complex and most mechanistic understanding 
focuses on the development of airway inflammation. Sensitising agents may be high-molecular 
weight (HMW, greater than 10 kilodaltons) or low-molecular weight (LMW, less than 10 kilodaltons). 
Most HMW allergens act as whole antigens, directly binding to specific immunoglobulin E (IgE) on B 
cells and inducing a subsequent immune response. HMW allergens are also frequently associated 
with a T helper 2 (Th-2) lymphocyte response in which eosinophilic inflammation predominates (5, 
10). In contrast, the mechanism by which LMW allergens cause disease is unclear. Some act as 
haptens, binding to larger proteins and inducing inflammation by binding to IgE, whereas other LMW 
allergens such as isocyanates are thought to up-regulate macrophage and monocyte function, 
causing chemokine release and a subsequent inflammatory response (10). LMW exposures most 
commonly cause Th-2 predominant airway inflammation, but LMW allergens have been associated 
with neutrophilic or mixed, rather than eosinophilic, airway inflammation (19). Specific IgE to LMW 




Mechanisms for low-dose irritant-induced asthma, such as that caused by cleaning agents, are even 
less well established. Direct airway epithelial injury is likely to play a role, and irritant-induced 
asthma has largely been associated with neutrophilic inflammation and the absence of specific IgE 
(10). Mechanisms through which occupational exposures result in clinical exacerbations, airway 
remodelling, and neuronal responses remain poorly understood, but increasing efforts are being 
made to understand the heterogeneity of OA in association with its implicated causes (5, 10). 
 
Nevertheless, allergen exposure is the key risk factor for sensitiser-induced OA with numerous 
studies reporting an increased risk of asthma in exposed versus non-exposed populations 
irrespective of their molecular weight (9, 12, 13, 20, 21). Many studies have also shown a positive 
exposure-response relationship between allergen exposure and asthma incidence, and the principle 
of exposure reduction has therefore become central in reducing the risk for OA (22). A principle of 
the Health and Safety at Work Act 1974 (HASAW) and subsequent legislation is that the risk of 
workplace exposure should be maintained at levels that are as low as reasonably practicable (ALARP) 
(23). In order to guide risk management in Britain, many common allergens have a defined 
workplace exposure limit (WEL) and these are enforceable by HSE (24). Through enforcing these 
legislative changes there has been a steady reduction in some workplace exposures over recent 
decades (25). 
 
However, the most recent data from the Surveillance of Work-related and Occupational Respiratory 
Disease (SWORD) suggests incidence of OA has remained static over the last four years, and that 
rates are similar to those 10 years ago (26). The scheme identifies flour, cleaning agents, and 
isocyanates as the most common causes of OA in Britain (Figure 1). Metal treating and processing is 
identified as a high-risk occupation, (19.9 per 100,000), and a number of other manufacturing 
industries are associated with an increased risk of diagnosis (26). Whilst extremely useful, these data 
are likely to be a significant underestimate of the true burden of OA in Britain (27). There is a lack of 
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quantitative research on OA in industries where risk is high. As such, little is known about the risk of 
respiratory symptoms, asthma, and lung function in such industries, making efforts to reduce 
disease incidence and improve disease outcomes more challenging. 
 
Figure 1: Most common agents for occupational asthma SWORD 2009-2013 and 2014-2018. From Work-
related asthma statistics in Great Britain, 2019: Health and Safety Executive. Contains public sector 
information licensed under the Open Government Licence v3.0. (26) Accessed on 15/12/2019 from 
https://www.hse.gov.uk/statistics/causdis/asthma.pdf. 
1.2.3 Health surveillance in occupational asthma 
Evidence supports early recognition of the symptoms of OA to allow timely exposure modification 
and improve prognosis (28). Under the Control of Substances Hazardous to Health (COSHH) 
Regulations, health surveillance is mandatory for all workers where there is a risk of exposure to an 
occupational asthmagen (29). As well as reducing risk and improving outcomes for OA, health 
surveillance programmes may be additionally beneficial as they provide information about the 
global impact of workplace exposures on the workforce, present an opportunity to educate and 
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engage workers on the risks of their job, and may also identify non-work related illnesses that 
benefit from early diagnosis and management (9). In Britain, these programmes largely focus on 
identifying symptomatic workers with early disease through questionnaires that enquire about 
work-related ocular, nasal, and respiratory symptoms. Some workers employed in specific sectors or 
exposed to certain allergens undergo spirometry and, where relevant, sensitisation testing to 
occupational allergens through either skin prick testing or serum specific IgE. 
 
In spite of this, health surveillance programmes have a number of potential flaws. Firstly, although 
easy to use and cheap to implement, the sensitivity and specificity of respiratory health 
questionnaires varies widely, with sensitivity reported at 58-100% and specificity at 45-100% to 
detect a diagnosis of OA (9). The true burden of OA may be underestimated where workers perceive 
risking their employment if they report symptoms, if symptoms are not recognised as work-related 
and therefore not reported as such, or if the questionnaires themselves are not sensitive for OA (30). 
Secondly, though spirometry remains an important part of health surveillance for OA, challenges in 
its use and interpretability have been reported. Commonly used spirometric measures in OA include 
forced expiratory volume in 1 second (FEV1); forced vital capacity (FVC); FEV1/FVC ratio; and peak 
expiratory flow (PEF). There is no universally accepted threshold of FEV1 decline to detect a 
significant change that should prompt escalation of health surveillance or alteration of the working 
environment for those at risk of OA. In population-based studies of asthma a 15% age-adjusted loss 
in FEV1 per year (31),  absolute decline of 30 to 50mls per year (32) and lower limit of detection 
methods have all been proposed (33). Thirdly, single measures of spirometry cannot account for the 
natural variability of asthma, where readings may vary depending on the degree of airway 
inflammation present on a particular day: airway inflammation may additionally vary depending on 
workplace exposures. More importantly, workers with OA may have normal spirometry, so may not 
meet abnormality criteria until their disease has advanced significantly and may be irreversible (9). 
Problems with reproducibility and reliability of workplace spirometry have been reported and may 
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lead to underestimation of lung function and failure to identify workers with abnormal spirometry 
(34).  
 
Finally, only a small proportion of at-risk workers undergo health surveillance in Britain. A recent 
survey suggested fewer than 20% of workplaces in sectors where the OA risk is high carried out 
health surveillance (35). Studies exploring asthma risk in industries where OA is highly prevalent are 
important in advising regulators and employers, in order to improve working conditions, provide 
evidence for enhanced surveillance schemes, and inform changes in legislation. These studies also 
represent an opportunity to explore novel physiological measurements in health surveillance, such 
as measures of airway inflammation, which may provide additional information to spirometry alone. 
1.2.4 The role of fractional exhaled nitric oxide in diagnosing occupational asthma 
Fractional exhaled nitric oxide (also called fraction of exhaled nitric oxide or FENO) is increasingly 
used in the diagnosis and management of asthma. Nitric oxide is a key signalling molecule in many 
physiological and pathological processes (36). In bronchial epithelium it is produced by upregulation 
of inducible nitric oxide synthase (iNOS) (37). Studies of new therapeutic drugs for asthma have 
shown FENO to be strongly related to interleukin (IL) 13 activity, with evidence for an association with 
other features of Th-2 inflammation including IL-4, sputum eosinophilia and periostin (37-39). As 
such, it has been used to identify individuals with eosinophilic airway disease and levels above 40 
parts per billion (ppb) are associated with an increased risk of eosinophilic asthma (4). As well as 
being a diagnostic tool, FENO has also been utilised in asthma management. Along with other 
biomarkers, FENO is useful in phenotyping patients with Th2-high disease that may be more 




The use of FENO in OA is debated. Rises in FENO have been demonstrated following positive specific 
inhalation challenge (SIC) in workers with OA to HMW agents, with fewer studies reporting 
significant FENO rises following LMW challenge (40). In workplace studies, rises in FENO have been 
shown to predict incident bronchial hyperresponsiveness in workers at risk of OA, supporting its use 
as a potential health surveillance tool (41). Rises in FENO have been associated with increasing 
exposure to HMW agents including flour, chilli pepper, and laboratory animal allergens, in particular 
in those with sensitisation measurable by specific IgE (42-44). In contrast, the association between 
LMW exposure and FENO is less clear, with one study reporting an increase in FENO associated with 
increasing isocyanate exposure only in atopic non-smoking workers (45). 
 
Guidance recommends using cut points for FENO that, correlated with clinical features, relate to an 
increased risk of asthma (46). Reference ranges incorporating modifying factors and cut-off points 
for interpretation have also been published (47). FENO has recently been recommended by the 
National Institute of Health and Care Excellence (NICE) in the diagnosis of asthma in primary care, 
and its use is supported by the recent British Thoracic Society/Scottish Intercollegiate Guideline 
Network (BTS/SIGN) Asthma Guideline (4, 48). FENO is simple to perform, reproducible, and 
equipment is increasingly available and inexpensive (46). Increasing availability and improved 
validation has led to FENO being considered as a potential health surveillance tool for OA. However, 
the implementation of FENO in screening allergen-exposed workers will require significant change to 
current practice, and any changes will require an evidence base.  
1.2.5 Gaps in the evidence 
Allergen exposure has been identified the major modifiable risk factor in the development of OA. 
The prevalence of OA remains high in certain sectors in Britain, including in wood, foundry, and 
laboratory animal workers. No recent epidemiological studies have been conducted in these 
industries, despite working populations being at high risk of exposure to occupational allergens and 
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other respiratory hazards and significant changes in practice over the last decade. There is a need to 
generate data to better understand the relationships between current allergen exposure and 
respiratory symptoms, self-reported asthma, and lung function, in order to predict and prevent 
future disease. 
 
The evidence for using FENO in the assessment of OA in workplaces is conflicting. Few studies have 
considered the role of FENO in wood, foundry, or laboratory animal workers, and studies that have 
examined the role of FENO are now decades old and do not relate to current working conditions. 
Some studies have suggested FENO provides additional information to standard measurements used 
in health surveillance, and thus may help in the earlier detection or diagnosis of OA and a potential 
improvement in outcomes. 
 Asthma risk and eosinophilic airway inflammation in allergen-exposed 
workers 
This thesis aims to address two key hypotheses: 
1. It considers the relationship between exposure to respiratory allergens and asthma in three 
sectors – woodworking, foundry working and laboratory work – where the risk of OA is 
already established to be high. I hypothesise that increasing allergen exposure heightens the 
risk of developing respiratory symptoms and asthma in a dose-dependent fashion. 
2. It addresses the utility of measuring eosinophilic airway inflammation (using FENO) in these 
industries, considering firstly whether FENO relates to other markers of asthma among 
allergen exposed workers, and secondly whether it relates to allergen exposure. By studying 
different exposure environments this thesis also aims to understand whether FENO relates 
better to markers of asthma in HMW or LMW exposed workers. I hypothesise that airway 
inflammation is associated with other markers of asthma, such as asthma symptoms or an 
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asthma diagnosis, and that risk of airway inflammation shows a dose-response effect with 
increasing allergen exposure. 
 
 Chapter overview 
This thesis addresses the hypotheses over five chapters: 
• Chapter two explores the key risk factors for OA in a systematic review, using the 
woodworking industry as a template.  
• Chapter three evaluates the risk of asthma in a cross-sectional study of woodworkers 
exposed primarily to wood dust, examining associations between allergen exposure and 
symptoms, airway inflammation, lung function, and sensitisation.  
• Chapter four examines asthma risk in foundry workers in a cross-sectional study of workers 
exposed to isocyanates and formaldehyde, evaluating associations between allergen 
exposure and respiratory symptoms, airway inflammation and lung function.  
• Chapter five explores asthma risk in laboratory animal workers exposed primarily to mouse 
allergens and asks whether increasing allergen exposure is associated with an increased risk 
of respiratory symptoms, airway inflammation, abnormal spirometry, or sensitisation.  
• Finally, chapter six examines FENO across the three study populations, exploring the key 
determinants of airway inflammation, how airway inflammation associates with other 








2 A systematic review of asthma risk in the furniture and wood 
processing industries 
2.1.1 Introduction 
2.1.2 Environmental wood dust exposure 
Wood is a naturally occurring substance composed mainly of cellulose, hemicellulose and lignin. The 
remaining 1% comprises aliphatic compounds such as fatty acids and glycerides, terpenes and 
phenolic acids (49). Trees grow abundantly throughout the world and wood has many different 
industrial and domestic applications: millions of people are exposed to wood and wood by-products 
every day (50). 
 
A variety of wood types are in common use. Hardwoods (deciduous angiosperms or tropical 
hardwoods) are generally denser and heavier in comparison to softwoods (coniferous 
gymnosperms). There are many timber derivatives in common use.  Veneers are made from thinly 
sliced timber sheets. Plywood is manufactured from thin ‘plies’ of veneer adhered together with 
glue or resin. Medium-density fibreboard (MDF), oriented strand board (OSB) and chipboard are 
engineered from strands or chips of wood bonded together, often using urea-formaldehyde resins. 
Products can be used wet (unseasoned) or dry (seasoned). These forms of wood are widely available 
commercially and used throughout industry in the manufacture of furniture and fitted units, boat 
building, and in construction (51). Between 2000-2003 an estimated 3.5 million people were 
occupationally exposed to wood dust in the EU, with around 200,000 exposed in the UK alone (50, 
52). Since that time there have been significant economic changes, and evidence points towards a 
downsizing of woodworking companies following the 2008 global recession (53). Exposure to wood 
dust in the new economic climate remains largely unquantified. 
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2.1.3 Wood dust and respiratory disease 
Wood dust has been identified as a potentially hazardous substance for hundreds of years. 
Bernadino Ramazzini, the father of occupational medicine, reported respiratory symptoms in a 
sawer in his work De Morbis Artificium Diatriba, published in 1700 (54). A case report from 1941 
describes asthma symptoms in a population of 50 men exposed to iroko wood dust (55). In her 
landmark 1969 study of furniture workers in High Wycombe, Hadfield described chronic respiratory 
symptoms and rhinitis in addition to increasing rates of sinonasal adenocarcinoma (56). 
 
Exposure to wood dust has been most commonly associated with allergic airways disease and 
asthma. Prevalence of OA in some populations of wood workers has been estimated at 5%, and a 
significant number of workers who develop the condition continue to suffer symptoms long after 
their exposure has ceased (57, 58). Occupational exposure to wood dust in the UK may have been 
declining over time, but wood dust remains a common cause of OA in reports from SWORD (25, 26). 
Other respiratory diseases have been associated with wood dust exposure. Excess mortality from 
chronic obstructive pulmonary disease (COPD) has been reported in wood dust-exposed non-
smoking Swedish construction (59). An increased risk of lung cancer has been reported in some 
woodworking populations (60). Epidemiological research has shown joiners to be at especially high 
risk of idiopathic pulmonary fibrosis (IPF) (61, 62). Although this research controlled for asbestos 
exposure, historically joiners have had high asbestos exposure which is thought to be a potential 
confounder in the risk of IPF in these people (63). Wood workers are also at increased risk of 
hypersensitivity pneumonitis through the handling of unseasoned mouldy wood (64, 65). 
2.1.4 Molecular mechanisms of wood dust allergy 
The mechanisms through which wood dust causes asthma remain poorly understood (66). Putative 
agents such as plicatic acid, monoterpenes, and endotoxin have been identified, but these agents 
are not universal to all species (67-69). Plicatic acid is a low-molecular weight agent shown to be 
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directly toxic to pulmonary epithelium, and causes histamine release from the basophils of workers 
with western red cedar (WRC) asthma (67, 70). The absence of a specific immunoglobulin E (SIgE) 
response to plicatic acid suggests immunological mechanisms other than type I hypersensitivity are 
important in the pathophysiology of WRC asthma, or at least not measurable through SIgE (71). 
Exposure to WRC dust has been associated with both early and late falls in FEV1, raised sputum 
eosinophils, but no significant change in fractional exhaled nitric oxide (FENO) following specific 
inhalation challenge (SIC) (72). 
 
In contrast to WRC asthma, SIgE has been measured in workers with OA` due to some tropical 
woods. Obeche (triplochiton scleroxylon) and iroko (milicia excelsa) exposure has been associated 
with a positive SIgE in workers with OA (73, 74). A number of high-molecular weight obeche proteins 
have been described with some showing cross-reactivity in individuals with latex allergy (75). Acute 
sustained falls in FEV1 have been reported following SIC with obeche along with associated rises in 
sputum eosinophilia, suggesting that eosinophilic airway inflammation is an important feature in 
such asthmatic responses (76). IgE sensitisation to soft woods has been demonstrated less 
commonly, with prevalence of SIgE in populations exposed to pine less than 5% (77). This suggests 
that immunological mechanisms for wood dust exposure vary between species, as well as with 
exposure. 
 
Terpenes are found in softwoods such as pine have been linked with both irritant and allergic 
respiratory disease. Exposures have been predominantly reported where wood is unseasoned in 
association with moulds, but high exposures in dry wood environments have also been reported (69, 
78, 79). Formaldehyde-based stablisers used in wood composite manufacture have also been 
implicated as respiratory sensitisers (80). 
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Much of the data on the short and long-term asthmagenic effects of wood has come from studies of 
woodworkers exposed to unseasoned or wet wood, with an emphasis on WRC workers and the 
actions of plicatic acid (81, 82). WRC is not native to the UK and its use is uncommon; other hard and 
soft woods, along with wood composites, are used more frequently (52). Moreover, the incidence of 
wood dust OA has been increasing in Britain (83). Few studies have considered whether new 
measures of eosinophilic airway inflammation, such as FENO, are useful in evaluating risk of OA in 
wood-exposed populations. Consequently, the aim of this review is to explore how wood dust 
exposure relates to asthma and its key clinical in the furniture and wood manufacturing industries. 
Further, it aims to explore the evidence for a dose-response relationship between wood dust 
exposure and FENO.  
 Methods 
2.2.1 Search criteria and methods 
A systematic review was performed in accordance with PRISMA guidelines (84). Search terms were 
agreed by three team members (Table 1). The major (or, in PubMed, MeSH) heading from column 
one in Table 1 was combined consecutively, and in descending order, with terms from column two, 
followed by column three until no new references were generated. This process was repeated 
keeping the major term for columns two and three. A free text search using the same terms was 
then conducted to ensure no references were missed. Web of Science, PubMed, Embase, ProQuest, 
OSHUPDATE (including ‘grey literature’ from HSELINE, NIOSHTIC, RILOSH, and CISDOC), and the HSE 
e-library were searched from January 1970 to December 2014. OmniVis software (Instem Scientific 
v6.1.12) a reference management tool, was used to cluster references using the same terms from 
Table 1. This software groups references using Booleans and keywords. The clusters were then 
manually assessed for relevance using the following inclusion and exclusion criteria in order to 
generate final abstracts for review.  
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Table 1: Search terms employed to perform literature review. The * wild card was used to find plurals and 
word variants 
 Column One Column Two Column Three 
Major (MeSH) headings Respiratory disease* Occupation* Wood* 
Minor headings Asthma Work-related Hardwood 
 Lung function Wood working Softwood 
 Airway inflammation Exposure Fibreboard 
 Atopy Toxicity  
 Sensitisation   
Subheadings Symptoms Joinery MDF 
 Dyspnoea Furniture Particleboard 
 Wheeze Manufacture  
 Cough Flat pack  
 Lung function Factory  
 Exhaled nitric oxide OR fraction* exhaled nitric oxide   
2.2.2 Abstract selection and review 
Abstracts were reviewed independently by two assessors and then evaluated for agreement. Where 
the relevance of the abstract was not clear, or there was disagreement, the full paper was reviewed. 
Studies were considered eligible for inclusion where they met the following criteria: (i) adult workers 
from wood processing or furniture manufacturing industries; (ii) meta-analyses, controlled trials, 
longitudinal studies or cross-sectional analyses; (iii) respiratory or nasal symptoms, asthma, lung 
physiology or sensitisation identified as a study outcome; and (iv) English language papers. Studies 
containing data from both the wet and dry wood industries were included. 
 
Papers were specifically excluded where they: (i) were case reports or letters; (ii) contained data 
only from the timber industry; (iii) contained hygiene data alone; or (iv) solely examined dermatitis, 
cancer, or immunological mechanisms.  
2.2.3 Data grouping and analysis 
As a high degree of heterogeneity was expected between the studies, articles were assessed for 
quality using both the Scottish Intercollegiate Guideline Network (SIGN) guidance and the Method 
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for Evaluating Research and Guideline Evidence (MERGE) (85, 86). MERGE was developed specifically 
for observational research and was employed as a second evaluation tool to ensure consistency, and 
that quality of papers was not under or overestimated (Table 2). 
 
Table 2: Studies by SIGN or MERGE rating. All articles were systematically graded using both tools with a 
predefined proforma. Data for all but the methodology paper are presented here. 
SIGN Number of papers  MERGE Number of papers 
1- 1  A 14 
2++ 4  B1 14 
2+ 18  B2 15 
2 - 31  C 11 
Total: 54  Total: 54 
 
Papers were grouped by common themes identified as specific study endpoints. These were: (i) 
ocular, nasal and respiratory symptoms; (ii) asthma; (iii) lung function; and (iv) sensitisation 
(including atopy, specific skin prick testing, and SIgE). Where wood exposures had been measured in 
the study population, evidence for a dose-response relationship was sought.  
 
Data pertaining to each study endpoint were extracted and recorded on an agreed proforma, and 
then tabulated for comparison (Appendix A). Studies receiving a higher grading through MERGE or 
SIGN were given greater importance (Table 3). Prevalence or mean data were compared, with odds 
ratios or risk ratios where calculated. Exposure-response relationships were compared across 
studies. Confidence intervals (CI) are referred to in the text or in Table 3, where appropriate. 
Common confounders are included in Table 3. Due to the high degree of heterogeneity among the 
studies, further meta-analysis of the data was not conducted (87). 
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 Results 
2.3.1 Evidence quality and characteristics 
Initial searching generated 1328 references, of which 446 abstracts were independently reviewed 
for relevance by the study team and 55 papers were included in the final review. Figure 2 shows the 
number of papers excluded at each stage.  
 
Figure 2: Flow diagram showing phases of literature review. Human adult studies in the wood processing and 
furniture manufacturing industry were included. 
 
Using SIGN criteria, one of the 55 studies was rated 1-, and four were rated 2++ (Table 2). The 
remaining 50 were rated 2+ or below. Using MERGE, 14 of the 55 papers were graded A. Summary 
details for these 14 studies, grouped by study endpoint, are presented in Table 3. Details of the 
remaining studies are shown in Appendix A. The search identified one meta-analysis and eight 
longitudinal studies; the remaining studies were cross sectional or case control in design. The only 
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UK study was published in 1981, and a single methodology paper was also identified but contained 
no clinical data, and so was not included in the tabulated results (88). 
 
 
Exposure measurements were made in 35 (64%) of the study populations. Seventeen studies 
measured inhalable dust concentrations; five of these recorded mean inhalable levels of wood dust 
less than 1mg/m3. Other exposures of interest included: unspecified, total and respirable wood dust; 
formaldehyde; terpenes; endotoxin; β-D-glucan; and bacterial cell counts.  
 
Thirty-three (60%) papers reported any data on prevalence or incidence of respiratory or nasal 
symptoms. Thirty-two (58%) measured lung physiology, including peak expiratory flow (PEFR); 
forced expiratory volume in one second (FEV1); forced vital capacity (FVC); ratio of FEV1 to FVC 
(FEV1/FVC); forced expiratory flow rate (FEF); mid-expiratory flow rate (MEF); bronchodilator-
induced reversibility (BDIR); bronchial hyperresponsiveness (BHR); transfer factor (TLCO) and specific 
inhalation challenge (SIC). FENO measurements were not made in any studies. Asthma was 
recognised as a study endpoint in 8 (15%) of studies, with seven (13%) studies reporting sensitisation 
data. 
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Table 3: Fourteen studies rated 2++ or above with SIGN or A with MERGE, grouped by study endpoint. 




No of workers 
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Summary findings (Symptom 
prevalence, OR, or RR with 
associated 95% CI)d 
Study endpoint: Respiratory and nasal symptoms 









546/565 Variety of African 
hardwoods, podo, 
cypress, pine.  
ID (gm) = 3.86 2+ 
A 
Ag, Sm OR in lower exposure group vs 
higher exposure group:  
wheeze = 4.6 (95% CI 1.9 – 11) vs 1.9 
(0.5 – 7.3); dyspnoea = 3.2 (1.6 – 6.3) 
vs 2.0 (0.7 – 5.4); cough = 3.6 (2.5 – 
5.1) vs 4.8 (3.0 – 7.8); sputum = 5.4 














161/91 Softwood, wood 
composites, less 
hardwood  
ID = 1.17 2+ 
A 
Ag, Sm, Sx, 
He, Wt, At 
VAS assessed nasal obstruction 
significantly difference in higher 
wood dust exposures: VAS 
difference after – before work in 
highest exposure group 0.63 (-10.0 - 
-7.7). vs 0.15 (-4.8 - -6.6) in lowest 
exposure group. 














for at least 
Ag and Sx.  
Pooled RR 1.5 (1.25 – 1.87) for 
asthma in woodworkers vs general 
population 
Heikkilä et 
al., 2008.  
Longitudinal; 
Finland 
Wet and dry wood 
industries; boat 
building and repair; 
construction. 
All employed Finns 
aged 20 – 59. 




TD = 0.02 – 1.5 2++ 
A 
Ag RR 1.5 (1.2 – 1.8) for male and 1.5 
(1.2 – 1.7) for female woodworkers 
vs general Finnish population.  
No relationship reported between 











373/71 Softwood, wood 
composites, less 
hardwood  
ID (gm) = 0.96 2++ 
A 
Ag, Sm, Sx, 
Ed 
OR for clinical asthma diagnosed on 
symptoms plus BHR, BDIR or PEF 
variability 3.3 (1.09 – 5.53) in highest 






exposure categories. Strong 
association between atopic workers 
and asthma.  













1506/195 Softwood, wood 
composites, less 
hardwood  
ID = 0.55 2++ 
A 
Sm, Sx, At OR 0.9 (0.3 – 3.5) for beech specific 
IgE and 0.2 (0.1 – 0.7) for pine 
specific IgE in those with asthma 
symptoms.  Significantly more 
specific IgE positivity in high 
exposure group.  













813/136 Softwood Median ID = 0.96 2+ 
A 
Ag, Sm, Sx, 
He, Wt, At, 
Ex 
No significant difference in 
longitudinal lung function between 













1377/297 Softwood Baseline ID = 
0.94; follow up 
ID = 0.6 
2+ 
A 
Ag, Sm, Sx, 
At. 
S: OR for cough (3.8; 1.5 – 9.7) and 
chronic bronchitis (6.0; 1.2 – 28.8) in 
female workers in highest vs lowest 
exposure categories.  
A: OR for ever asthma (3.4; 0.9 – 
12.5) and current asthma (6.9; 0.9 – 
55.8) in female workers vs controls. 
For female workers with no baseline 
symptoms OR for asthma symptoms 
= 11.3 (1.3 – 96.8) 
Sripaiboonkij 








103/94 Rubber tree ID = 0.02 - 2.93 2+ 
A 
Ag, Sm, Sx, 
He, Wt, Ed 
S: No significant difference in 
adjusted OR for different exposure 
levels 
A: OR 6.1 (0.7 – 53.7) for ever 
asthma in exposed workers. OR 8.4 
(1.1 – 66.6) for ever asthma in low 
exposure vs control category. No 
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effect across other exposure 
categories.  
LF: Incremental FEV1 and FVC loss 
significantly more in factory workers 
vs controls and in highest vs lowest 
exposed groups.  
Glindmeyer 









1164 >70% hardwood in 
cabinet and 
furniture facilities.  
>90% softwood in 
sawmill and 
plywood 




Ag, Sm, Sx, 
Wt 
S: Across industry groups, self-
reported upper respiratory tract 
symptoms ranged from 45 – 53%, 
lower respiratory tract symptoms 
from 25-39%, ever asthma from 8.3 
– 13%, pneumonia from 9.4 – 29%, 
and COPD from 2 – 4%.  
LF: Negative effect for respirable 
residual particulate matter in milling 
industry. Positive effect for 
respirable wood solids in 
sawmill/planing. 
No effect on LF in 













1112/235 Softwood Baseline ID = 
0.94; follow up 
ID = 0.6 
2+ 
A 
Ag, Sm, Sx, 
He, Wt 
Negative effect on LF for female 
woodworkers who smoked: annual 
change in % predicted FEV1 per year 
= -1.28 ml/yr (SD 1.65). Dose 
response relationship observed 














2033/475 Softwood, wood 
composites, less 
hardwood  
ID = 1.17 2+ 
A 
Ag, Sm, Sx, 
He, Wt,  
S: OR for morning cough (2.7; 1.2 – 
6.0), wheeze (2.5; 1.1 – 5.7), and 
chronic bronchitis (6.9; 1.3 – 36.0) 
higher in women with 2-8 years 
industry service compared to 
controls.  
A: OR 5.4 (3.6 – 8.1) in female 
workers with atopy and self-
reported asthma; 5.6 (0.9 – 34.0) for 
female workers with exposures 
>1.42mg/m3 and self-reported 
asthma.  
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LF: No significant difference 
observed when stratified by 
exposure. 
Bohadana et 







workers in same 




114/213 Beech and oak ID = 4.08 – 12.74 2+ 
A 
Ag, Sm, Sx S: No significant difference in 
symptoms observed between 
exposure groups.  
LF: Excess FEV1 and FVC observed 
across exposure groups compared to 
controls. BHR increased significantly 






Sawmill and cabinet 
manufacture. 
Maintenance 
workers from same 
industry.  
197/30 Mostly eucalyptus. 
Other Australian 
hardwoods, MDF 
and WRC also in 
use. 
ID = 0.83 – 
15.33; RD = 0.16 
– 1.01; END 
ng/m3 = 0.74 – 
21.08; BDG = 




Ag, Sm, Sx, 
He, Ex 
S: Nasal and respiratory symptoms 
more common in exposed vs control 
populations.  
LF: Cross-shift loss in lung function 
significantly higher in joiners vs 
controls.  
a Wood types where stated: MDF = medium density fibreboard; OSB = oriented strand board, WRC = western red cedar 
b Exposures are expressed as single value or range: ID = inhalable dust, RD = respirable dust, TD = total dust, FORM = formaldehyde, END = endotoxin, TERP = terpenes, BGD = (1,3)-β-D-
glucan, gm = geometric mean, ppm = parts per million. 
c Common confounders controlled for in models: Ag = age; Sm = smoking; Sx = sex/gender; He = height; Wt = weight (including control for BMI); At = atopy; Ex = exposures (relevant 
exposures measured during the study); Ed = education level.   




2.3.2 Upper and lower airway symptoms 
Most studies reported either mean symptom frequency, or odds ratios (OR), the latter measuring 
the increased risk of a particular health outcome as a function of exposure group; normally 
comparing exposed woodworkers with either lesser or non-exposed populations (Table 3 and 
Appendix A).  
 
The most frequently reported respiratory symptom was cough, affecting between 6 and 80% of 
exposed workers (ORs ranged between 1.2 and 5.5). Wheeze and chest tightness were also 
commonly seen in exposed workers, with frequencies of between 9 and 40% (ORs between 1.3 and 
5.9). Shortness of breath was excessively reported in woodworkers, with a range of frequencies of 
between 10 and 39% (ORs ranged between 1.7 and 10.6). Sputum production and bronchitis (or 
chronic bronchitis) were described in fewer studies, but in generally high levels (frequencies 
reported between 12 and 67% of exposed individuals, ORs ranged between 0.9 and 20).  
 
Nasal symptoms in woodworkers were reported in approximately half of the 55 studies. The 
prevalence in exposed workers ranged between 25 and 64% in the 26 relevant studies (ORs ranged 
between 0.8 and 16.4). Similarly, ocular or throat symptoms were common (ranging from 20 to 51% 
in the included studies; ORs of between 1.1 and 13.5).  
 
Work-related respiratory symptoms (WRRS), suggestive but not diagnostic of OA, were 
inconsistently defined between differing studies, and were reported in fewer studies. Where WRRS 
were described, the prevalence among exposed workers ranged from 25% for work-related wheeze 
to 52% for work-related cough (79, 89). Two studies reported increased ORs for WRRS or work-
related nasal symptoms, ranging from 1.8 to 6.0 (90, 91).  
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Possible relationships between wood dust exposure and the presence of symptoms (or dose-
response relationships) were explored in eight studies. For example, Jacobsen et. al. reported 
significantly increased risk for both cough and chronic bronchitis in female workers in high versus 
low exposure categories (92). The same research group showed a dose-response relationship for 
nasal symptoms in two earlier studies (93, 94). In contrast, three studies found no increase in 
symptoms when stratified by exposure (95-97). In one study of Tanzanian woodworkers, risks for 
wheeze and shortness of breath were reported to be higher in workers with lower wood dust 
exposures (91). The authors highlighted the increased use of respiratory protective equipment 
among workers with higher exposures as a possible explanation for this.  
2.3.3 Asthma 
Asthma was defined in varying ways across studies. For example, five papers identified asthma cases 
using worker questionnaire responses (89, 92, 94, 97, 98), and one study used insurance data and 
ICD-10 codes to identify population-based asthma incidence (99). A further study included a nested 
case-control analysis and performed objective measures of asthma including PEFR variability, BHR, 
and BDIR (100). A single meta-analysis was also identified; that included asthma studies where the 
diagnosis was made with objective measures or was self-reported through interview (101). 
Asthma was reported in an additional nine studies where the method for identifying cases was 
unclear. These papers reported asthma prevalence of between 5 and 30%, representing ORs 
between 3.7 and 5.5 in comparison to lesser or non-exposed populations. Studies using serial PEF 
recordings to support a diagnosis of asthma included Norrish et al., who identified 12% of exposed 
furniture workers with the condition (89). Lipscomb et. al. reported similar prevalence, with 10.6% 
of their exposed population reporting “ever asthma”, and 8% reporting an asthma attack in the last 
12 months (98).  
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In a large Finnish epidemiological study, Heikkilä et al. identified a relative risk (RR) of asthma of 1.5 
for both male and female woodworkers compared to the general Finnish population, similar to that 
reported in other non-exposed blue-collar workers (RR 1.4) (99). Pérez-Ríos et al. found comparable 
results in their meta-analysis of 19 studies, with RR of 1.5 for asthma in woodworkers (101). 
 
Three studies found atopic woodworkers to have higher risks for both asthma and airway 
responsiveness, again compared to non-exposed controls (89, 92, 100). Schlünssen et al. also found 
that atopic woodworkers in the highest exposure category had an increased risk for asthma and the 
presence of BHR (OR 22.9). Non-atopic woodworkers in the highest exposure category had an OR of 
20.3 for asthma and work-related symptoms. However, no dose-response effect was seen in the 
study of Heikkilä et al. or in that of Sripaiboonkij et al. 
 
Female gender was also identified to be a risk factor for asthma in one particular study (OR of 11.3 
reported for asthma symptoms in women with no baseline symptoms in the longitudinal cohort), 
although no other studies specifically identified gender as an independent predictor for either the 
presence or development of asthma in woodworkers (92).  
2.3.4 Lung function and airway inflammation 
No papers were found reporting data on airway inflammation using sputum cell counts or FENO in 
workers from wood processing or manufacturing industries. One study reported no difference in 
nasal eosinophil cationic protein, albumin, or neutrophils between exposed woodworkers and 
controls but was graded as low quality (102).  
 
All but two studies reported some lung function measures in woodworkers; including FEV1, FVC, 
FEV1/FVC, FEF, and MEF. In addition, two papers presented data on non-specific bronchial 
hyperresponsiveness, and a further paper reported transfer factor (TLCO). It was evident that 
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spirometry was performed using differing protocols, suggesting that overall quality and 
reproducibility may not be homogeneous, and control populations differed (Table 3 and Appendix 
A). Eighteen studies measured lung function at a single time point (STP), 11 measured cross-shift 
lung function changes, and a further three assessed longitudinal decline. 
 
78% (14) of studies reported significantly lower STP FEV1 or FVC in their exposed populations, with 
two studies reporting more obstructive spirometry (as defined by an FEV1/FVC <0.7) among exposed 
versus control populations (103, 104). Shamssain et al. also identified that 56% of woodworkers 
employed between 10 and 19 years had an FEV1/FVC of less than 70%, compared with 27% 
employed between 1 to 9 years. By contrast, four studies reported no difference in STP lung function 
between exposed and control populations (Appendix A). 
 
Bohadana et al. reported higher than predicted FEV1 and FVC in exposed woodworkers, but did show 
a significant increase in BHR across exposure categories, with only 8% of workers in the lowest 
exposure category versus 27% of workers in the highest exposure category having BHR (95). 
However, an earlier Italian study did not demonstrate any increase in BHR between exposure 
populations, with OR 0.6 (95% CI 0.3 – 1.6) in woodworkers not significantly increased from controls 
(105). 
  
Ten studies that measured cross-shift changes in lung function reported lower FEV1 or FVC values in 
their exposed populations. Mean cross-shift loss in FEV1 ranged between 0.11 and 14.9%; in FVC 
between 0.12 and 5.85%; and in MEF and FEF values between 4.8 and 22.2%. Mandryk et al. found 
cross-shift FEV1 and FVC decrements in joiners were significantly associated with number of years 
wood dust exposed, with correlation coefficients of -0.77 and -0.8 respectively (78). Conversely, 
however, Jacobsen et al. found no evidence that cross-shift change correlated with longitudinal lung 
function decline (106).  
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Two further studies (including over 1000 workers) examined longitudinal lung function decline in 
woodworkers. In their North American cohort, Glindmeyer et al. measured mean inhalable dust 
concentrations of 1.45 mg/m3 (range 0.77 – 2.51 mg/m3) and mean respirable dust concentrations of 
0.18 mg/m3 (range 0.1 – 0.21 mg/m3) (107). In this context, they reported a negative effect of 
cumulative exposure to respirable dust in the milling and in the sawmill/planing/plywood industries 
on FEV1, FEV1/FVC and FEF levels, and in the sawmill/planing/plywood industry for FVC. No effect 
was observed in furniture and cabinet workers. Conversely, Jacobsen et al. found accelerated lung 
function decline in female furniture workers who smoked, this effect being more marked in those 
workers with higher wood dust exposures (108). They also found small, but significant, excess 
longitudinal FEV1 decline in both male and female workers still employed in the wood industry at 
follow-up.  
2.3.5 Atopy and specific sensitisation 
Seven papers reported data on sensitisation. A variety of methods were used to test sensitisation: 
skin prick tests (SPT) to common aeroallergens and to specific woods and moulds; total serum IgE; 
and serum IgE to specific wood species. Atopy (defined as SPT positivity to common aeroallergens) 
was common in exposed populations (ranging between a prevalence of 9 and 80%). Skovsted et al. 
reported no difference in prevalence of SIgE to pine in atopic compared to non-atopic workers (77). 
In their follow-up study however, Schlünssen et al. reported high levels of atopy among pine and 
beech workers, with a significant correlation between atopy and reported respiratory symptoms 
(109). 
 
Where studies reported SIgE to wood types, positive results were uncommon. Ricciardi et al. found 
no SIgE to iroko wood in a group of asthmatics, all of whom had a sustained fall in PEF on SIC to iroko 
extract (74). Notably, this group also demonstrated a significant increase in blood eosinophils and 
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positive methacholine challenge post SIC suggesting these individuals had mounted a significant 
allergic response to iroko inhalation.  
 
Furthermore, Skovsted et al. found no difference in prevalence of SIgE between exposed and non-
exposed workers (both 3%), and Schlünssen et al. reported only 1.7% of exposed pine workers 
having pine-specific IgE, and 3.1% of exposed beech workers having beech-specific IgE (77, 109). The 
latter study did not firmly establish a relationship between specific sensitisation and respiratory 
symptoms but did find an association with increasing wood exposures and higher rates of SIgE: 7.8% 
of workers in the highest exposure category were sensitised to pine, with 9.8% of beech workers in 
the highest exposure category sensitised.  
 Discussion 
A number of high-quality observational studies were identified for this review although the majority 
of papers were of a lower evidence rating. Only five studies were graded SIGN 2++ or above (Table 
2), although MERGE identified more highly rated studies. This finding emphasises the importance of 
using tools specifically designed for reviewing occupational research, where the validity and 
applicability of studies may otherwise be underestimated (87). 
 
Exposure to wood dust in the furniture and wood manufacturing industries was associated with an 
increased risk of a variety of reported respiratory symptoms, and particularly cough. This was based 
on evidence from both cross-sectional and longitudinal studies. Indeed, reported symptoms were 
more common in higher exposed woodworkers in all but one study reporting airway symptoms. It is 
plausible that some of this excess relates to recall bias, but there is evidence to suggest that though 
respiratory illness may alter symptom reporting, workers continue to self-report with high sensitivity 
(106). 
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2.4.1 Wood dust exposure, respiratory symptoms and asthma: evidence for a dose-
response relationship 
There was conflicting evidence to support a dose-response relationship for respiratory symptoms in 
woodworkers. Neither Rongo et al. nor Sripaiboonkij et al. found increasing levels of wheeze or 
chest tightness with increasing dust exposure, despite large study numbers and relatively high wood 
dust exposures; inhalable dust ranging from 0.02 – 2.93 mg/m3 and 1.43 – 22.76 mg/m3 respectively 
(91, 97). 
 
Woodworkers in the furniture and wood manufacturing industry were also found to be at a greater 
risk of asthma, despite measured exposure to dust levels being lower than may be expected in some 
European countries. Schlünssen et al. found an excess of self-reported and physician-diagnosed 
asthma in atopic female wood workers (100). They also reported that atopic workers in the highest 
exposure category had significantly more asthma symptoms and BHR. Conversely, non-atopic 
workers in the same exposure category had less BHR and more work-related asthma symptoms. 
Though confidence intervals were wide, this finding suggested that non-atopic and atopic wood 
workers may manifest different clinical outcomes as a result of wood dust exposure. More 
conclusive work is needed to better understand these responses.  
 
The only meta-analysis included in the review reported an increased relative risk for asthma in 
woodworkers of 1.5 compared with the general population (101). Heikkilä et al. found similar 
relative risks (1.5 in both female and male woodworkers) comparable to blue-collar workers in the 
same industry, although did not identify a dose effect (99). Inclusion in the study depended on 
inclusion in a national registry, potentially missing workers with a past, or missed, asthma diagnosis. 
Jacobsen et al. demonstrated an increased risk of asthma for female woodworkers in the highest 
exposure category (92). Interestingly, they also reported significantly more asthma in female 
workers who had left the furniture industry at follow up, suggesting a healthy worker effect (HWE).  
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2.4.2 Cross-shift and longitudinal lung function in wood dust exposed workers 
Cross-shift changes in lung function have been reported in other industries including dairy workers 
and mussel pickers (110, 111). Their utility is uncertain when diagnosing occupational respiratory 
problems (9). Whilst these measures evidently document an acute respiratory response to the work 
environment, they may be affected by the normal diurnal variation in lung function, which is 
classically exaggerated in asthma. They may be further confounded by shift work and poor 
spirometry measurement, and cross-shift change has been shown to have a high specificity but low 
sensitivity for identifying cases of occupational asthma (9). 
 
Jacobsen et al. found no relationship between acute, cross-shift changes, and longer-term lung 
function loss in their study of woodworkers (106). This may reflect exposures other than wood in the 
workplace. For example, Mandryk et al. demonstrated significant cross-shift lung function change in 
a workplace where substantial endotoxin, bacterial and fungal exposures were measured (78).  
 
This review identified conflicting evidence for impairment of lung function among exposed 
woodworkers. Certain cross-sectional studies reported a difference in measured values between 
exposed and control populations. However, evidence for excess longitudinal lung function decline 
was only demonstrated in certain subgroups. Two studies reported annual decline in lung function, 
but with mixed conclusions. Jacobsen et al. found female smokers exposed to wood dust had 
significantly accelerated lung function decline (108). In contrast, Glindmeyer et al. found no 
relationship between longitudinal lung function decline and employment in the furniture or cabinet 
making industry (107). Studies in WRC workers have demonstrated irreversible longitudinal lung 
function decline, findings that have been replicated with other forms of OA (14, 72). 
 
No papers were found reporting data on non-invasive measures of airway inflammation in workers 
from the wood processing or manufacturing industries. Only one paper of low-quality reported data 
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on nasal cell counts and protein showing no difference between exposed and control populations. A 
rise in sputum eosinophils has previously been shown among workers with WRC asthma and a 
positive SIC (112). Sputum eosinophilia, but not FENO, has previously been shown to relate to FEV1 
impairment and asthma severity in WRC asthma (72). However, the same study group found that 
FENO correlated with sputum eosinophilia, suggesting it may be a useful non-invasive marker for 
eosinophilic airway inflammation in WRC workers. FENO is increasingly used in the diagnosis and 
management of OA and is recommended in recent BTS/SIGN and NICE asthma guidelines (4, 48). 
FENO has been shown to predict incident bronchial hyperresponsiveness in exposed bakers and 
hairdressers at risk of OA (41). FENO has also been shown to reduce following allergen exposure 
reduction in farmers, with a corresponding reduction in respiratory symptoms (113). Further study 
of airway inflammation in woodworkers is needed to examine its potential usefulness in surveillance 
and diagnosis of work-related asthma. 
2.4.3 Mechanisms of disease 
Whilst this review provides some information on mechanisms for asthma in wood dust-exposed 
populations, it is not the aim of this study to review all the evidence relating to mechanisms by 
which wood dust causes respiratory disease. Whilst the exact causative agent (or agents) responsible 
is not clearly identified, one study suggested that high levels of endotoxin were linked to the 
reporting of cough in furniture workers (79). In addition, the relationship between chronic bronchitis 
and wood processing was particularly strong, even when the effects of smoking had been taken into 
consideration. Jacobsen et al. reported increased risks for chronic bronchitis in a longitudinal study 
of female woodworkers and showed that increasing exposures in this group increased the likelihood 
of bronchitis (92). Whether this finding represented an “irritant” effect is not clear, but symptoms 
may have reflected underlying disease mechanisms not typical of type 1 hypersensitivity or 
eosinophilic allergy (66). In addition to intensity of exposure, the propensity of wood to cause 
asthma is likely to be influenced by other factors including the chemical properties of specific 
 51 
species, the particle size generated, the route of exposure, and individual susceptibility to disease 
(114). 
 
Whilst certain studies supported the development of sensitisation to wood dust as being a 
potentially important process in the development of respiratory symptoms and asthma, the 
mechanism remains unclear. Skovsted et al. identified a potentially pathogenic protein band in 
beech and pine, but reported very low levels of pine and beech specific IgE in exposed workers (77). 
Similarly, Ricciardi et al. reported 100% SIC positivity in patients with iroko asthma, but 0% specific 
IgE positivity, despite these patients demonstrating a sustained asthmatic response to iroko extract 
(74). Overall, IgE positivity was low throughout the included studies. A number of non-IgE 
mechanisms for sensitisation have been reported: further research in this field is important to better 
understand the both micro- and macroenvironmental circumstances that give rise to allergic disease 
in order to improve controls, reduce risk to workforces, and develop more targeted therapies (114).  
2.4.4 Limitations 
This review is the only systematic review of asthma in workers employed in the furniture or wood 
manufacturing industries. Its findings are comparable to a previous review of the dry wood industry 
(82). Since a greater number of papers were included in the current review, and a wide range of 
search terms employed over a long period of interest, it is unlikely that a significant number of 
relevant studies were missed. Although there was heterogeneity between studies, consideration of a 
range of endpoints allowed us to extract data relevant to several areas of interest and raise points 
for further investigation.  
 
There are, however, certain downsides to consider. Our review findings were difficult to compare for 
a number of reasons. Exposed populations were drawn from a variety of sources including worksites, 
outbreaks, or from hospital cohorts. Population size, country, exposure level and design also varied 
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between papers. A number of studies were published prior to the year 2000, and before mandatory 
changes to exposure limits in both North America and Europe. As such, some data may not 
accurately reflect current practice; although recent international data suggests that exposure to 
wood dust continues to differ both within and between countries (50). 
 
In addition, exposure misclassification represents an important potential source of bias within this 
review. Some studies reported data on inhalable or respirable dust, whereas others reported only 
total or non-specific dust readings. Variation in measurement techniques could also have influenced 
clinical risk attributed to exposure and bias results, potentially underestimating (or overestimating) 
the magnitude of past exposures especially where workers have subsequently moved to lower 
exposed tasks (88). 
2.4.5 Summary 
In summary, this review found an increased risk of respiratory symptoms and asthma in people 
working in the wood processing and furniture manufacturing industries. Accelerated lung function 
decline due to ongoing exposure was evident for specific study groups. It is important to note that 
although much of the more robust research included was conducted in lower exposure 
environments, ill-health occurred across all exposure groups. Further study exploring measures of 
airway inflammation in the workplace may help explore the mechanisms through which wood dust 
causes respiratory disease and asthma, and more importantly how to define interventions to reduce 









3 Respiratory symptoms, airway inflammation and asthma in British 
woodworkers 
 Background 
3.1.1 Asthma and wood dust exposure 
Between 2000 and 2003 an estimated 200,000 people were annually exposed to wood dust in the 
UK, working in diverse sectors such as forestry, furniture manufacture, boat building, and 
construction (52). Exposures to wood dust have changed significantly over the last two decades, 
with increased mechanisation of tasks, reduction in hard wood use, increase in use of wood 
composites, and an overall reduction in exposure (25). However, despite exposure reduction and a 
smaller population of workers exposed, OA remains prevalent among woodworkers. Over the last 
decade, SWORD data has shown an increase in the incidence of OA caused by wood dust, with wood 
dust among the top five causes of OA in Great Britain in 2019 (26). Data from reporting schemes in 
France and Australia also identify wood dust as a leading cause of occupational asthma (115, 116). 
Despite this, few recent studies have studied the risk of OA in woodworkers (117). 
 
Wood dust exposure is the key risk factor for asthma in woodworkers. Population-based studies 
have demonstrated woodworkers have a 50% increased risk of asthma compared to the general 
population (101). Wood dust exposure is associated with an increased risk of respiratory symptoms, 
particularly cough (117). Population-based studies have demonstrated a link between hard and soft 
wood dust exposure and airway responsiveness (100), excess lung function decline (108), and 
asthma (99). Both immediate and dual asthmatic reactions have been reported following specific 
inhalation challenge to hardwoods including oak (118), iroko (74), and chengal wood (119). Western 
red cedar is a well-documented cause of OA, and studies have reported increased presence of 
inflammatory cells including eosinophils in bronchioalveolar lavage of patients with WRC OA (120). 
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3.1.2 Mechanisms of wood dust OA 
A variety of wood species, including both hard and soft woods, have been implicated in causing OA 
(117). However, the immunological mechanism through which wood dust causes OA remains 
unclear. Wood dust has been categorised as both an HMW and LMW allergen (121). IgE mechanisms 
of disease have been inconsistently described. Some wood species, in particular tropical hardwoods, 
have been associated with detectable SIgE and associated HMW proteins (122). However, most 
cases of wood dust OA have not been associated with detectable SIgE. For WRC OA, an IgE-
independent process where plicatic acid acts as a hapten and initiates histamine release and 
basophil degranulation has been described (70). Other studies have demonstrated hard and soft 
wood constituents to have both inflammatory and genotoxic effects on pulmonary epithelium in 
vivo, suggesting wood may induce asthma through direct bronchial injury rather than through an 
immunological mechanism (67). Since OA is commonly described by its causative exposure, 
characterising relationships between wood dust exposure and OA is challenging, particularly since 
workers may be exposed to multiple wood species. 
3.1.3 Measures of airway inflammation in wood dust exposed workers 
Exposure to wood dust is regulated by HSE and where exposures cannot be reduced to levels as low 
as reasonably practicable, health surveillance is mandatory (29). Low-level health surveillance 
includes worker respiratory questionnaires, with those at higher risk of exposure also requiring serial 
spirometry (123). In addition, measurements of airway inflammation such as non-specific BHR and 
FENO may be used for diagnosing wood dust OA, but their use in such settings is not established 
(117). Since assessment of BHR requires specialist delivery, it has not been routinely used in health 
surveillance programmes. In contrast, FENO is non-invasive, easy to use, and reproducible, and 
therefore has been explored as a potentially useful tool for identifying workers at risk of OA (124). 
FENO is recommended in the diagnosis and monitoring of asthma in the UK (4). Its presence relates to 
Th-2 inflammation and it is particularly associated with other inflammatory markers including 
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eosinophils, IL-4, IL-13, and antigen-specific IgE (125). This inflammatory response pattern has been 
more strongly associated with HMW rather than LMW exposures in OA (126). In WRC workers, rises 
in FENO have been shown to correlate strongly with increases in sputum eosinophilia but not with 
positive SIC (112). Since wood dust is varyingly characterised as both an HMW and LMW allergen, 
the utility of FENO as a measure of airway inflammation in wood dust OA has yet to be determined. 
3.1.4 Exposure thresholds for asthma in wood dust exposure 
Respiratory symptoms, SIgE, NSBHR and OA have all been reported at wood dust exposures lower 
than the current UK WEL of 5mg/m3 (117). Exposures of less than 2 mg/m3 inhalable dust have been 
associated with increased respiratory symptoms, bronchial hyperresponsiveness, and reduced lung 
function compared to lower or non-exposed groups (100, 108). There is no safe limit for exposure to 
an asthmagen, and this suggests that wood dust OA occurs at levels lower than the current UK WEL.  
 
There have been no recent studies of respiratory ill-health in British woodworkers despite wood 
dust being consistently reported as a common cause of OA in UK for the past decade, the changing 
shape of the industry due to economic pressures, and the increasing use of wood composite 
materials. No previous studies have explored widely available measures of airway inflammation such 
as FENO and its relationship with measured workplace exposures, respiratory symptoms, and asthma 
outcomes in woodworkers. The aim of this study is to examine how wood dust exposure influences 
respiratory symptoms, airway inflammation, sensitisation, and abnormal lung function among British 
woodworkers.  
 
This study was reviewed and approved by the NHS Health Research Authority National Research 
Ethics Committee: London (REC reference 14/LO/1262).  
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 Methods 
Research into woodworkers was conducted by CWH. I developed the study protocol, obtained 
ethical approval, and conducted data collection visits alongside my CWH colleagues Jade Sumner 
and Ed Robinson. I developed a data analysis plan alongside Charlotte Young, HSE statistician. I was 
responsible for data management, analysis, and interpretation. The data from this study has not 
been reported elsewhere. 
 
3.2.1 Site identification 
British woodworkers were recruited to a cross-sectional study conducted as part of HSE’s Health 
SRP.  All registered worksites manufacturing or processing wood or timber within Great Britain were 
potentially eligible to participate. Worksites that had recent (within three months) or ongoing HSE 
investigations were not approached to take part in the study. Initially woodworking companies 
participating in an HSE occupational hygiene study in 1999/2000 were approached to take part (52). 
The original hygiene study included worksites from the following sectors involving wood dust 
exposure:  
• timber and sawmills; 
• furniture manufacture; 
• wood processing; 
• boat building.  
No construction sites were included in the 1999/2000 study.  
 
Further sites were identified using the HSE Corporate Operational Information System (COIN) 
database. Every intervention by a HSE duty holder is recorded on the COIN system, which holds an 
address and contact number of most worksites in Great Britain (127). 
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Managers or health and safety representatives at worksites were contacted via telephone. 
Interested worksites were sent information sheets about the study for circulation to management 
and employees (Appendix B). Each worksite then received a recruitment visit from the study team 
where a detailed explanation of the study was provided to workers and site managers, and workers 
and managerial staff were given the opportunity to ask questions about the research. Worksites 
were then re-contacted the following week and asked whether they agreed to participate. 
Arrangements were then made to re-visit participating worksites at mutually agreeable times.  
3.2.2 Power calculation 
Since there were no recent studies reporting asthma rates in British woodworkers, a study reporting 
equivalent exposures was used to determine the number of workers required to achieve 80% study 
power at a 5% significance level. The most recent British exposure data in woodworkers reported 
median inhalable wood dust exposures of 2.6 mg/m3 (52). In their study of New Zealand 
woodworkers, Norrish et. al. reported 25% of exposed woodworkers had work-related chest 
tightness or wheeze at a mean inhalable dust exposure of 3.6 mg/m3 (89). The same research group 
reported a prevalence of asthma of 18% in sawmill workers, with an odds ratio (OR) of 1.4 between 
high and low exposure groups (128). This research compares to more recent evidence from British 
bakery workers where work-related respiratory symptoms were reported in 18.7% of workers, with 
mean OR for medium and high exposure versus low exposure groups of 2.3 and 2.0 respectively 
(129). Mean exposures to flour dust in three groups were 2.1, 3.6 and 5.0 mg/m3 respectively. 
 
On this basis, a power calculation was made using logistic regression in MATLAB (130). A sample of 
240 workers was estimated to provide 80% power to detect an association between wood dust 
exposure and work-related respiratory symptoms with an expected 95% CI of 13.4% to 23.5%, 
assuming a two-sided 5% significance level, a true underlying symptom prevalence of 18% and an OR 
of 1.4 per doubling of exposure.   
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3.2.3 Worker recruitment 
All workers exposed to wood dust and over the age of 16 at were eligible to participate. All workers 
on site during the visit were invited to take part. Worksites varied in size and shift pattern. Data 
collection visits included extended day, evening, or night visits to ensure the maximum number of 
workers, including late and night shift workers, were able to participate. Multiple visits were made 
to larger worksites to ensure saturation of participation.  
3.2.4 Questionnaire 
Each worker underwent an interviewer-administered validated questionnaire detailing upper and 
lower respiratory symptoms, nasal symptoms, and ocular symptoms based on the Medical Research 
Council (MRC) and European Community Respiratory Health Survey (ECRHS) questionnaires 
(Appendix B) (12, 131). Questions on asthma control and medication use were asked using the 
asthma control test (ACT) (132). A detailed job history was taken including current and previous jobs 
and processes and materials involved. Use of any respiratory protective equipment (RPE) was 
recorded, including type (if any) and length of time used.  
3.2.5 Spirometry and fractional exhaled nitric oxide measurement 
All participating workers were invited to undertake spirometry and FENO measurement. FENO was 
performed before spirometry using a NOBreath device (Bedfont Scientific, Kent) according to 
ATS/ERS standards (46). A minimum of two technically acceptable blows at 50mls.s-1 were recorded 
to within 10% of one another (or 1 part per billion (ppb) for readings below 10ppb) and before 
spirometry wherever possible. Spirometry was measured using an NDD Easy-On spirometer (Zurich, 
Switzerland) according to ATS/ERS standards (133). Subjects were examined sitting and without a 
nose clip. A minimum of three technically acceptable manoeuvres were made, and the best two 
measurements of FEV1 and FVC measured to within 150mls of one another. FEV1, FVC, PEF, and 
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FEV1/FVC ratio were recorded, and percentage predicted values generated using age, sex, height, 
and ethnicity standardised reference values included in the spirometry software.   
3.2.6 Total IgE and specific IgE to hard and soft wood 
Blood was obtained from consenting workers at worksites and kept on ice after drawing. Samples 
were centrifuged and frozen at HSL and underwent immunological testing for TIgE and SIgE to hard 
(oak, mahogany and obeche) and soft (beech, pine, cedar and silver fir) woods using standard 
ImmunoCAP testing (Phadia, Sweden, 2012).  
 
3.2.7 Occupational hygiene assessment 
An assessment of wood dust exposure was conducted at each participating worksite by a certified 
HSE occupational hygienist. Workers underwent personal exposure monitoring using the Methods 
for the Determination of Hazardous Substances (MDHS) 14/4 (134). In brief, a passive sampling 
device was worn on the lapel for the duration of a working shift. Standard eight-hour time-weighted 
averages (8-hr TWA) were calculated for inhalable wood dust for the tasks sampled. Worksites also 
underwent comprehensive occupational hygiene assessment including evaluation of material 
exposures, processes undertaken, exposure controls employed, application of the COSHH guidelines, 
and use of any RPE. 
3.2.8 Job exposure matrix 
Each worker was assigned a job code using task-specific codes developed for the woodworking 
industry (52). Where workers held more than one current position (for example a managerial and a 
manufacturing role), a ratio of time spent in each job was applied. The proportion of time in all 
positions did not exceed one. In addition, Standard Occupational Classification 2010 (SOC 2010) 
codes were applied to current jobs using a Computer Assisted Structured Coding Tool (CASCOT) 
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(135, 136). Historical jobs were assigned a three or five-digit SOC 2010 code based on the level of 
information provided by workers.  
 
Inhalable wood dust exposures for each worker were estimated based on a linear mixed effects 
model fitted to the logarithm of the measured 8-hour TWA values (88). In total, 168 valid 
measurements were taken across all sites. Site was treated as a random effect and task as a mixed 
effect, with between-worker variation treated as normally distributed residual errors. Mean 
exposure for each task at each site was calculated from the corresponding mean of log-exposure 
estimated by the model and the residual error standard deviation. For individual workers, model 
exposures were then weighted by the fraction of time each worker spent undertaking each task. 
3.2.9 Definitions 
Work-related respiratory symptoms (WRRS) were identified where workers reported deterioration 
in cough, shortness of breath, wheeze, or chest tightness at work, or an improvement away from 
work or on holiday. Self-reported asthma was defined by individuals reporting a physician diagnosis 
of asthma. Current asthma was defined as either a current or past physician-diagnosis of asthma and 
current asthma symptoms (CAS - wheezing, nocturnal chest tightness, breathlessness on exertion, at 
rest, or at night, or asthma medication use within the last 12 months) as per ERCHS criteria (12).  
 
Only technically acceptable spirometry and FENO measurements were used in the final analysis. FEV1, 
FVC, PEF and FEV1/FVC values falling two standard deviations below the mean (lower limit of normal 
or LLN) were considered abnormal (137). FENO values above 40ppb were considered high (4).  
 
Participants were considered sensitised if their IgE to hard or soft wood exceeded 0.35KuA/L (109). 
Atopy was defined as a TIgE above 100 kU/L (138). 
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3.2.10 Data analysis 
Demographic details were displayed as means and standard deviations. Normally distributed data 
were compared using independent t-tests and ANOVA analyses for continuous variables of interest, 
and chi squared tests were used for categorical variables. FENO and TIgE data did not meet normality 
assumptions. Mann-Whitney-U tests were used to compare means, and data were log transformed 
for use in regression models.  
 
The outcomes of interest including current asthma symptoms, WRRS, current asthma, FENO >40ppb, 
and FEV1/FVC <LLN were used as dependent variables in logistic regression models, with quartiles of 
exposure as the key independent variable. Workers in the lowest exposure quartile were used as the 
control group. Models were adjusted for ever smoking, BMI, atopy, age, sex, and RPE use. FENO 
models were controlled for current smoking and height (46). Odds ratios with associated 95% 
confidence intervals were reported.  
 
Linear regression models were constructed to analyse lung function and FENO data in relation to 
wood dust exposure. Because FENO was not normally distributed, log10 FENO was used as the 
dependent variable with current wood dust exposure as the key independent variable. Data were 
back-transformed and expressed as the geometric mean ratio (GMR) of FENO per 1mg/m3 increase in 
wood dust exposure (45, 139). Models were adjusted for atopy, age, sex, current smoking, and 
height. Absolute FEV1 and FVC in millilitres were used as dependents with current exposure to wood 
dust as the key independent variable. Models were controlled for age, sex, height, and ever having 
smoked more than one pack year of cigarettes.  
 
Linear regression models were used to examine the presence of a healthy worker effect (HWE). Self-
reported years of exposure to vapours, dust, gases and fumes (VDGF) was used as the dependent 
variable, where possible to account for exposure to wood dust in previous jobs within the 
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woodworking industry. Respiratory symptoms, work-related respiratory symptoms, and current 
asthma were used as independent variables. Models were adjusted for age, ever smoking, atopy, 
RPE use, and BMI.  
 
Since asthma is a heterogeneous condition with variable manifestations, relationships between 
exposure and combinations of asthma markers (asthma indices) were explored (100). Logistic 
regression models were constructed examining the composite asthma indices: (i) CAS+atopy; (ii) 
CAS+FENO >40ppb; (iii) current asthma+atopy; and (iv) current asthma+FENO >40ppb across exposure 
quartiles. Odds ratios with associated 95% confidence intervals were reported. Finally, contingency 
analyses were conducted between workers with CAS, FENO >40ppb and airflow obstruction 
(FEV1/FVC <LLN) using intersecting Venn diagrams created using Venny, a freely available 
bioinformatics tool (140). All statistical analysis was performed using SPSS Statistics, v23 (141).  
 Results 
3.3.1 Study population 
Thirty-seven companies were contacted to participate. From the original 1999/2000 list, six 
companies had gone out of business. A further 18 companies contacted declined to take part. If 
reasons for non-participation were given, they included lack of time for research, concerns about 
productivity loss, and an unwillingness to allow HSE into the workplace. Thirteen companies were 
subsequently recruited across 14 sites. Companies from the furniture manufacture, boat building, 
and wood processing industries were included in the study. Two-hundred-and-sixty-nine out of a 
possible 376 workers participated (participation rate 72%). Reasons for non-participation included 
inability to capture workers due to shift work, inability of workers to take time away from shift, 
worker annual leave, and worker refusal.  
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Table four lists the key demographic and exposure characteristics of the study population. The 
population was mostly male (n=261, 97%) with an average age of 42.4 (SD 12.6) years. Seventy 
(26%) workers were current smokers, with 140 (52%) ever having smoked more than one pack year. 
Workers had spent an average 18.9 (SD 12.8) years exposed to wood dust, with 7.9 (SD 7) years 
spent in their current job. The majority of workers (63%) used a mixture of hardwood, softwood, and 
composites, and most (70%) performed more than one task at their worksite.  
 
Mean current exposure to wood dust was 1.9mg/m3 (SD 0.9, IQR 1.4), with a mean cumulative 
exposure to wood dust of 13.9mg/m3 (SD 14.9, IQR 19.3). Mean current exposures to wood dust 
were 0.69 (0.37) mg/m3, 1.74 (0.27) mg/m3, 2.12 (0.09) mg/m3, and 2.98 (0.80) mg/m3 in the lowest, 
low, high, and highest exposure quartiles respectively (Table 4). One third of the highest exposed 
workers were involved in sanding and assembly (30% vs 13% in lowest exposed, p <0.01). Workers in 
all but the lowest exposure quartile were more likely to use RPE (p for trend <0.05). Workers in the 
high exposure quartile were significantly more likely to work with hardwood than workers in other 









Table 4: Key demographic and exposure characteristics of 269 of British woodworkers, stratified by 
exposure quartile. Exposure range for each quartile is reported in parentheses in mg/m3. Number of workers 


















Age, years (SD) 42.45 (10.51) 44.64 (13.69) 41.31 (13.00) 40.93 (12.68) 42.4 (12.6) 
Sex, m (%) 65 (97) 71 (99) 62 (98) 63 (94) 261 (97) 
Height, cm (SD) 176.13 (8.11) 175.80 (6.25) 174.80 (10.14) 177.16 (8.20) 
175.99 
(8.22) 
Current smoker, n (%) 17 (25) 22 (30) 14 (22) 17 (25) 70 (26) 














Uses RPE, n (%) 44 (66) 55 (76)* 51 (81)* 57 (85)* 207 (77) 
Multitasking, n (%) 38 (57) 54 (75) 56 (89) 39 (58) 187 (70) 
Sawing, n (%) 4 (6) 7 (10) 1 (2) 1 (2) 13 (5) 
Moulding/shaping, n (%) 1 (2) 2 (3) 0 (0) 0 (0) 
3 (1) 
 
Sanding/assembly, n (%) 9 (13) 4 (6) 1 (2) 20 (30)** 34 (13) 
Cleaning/maintenance, n (%) 5 (8) 5 (7) 5 (8) 7 (10) 22 (8) 
Other non-woodworking, n 
(%) 
10 (15) 0 (0)** 0 (0)** 0 (0)** 10 (4) 
Time in current job, years 
(SD) 
7.40 (6.02) 7.91 (6.57) 8.94 (8.00) 7.28 (7.30) 7.9 (7.0) 
Time in woodworking 
industry, years (SD) 
17.95 (11.03) 19.71 (12.52) 20.86 (14.58) 17.11 (12.90) 18.9 (12.8) 
Mean current exposure, 
mg/m3 (SD) 






17.93 (16.21) 19.22(19.04) 13.9 (14.9) 
*p <0.05, **p <0.01. RPE = respiratory protective equipment. 
 
Table five shows the key health characteristics of the study population, stratified by exposure 
quartile. Overall, CAS were common, reported by almost half the study population (n=123, 46%). 
CAS rates were high across exposure quartiles, although were slightly lower in the highest exposed 
group (39%). WRRS were less frequent, reported by 29 (11%) workers. WRRS tended to be 
commoner among the lower exposed, with 16% in the lowest exposed versus 3% in the highest 
exposed groups reporting any WRRS. There was no significant difference in prevalence of CAS or 
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WRRS across exposure quartiles. Work-related ocular symptoms were significantly more common in 
the higher exposed groups, with 22% in the highest exposed versus 9% in the lowest exposed 
reporting symptoms (p<0.05). No difference was observed for work-related nasal symptoms. 
 
One sixth of the study population (n=40, 15%) fulfilled ECRHS criteria for current asthma, although a 
smaller proportion (n=22, 8%) self-reported a current diagnosis (Table 5). There were no significant 
differences between self-reported or ECRHS asthma across exposure quartiles. Those in lower 
exposure quartiles tended to have higher rates of asthma, with 9% of the lowest and 14% of the low 
exposed versus only 3% of the highest exposed reporting a diagnosis. Similarly, prevalence of 
current asthma tended to be higher in lower exposure quartiles; prevalence was 16% in the lowest 
exposed versus 7% in the highest exposed. Nine workers reported recent steroid inhaler use (3%), 
with no significant differences between exposure groups.  
 
TIgE levels varied widely and were not normally distributed. Geometric mean (GM) TIgE was 35.08 
(4.43) kU/L. There was no significant difference between either arithmetic or geometric mean TIgE 
across exposure groups. Mean rank TIgE was significantly higher in workers with a history of allergy 
(Mann-Whitney-U mean rank TIgE 132 IU/kL versus 114 IU/kL, p 0.04, Figure 3). Atopy (TIgE >100 
IU/L) affected 20% of workers. Rates of SIgE sensitisation were very low, with only one worker 





Table 5: Respiratory symptoms, asthma, atopy and specific sensitisation among 269 British woodworkers, 
stratified by exposure quartile. Exposure range for each quartile is reported in parentheses in mg/m3. Number 


















symptoms, n (%)a 
34 (50) 34 (47) 27 (46) 26 (39) 123 (46) 
Any work-related 
respiratory symptom, n 
(%) 
11 (16) 8 (11) 8 (13) 2 (3) 29 (11) 
Work-related cough, n 
(%) 
7 (10) 4 (6) 2 (3) 1 (2) 14 (5) 
Work-related wheeze, n 
(%) 
5 (8) 5 (7) 1 (2) 0 (0) 11 (4) 
Work-related chest-
tightness, n (%) 
2 (3) 2 (3) 3 (5) 1 (2) 8 (3) 
Work-related 
breathlessness, n (%) 
4 (6) 3 (4) 3 (5) 0 (0) 10 (4) 
Work-related nasal 
symptoms, n (%) 
5 (8) 8 (11) 11 (18) 11 (16) 35 (13) 
Work-related ocular 
symptoms, n (%) 
6 (9) 13 (18) 3 (5) 15 (22)* 37 (14) 
Asthma and COPD 
Current inhaled steroid 
use, n (%) 
3 (5) 2 (3) 3 (5) 1 (2) 9 (3) 
Self-reported asthma, n 
(%)b 
6 (9) 10 (14) 4 (6) 2 (3) 22 (8) 
Current asthma, n (%)c 11 (16) 16 (22) 8 (13) 5 (7) 40 (15) 
Physician diagnosed 
COPD, n (%) 
3 (4) 0 (0) 1 (2) 0 (0) 4 (1) 
Atopy and sensitisation 






GM TIgE, kU/L (SD) 36.18 (4.96) 37.97 (4.28) 40.23 (4.72) 26.65 (3.76) 35.08 (4.43) 
Atopic, n (%)d 13 (19) 17 (23) 16 (25) 7 (10) 53 (20) 
Positive SIgE to 
hardwood, n (%) 
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Positive SIgE to 
softwood, n (%) 
0 (0) 0 (0) 1(1) 0 (0) 1 (1) 
*p <0.05, **p <0.01 
a= current asthma symptoms defined by wheezing, nocturnal chest tightness, breathlessness on exertion, at rest, or at 
night, or asthma medication use within the last 12 months as per ECRHS. b= self-reported asthma defined by workers 
self-reporting a current doctor diagnosis of asthma.  c= Current asthma defined by current asthma symptoms plus a past 





Figure 3: Mean rank total IgE between workers with or without a self-reported history of allergy (eczema, 
rhinitis, or asthma). 
Table six shows FENO and spirometry data across the four exposure groups.  Spirometry met ATS 
criteria for FEV1 and FVC in 228 (85%) cases. Of those cases where spirometry was not reproducible, 
59% failed to meet FEV1 criteria and 81% failed to meet FVC criteria. Valid FENO measurements were 
obtained in 225 (84%) workers. Reasons for failure to obtain a valid FENO measurement included 
inability to perform technically acceptable manoeuvre (59%), inability to perform reproducible 
manoeuvre within 10 ppb (14%), lack of availability for testing (25%), and testing declined (2%).  
 
FENO data was not normally distributed. AM FENO was 27.2 (27.7) ppb, and GM FENO was 18.4 (2.5) 
ppb. Median FENO was 18.71 ppb with 5th and 95th percentiles of 3.50 and 85.44 ppb respectively. 
When stratified by smoking, median FENO was 20.17 ppb (5th and  95th percentile 6.00 - 87.62 ppb) 
for non-smokers, and 10.75 ppb (5th and 95th percentiles 2.08 - 50.25 ppb) for smokers (Mann-
Whitney-U, p <0.01, Figure 4). No differences were observed between mean AM or GM FENO across 
exposure groups in univariate analyses (table 6). Over a sixth (n=41, 18%) of workers met the 




Figure 4: Median FENO in British woodworkers stratified by smoking status. 
Four workers (2%) self-reported a doctor diagnosis of COPD, although 10 (4%) had an FEV1/FVC ratio 
less than the LLN (Table 6). Mean percentage predicted FEV1, FVC and PEF did not vary across 
exposures. Mean FVC and PEF readings were better than predicted in all exposure groups. There was 









Table 6: FENO and lung function among 269 British woodworkers, stratified by exposure quartile. Exposure 


















AM FENO a 24.40 (23.90) 32.45 (32.31) 24.90 (20.29) 26.39 (32.45) 27.2 (27.7) 
GM FENO 18.20 (2.19) 21.38 (2.57) 17.78 (2.45) 16.98 (2.63) 18.4 (2.5) 
FENO >40ppb, n (%) 7(10) 15 (21) 9 (14) 10 (15) 41 (18) 
Spirometry 
Mean % predicted FEV1 
(SD)b 
99.90 (13.45) 98.61 (12.34) 99.35 (12.25) 101.41 (13.09) 99.8 (12.7) 
Mean % predicted FVC 
(SD) 
103.48 (12.52) 101.16 (12.16) 101.63 (12.81) 105.41 (13.59) 
102.9 
(12.8) 
Mean % predicted PEF 
(SD) 
108.16 (16.91) 109.80 (16.63) 107.56 (13.86) 108.27 (16.14) 
108.5 
(15.9) 
Mean FEV1, mls (SD) 3809 (658) 3697 (720) 3823 (656) 3986 (739) 3824 (699) 
Mean FVC, mls (SD) 4825 (818) 4658 (899) 4759 (750) 5027 (905) 4813 (854) 
Mean PEF, mls (SD) 584 (116) 587 (98) 581 (95) 588 (102) 588 (102) 
FEV1 <LLN, n (%) 2 (3) 4 (6) 3 (5) 3 (4) 12 (4) 
FVC <LLN, n (%) 1 (1) 1 (1) 2 (3) 2 (3) 6 (2) 
PEF <LLN, n (%) 1 (1) 3 (4) 2 (3) 4 (6) 10 (4) 
FEV1/FVC <LLN, n (%) 4 (6) 3 (4) 1 (2) 2 (3) 10 (4) 
*p <0.05, **p <0.01 
a=valid FENO in 225 workers. b=valid spirometry in 228 participants. AM = arithmetic mean. GM = geometric mean. 
LLN=lower limit of normal.  
 
3.3.2 Respiratory symptoms, allergy and asthma across exposure group 
Logistic regression analyses for associations between exposure, symptoms and asthma are 
presented in table seven. No significant relationships were observed for age, BMI, inhaled steroid 
use and RPE. Risk of WRRS was significantly lower in the highest versus lowest exposed group (OR 
0.16, 95% CI 0.03-0.81, p <0.05). Increasing exposure was not significantly associated with risk of any 
other work-related respiratory, nasal, or ocular symptom, although there was a tendency for work-
related nasal and ocular symptoms to be more common in the highest compared to the lowest 
exposed group. There was no significant difference in the risk for CAS, self-reported or current 
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asthma across exposure groups. However, higher exposures tended to decrease the risk for either 
self-reported or current asthma (Table 7).  
 
Atopy was significantly associated with risk of work-related symptoms and asthma among 
woodworkers. Even after controlling for confounders, atopic workers were at significantly increased 
risk of CAS (2.07, 1.07-4.03), self-reported (3.95, 1.45-10.79) and current asthma (4.3, 1.87-9.88). In 
addition, atopic woodworkers were at significantly increased risk of WRRS (OR 3.31, 1.29-8.48), 
particularly work-related chest tightness (14.18, 2.28-88.2). Atopy was also associated with a two-
fold increased risk of work-related ocular symptoms (2.73, 1.12-6.64), although was not related to 
an increased risk of work-related nasal symptoms. In contrast, ever smoking was associated with a 
significantly lower risk of WRRS but increased risk of CAS.  
 
Table 7: Associations between work-related respiratory symptoms, current asthma symptoms, asthma 






























































































Models also adjusted for age, BMI, inhaled steroid and RPE use, only significant predictors shown. Numbers included in 
models shown in parentheses: in total, 239 workers had valid atopy, smoking and exposure data.  
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3.3.3 Airway inflammation and lung function across exposure quartiles 
Table eight shows the results of the logistic regression analysis for categorical FENO and lung function 
outcomes, stratified by exposure group. Inclusion of inhaled steroid use in models did not influence 
the outcome. Compared with the lowest exposure group, low exposure to wood dust was associated 
with an increased risk of significant airway inflammation (OR for FENO >40ppb 3.43, 95% CI 1.06-
11.15). Any exposure was associated with an increased risk of airway inflammation compared with 
the lowest exposure group, although risk tended to attenuate in the highest exposed (FENO in highest 
versus lowest 1.45, 0.40-5.19), and relationships were not significant. Both smoking and atopy had a 
significant impact on risk of airway inflammation. Current smoking dramatically reduced the risk of 
high FENO (0.13, 0.03-0.57). Atopy significantly increased the risk of airway inflammation, with over a 
doubling of risk of eosinophilic airway inflammation among atopics (2.58, 1.07-6.19).  
 
Table 8: Associations between categorical FENO and lung function variables with wood dust exposure, atopy 
and smoking. Odds ratios are displayed with 95% confidence intervals in parentheses. 
 


































































–: no workers in the low exposure group had an FVC <LLN.  
a: FENO models adjusted for current smoking, atopy, height, age and RPE use. b: Spirometry models adjusted for ever 
having smoked more than one pack year, atopy, height, age, and RPE use. Only significant predictors shown. Numbers 
included in models shown in parentheses: in total, 200 workers had valid atopy, smoking FENO and spirometry data.  
 
No clear relationships were observed between lung function and exposure quartiles in logistic 
regression models. Higher exposed workers tended to be more likely to have an FEV1 and PEF <LLN. 
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There was no trend observed across exposure groups for FEV1/FVC <LLN. Ever having smoked more 
than one pack year was non-significantly associated with an increased risk of having lung function 
<LLN across all categories, but especially for FEV1/FVC <LLN (8.25, 0.79-85.95).  
3.3.4 Examining a healthy worker effect 
Relationships between years’ exposure to VDGF, respiratory symptoms and asthma are shown in 
Table nine. Models were adjusted for age, ever smoking, atopy, RPE use, and BMI. Work-related 
wheeze was associated with a small but significant reduction in years’ exposure to VDGF 
(unstandardised β -0.004 years, p=0.02). A similar trend was seen for work-related cough and WRRS 
but did not reach significance at the 5% level. No significant relationships between increasing years’ 
VDGF exposure and CAS or current asthma were observed.  
 
Table 9: Linear regression models for cumulative years’ exposure to VDGF, respiratory symptoms, and 
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 *p=0.02, ^p=0.1 
VDGF = vapours, dusts, gases, and fumes. WRRS = work-related respiratory symptoms. WR cough = work-related cough. 
WR CT = work-related chest tightness. WR SOB = work-related shortness of breath. WR NS = work-related nasal 
symptoms. WR OS = work-related ocular symptoms. CAS = current asthma symptoms.  
 
3.3.5 Indices of asthma across exposure quartile 
Relationships between wood dust exposure and composite asthma indices are shown in Table ten. 
Models were adjusted for age, height, current smoking, RPE use and atopy (where not included in 
the composite index). Low exposed workers tended to be at increased risk of all composite asthma 
indices compared with the lowest exposed, with odds ratios of 2.02 (95% CI 0.47-8.74) for CAS+FENO 
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>40ppb, and 10.97 (0.79-152.70) for current asthma+FENO >40ppb respectively. When exposure was 
dichotomised, high exposure to wood dust (the highest three exposure quartiles) was non-
significantly associated with an increased risk of CAS+FENO, current asthma+atopy and current 
asthma+FENO >40ppb. In the high versus low exposed, risk was increased for CAS+FENO >40ppb (1.86, 
0.51-6.78) and for current asthma+FENO >40ppb (1.47, 0.30-7.27). 
 
Atopic woodworkers were at significantly increased risk for CAS+FENO >40ppb and current 
asthma+FENO >40ppb when compared with non-atopic woodworkers, with OR of 4.10 (1.38-12.19) 
and 21.21 (3.89-115.56) respectively. Effect sizes for composite indices exceeded those seen 
between FENO >40ppb and either atopy or CAS alone. In contrast, current smoking was associated 
with significantly lower risk of current asthma+FENO >40 ppb (0.07, 0.01-0.70).  
 
Table 10: Logistic regression models showing relationships between composite asthma indices and exposure 














Low vs lowest 
 
1.29 (0.47-3.56) 2.02 (0.47-8.74) 3.05 (0.58-16.03) 10.97 (0.79-152.70) 
Medium vs lowest 1.32 (0.47-3.67) 2.15 (0.49-9.38) 1.96 (0.34-11.42) 2.55 (0.13-49.60) 
High vs lowest  0.34 (0.08-1.36) 1.46 (0.32-6.64) 1.35 (0.21-8.60) 1.53 (0.10-24.53) 
Highest 3 quartiles vs 
lowest quartile 
0.96 (0.40-2.31) 1.86 (0.51-6.78) 2.12 (0.45-9.83) 1.47 (0.30-7.27) 
Atopy yes vs no - 4.10 (1.38-12.19)* - 
21.21 (3.89-
115.56)** 
Smoking yes vs no 0.75 (0.3-1.85) 0.29 (0.07-1.35) 0.38 (0.08-1.74) 0.07 (0.01-0.70)* 
*p<0.05, **p<0.01. 
Models also adjusted for age, height and RPE use, only significant predictors shown. Numbers included in models 
shown in parentheses: in total, 200 workers had valid atopy, smoking FENO and spirometry data. 
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3.3.6 Linear relationships between wood dust exposure, FENO and lung function  
Table 11 shows data from linear regression models for relationships between inhalable wood dust 
exposure and FEV1 in mls, FVC in mls, and GMR FENO. R squared for all models was significant 
(p<0.01).  
 
Atopy and smoking had a greater impact on GMR FENO than exposure to wood dust. Smoking was 
negatively associated with GMR FENO and atopy was positively associated. Atopic workers had a GMR 
FENO 50% higher than non-atopic workers, and smokers had a GMR FENO 40% lower than never 
smokers. An increase of 1mg/m3 in exposure was non-significantly associated with increases in GMR 
FENO of 1%. Exposure was not a significant predictor of either FEV1 or FVC. Both FEV1 and FVC were 
positively associated with exposure to wood dust, with increases of 18.31mls and 12.90mls per 1 
mg/m3 increase respectively. Ever having smoked one pack year was negatively associated with FEV1 
(unstandardised β -42.37mls) but positively associated with FVC (unstandardised β 36.67mls). 
Interestingly, RPE use appeared to have a sizeable effect on both FEV1 and FVC. Using RPE was 
associated with a significantly higher FEV1 (unstandardised β 240.36mls, p <0.01) and FVC (β 
167.71mls, p 0.12) compared with not using RPE. 
 
Table 11: Linear regression models for inhalable wood dust exposure and airway inflammation (GMR FENO), 
FEV1 (millilitres) and FVC (millilitres).  FENO is reported as geometric mean ratio data with 95% confidence 
intervals. For spirometry, unstandardised β coefficients are reported with 95% confidence intervals. 
 GMR FENO (n=200) FEV1, mls (n=200) FVC, mls (n=200) 




(-58.43 – 95.05) 
12.90 
(-80.37 – 101.17) 




(-151.23 – 183.94) 
30.74 
(-172.94 – 211.93) 
Smoking yes vs no 
0.63  
(0.49 – 0.80)** 
-42.37 
(-186.57 – 101.82) 
36.67 
(-138.58 – 211.93) 
RPE use yes vs no 
1.16 
(0.88 – 1.55) 
240.36** 
(68.59 – 412.12) 
167.71 
(-41.06 – 376.47) 
R2; p for model 0.08; <0.01 0.50; <0.01 0.50; <0.01 
**p=<0.01 
Models adjusted for age, smoking, height, and RPE use. FENO models additionally adjusted for atopy. Numbers included 
in models shown in parentheses: in total 200 workers had valid atopy, smoking FENO and spirometry data. 
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3.3.7 Relationships between current asthma symptoms, airway inflammation, and 
airflow obstruction in British woodworkers 
Intersections between participants with CAS, airway inflammation (FENO >40 ppb), and airflow 
obstruction (FEV1/FVC <LLN) were explored using contingency analysis. Figure five shows data from 
147 workers with either CAS, airway inflammation and/or airflow obstruction. The remaining 
workers reported no CAS and had no airway inflammation or airflow obstruction.  
 
Two-thirds of those with CAS (n=85, 58% of total) had neither evidence of airway inflammation 
measured by FENO nor obstructive spirometry using LLN criteria. Over twice as many workers had 
CAS and airway inflammation (n=26, 18%) compared with CAS and obstructive spirometry (n=11, 
8%). Twenty-three (16%) workers had evidence of airway inflammation but no symptoms of current 
asthma. There was little overlap between airway inflammation and obstructive lung function. Only 
one worker had CAS, airway inflammation, and obstructive spirometry with no workers having 
obstructive spirometry and airway inflammation alone.  
 
Figure six shows intersections between 84 participants with WRRS, airway inflammation and airflow 
obstruction. Most workers with WRRS had neither airway inflammation nor airflow obstruction. In 
total, six (7%) workers with WRRS had airway inflammation; the remaining 23 (27%) had no airway 
inflammation. Even fewer (n=1, 1%) had airflow obstruction. There was little overlap between 
workers with airflow obstruction and airway inflammation, with only one worker having both airway 
inflammation and airflow obstruction, and no participants having WRRS, airway inflammation and 
airflow obstruction.  
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Figure 5: Venn diagram showing intersections between workers with current asthma symptoms, airway 
inflammation (FENO >40ppb) and airflow obstruction (FEV1/FVC <LLN) among 147 study participants 
 
Figure 6: Venn diagram showing intersections between current asthma symptoms, airway inflammation 
(FENO >40ppb) and airflow obstruction (FEV1/FVC<LLN) among 84 study participants. 
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Figure seven shows asthma diagnoses among the six workers with WRRS and airway inflammation 
and the 27 workers with CAS and airway inflammation. Only 13 (48%) of symptomatic workers with 
a FENO >40ppb had an asthma diagnosis: the figure for symptomatic workers with WRRS was lower 
(n=4, 66%). However, the presence CAS and airway inflammation was significantly associated with a 
diagnosis of current asthma: 34% of workers with current asthma had CAS and airway inflammation 
versus 6% of those without a current asthma diagnosis (Chi squared for difference 27.96, p <0.01).  
 
 
Figure 7: Data for six workers with WRRS and airway inflammation (FENO >40ppb) and 27 workers with CAS 
and airway inflammation, split by current asthma diagnosis. 
 Discussion 
Overall, asthma symptoms were common among woodworkers and were prevalent even at levels of 
exposure half the current UK WEL. Furthermore, current asthma (defined by ECRHS criteria) was 
present in one-sixth of the study population, twice the UK prevalence of one in 12 (1). Rates of 
specific IgE sensitisation were less than 1%. Atopy was a significant modifier of risk for asthma 
symptoms, WRRS, current asthma, and airway inflammation, even after controlling for confounders. 
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Furthermore, atopic woodworkers were at significantly increased risk for composite asthma indices 
including CAS+FENO >40 ppb and current asthma+FENO >40 ppb, with effect sizes exceeding those 
seen for atopic workers with CAS, current asthma, or airway inflammation alone.  
 
Wood dust exposure was associated with an increased risk of asthma symptoms, work-related 
respiratory symptoms, and asthma, although with no clear dose-response effect. Risk for airway 
inflammation was significantly higher among the low versus the lowest exposed, although a similar 
lack of dose-response effect was observed across exposure groups. Similarly, risk for composite 
asthma indices, including current asthma and airway inflammation, tended to be higher in all but the 
lowest exposed, although no dose-response was seen. In linear regression models, clear dose-
response relationships between current dust exposure, spirometry, or FENO were not observed.  
 
Set analysis revealed little overlap between airway inflammation and airflow obstruction in 
symptomatic workers. More workers were identified with CAS and airway inflammation than with 
CAS and airflow obstruction. The majority of those with respiratory symptoms and airway 
inflammation did not have an asthma diagnosis, suggesting FENO may be a useful addition to 
spirometry in identifying workers at risk of OA.  
3.4.1 Limitations 
There have been no epidemiological studies of asthma in British woodworkers for over 30 years. 
Wood dust exposure in the current population was relatively well controlled, with a 95% CI of 1.76-
1.99 mg/m3 and range of 0-5.44 mg/m3. Only 3% of workers had exposures above the UK WEL of 5 
mg/ m3 and only 17% above half the WEL of 2.5 mg/m3. As this study was powered to detect a 
significant difference at levels of exposure at the UK WEL, it may have lacked power to detect 
significant differences at lower levels of exposure. This is reflected in the finding of positive but not 
significant effect of exposure on symptoms, FENO and spirometry.  
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Cross-sectional studies of this kind are liable to exposure misclassification, as individual exposures 
vary over time and are influenced by other factors such as workforce, factory size, and health and 
safety practices (88). Exposure measurements in the current study were made over a single time 
period and therefore could not capture changes in day-to-day or week-to-week exposure. Exposure 
misclassification on polytomous scales may dilute effect sizes at higher exposures, and thus lead to 
error biases towards the null (142). Such non-differential errors may also reduce study power, 
reducing the ability of a study to find a significant result.  
 
Worksite recruitment may provide another source of bias within this study. As part of this research, 
worksites underwent a full occupational hygiene assessment. This may expose poor or even illegal 
practice where workers were placed at unacceptable risk. Since worksites were aware of this 
hygiene assessment prior to agreeing to take part, they may have avoided participation if they were 
concerned about exposing poor working practices and subjecting themselves to potential 
investigation. This is likely to have resulted in ‘better’ worksites participating in the study, falsely 
underestimating exposures within the whole population. Thus, the relatively high rates of 
respiratory symptoms and asthma reported in the current study may be an underestimate of those 
seen within the wider woodworking industry.  
 
It is possible that some of the respiratory symptoms reported in the current study were caused by 
irritant, not allergic, disorders. Woodworkers are at risk of exposure to irritant dusts, vapours, gases 
and fumes, as well as heat, cold, or moisture (52). Incorrectly attributing irritant symptoms to wood 
dust exposures may explain the absence of an exposure-response relationship observed between 
increasing wood dust exposure and respiratory symptoms. Furthermore, woodworkers may be 
exposed to respiratory allergens other than wood dust including isocyanates, formaldehyde, and 
epoxy resins (50). Exposure to allergens other than wood dust may lead to an increase in symptom 
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prevalence and an overestimation of work-related or respiratory symptoms. As respiratory 
symptoms and WRRS were less frequent than previously reported in a UK study, overestimation of 
symptoms in the current study is unlikely (104).  
 
Skin prick tests were not performed in the current study. As such, a total IgE above 100 IU/l was 
used to identify atopic workers. Since atopy had a significant modifying effect on risk of respiratory 
symptoms, asthma, and airway inflammation, misclassifying atopic workers could have a significant 
impact on the study results. An IgE over 100 IU/l IgE has been shown to have good positive 
predictive value but only modest negative predictive value for at least one positive allergy test in 
individuals with asthma symptoms (138). Compared to skin-prick tests, total IgE correlates better 
with the total allergic component of asthma and is more easily comparable between populations 
(143). Furthermore, there is evidence that total IgE may be useful in predicting atopy in individuals 
where a specific IgE for an inhalant is negative (144). Since rates of SIgE were low among the 
population, it is unlikely that this interfered with TIgE results.   
3.4.2 Respiratory symptoms are common among woodworkers even at low exposures 
Our observed mean wood dust exposures of 1.88 (1.76 – 1.99) mg/m3 were substantially lower than 
the 5mg/m3 WEL currently set out by HSE (24). Furthermore, although the data range was 5.44 
mg/m3, the 25% to 75% range lay close to the mean with 25% of exposure measurements exceeding 
the 2.33 mg/m3 75th percentile. Overall dust exposures were significantly lower than reported in the 
most recent UK hygiene data. In 2009, Galea et al. reported mean exposures of 5.2 mg/m3 among 
their study population (25). In their national survey of British woodworking sites, Black et al. 
reported 50% of workers were occupationally exposed to levels of wood dust higher than 2mg/m3 
(52). Despite lower exposures, symptoms, asthma, and airway inflammation were still prevalent in 
the current study, with rates comparing to recent reviews on asthma in woodworkers (82, 117). This 
 81 
suggests that symptoms and airway inflammation are still present at levels of wood dust exposure 
substantially lower than the current UK WEL.  
3.4.3 Work-related symptoms in British woodworkers 
One-in-ten workers in the current study reported WRRS. This prevalence is lower than has been 
reported in other studies where levels of exposure to wood dust were comparable (89, 91). 
Furthermore, we found workers in the highest exposure quartile to be at significantly reduced risk of 
WRRS versus those in the lowest exposure quartile (OR 0.16, 95% CI 0.03-0.81, p <0.05). Factors that 
may influence a reduction in symptom prevalence and exposure-response effect include an overall 
reduction in wood-dust exposure (25), increasing use of RPE (145), or relocation of symptomatic 
workers away from high exposures through either health surveillance or exit from the workplace 
(146). In addition, there is evidence to support underreporting of work-related symptoms among 
exposed workers. In their study of bakers, Gordon et al. found a proportion of workers who reported 
no work-related symptoms but were subsequently found to have OA (30). In their qualitative study 
of workers with OA, Bradshaw et al. described asthmatic workers reluctant to divulge symptoms to 
employees, citing fear of loss of earnings and job security as key explanatory factors (16). 
Underreporting of symptoms may explain the discrepancy between the lower rates of work-related 
symptoms in the current study and the recent national increase in cases of wood dust OA (27). 
 
Work-related nasal and ocular symptoms were more prevalent than WRRS in the current study and 
showed a stronger relationship with wood dust exposure. Prevalence was similar to a study of 
carpenters exposed to a variety of hard and soft woods, where Campo et al. reported nasal 
symptoms in 40% (147). Risk of work-related nasal and ocular symptoms was twice as high in the 
highest versus lowest exposure quartiles. Rhinoconjunctivitis may precede the onset of OA in up to 
50% of workers, and work-related upper airway symptoms are an important risk factor for 
developing disease (11). Higher rates of nasal and ocular symptoms in the current study may point 
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to individuals at risk of developing OA who should undergo enhanced health surveillance. 
Longitudinal studies are required to identify the proportion of such workers who go on to develop 
allergic airways disease.  
3.4.4 Asthma symptoms and evidence for a dose-response effect 
This study reflects findings elsewhere of an increased risk of asthma symptoms in woodworkers, 
with conflicting evidence for a dose-response effect (91, 92, 97, 107). Asthma symptoms were 
common among the current study population, with almost half of all workers reporting CAS. 
Prevalence of CAS did not differ across exposure groups, suggesting additional drivers for respiratory 
symptoms than wood dust exposure alone. As well as wood dust, workers in the current study were 
exposed to glues, solvents, paints, and resins, and a small number also worked with isocyanates. 
These substances are both irritant and allergenic and may explain the high rates of respiratory 
symptoms across exposure groups and the lack of a dose-dependent relationship. In addition, 
workers in the lowest exposure quartile were more likely to perform cleaning and maintenance 
tasks. Cleaning and maintenance are associated with higher single time-point exposures, but a lower 
overall exposure, compared with other job tasks. Previous research has suggested that intensity of 
exposure to wood dust may be as important as overall exposure when assessing risk for asthma, and 
individuals with multiple high-dose exposures are at increased asthma risk even if overall exposures 
are lower (148). Longitudinal studies are needed to understand how the nature of exposure modifies 
future asthma risk among woodworkers.  
 
Woodworkers have been previously been found to be at significantly increased risk of asthma 
symptoms compared to non-exposed controls (79, 107). However, evidence for increasing risk of 
asthma symptoms across exposure groups has been conflicting, particularly where wood dust 
exposure is low. Female, but not male, woodworkers have been previously reported to be at 
increased risk for chronic bronchitis at higher wood dust exposures (92). Since female 
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representation in the current study was very low (3%), analysis on the effects of gender was not 
possible. When considered alone, no clear dose-response relationship between wood dust exposure 
and CAS was found. However, when FENO was included in analysis, risk ratios became more positive, 
albeit non-significantly so. This suggests an effect of exposure on asthma symptoms that is more 
pronounced in the presence of eosinophilic airway inflammation.  
 
Two studies have found paradoxical relationships between wood dust exposure and CAS, with 
higher symptom risk in lower exposed groups (91, 97). The respective authors of these studies 
suggested variation in dust exposure and RPE use as potential reasons for the inverse dose-response 
effect. Overall levels of RPE use were high in the study population, with between 65% and 88% of 
participants saying they used RPE. Indeed, workers wearing RPE had significantly better FEV1 and 
FVC than those without. This could explain the relative reduction in symptoms observed among the 
current population. 
 
The lack of a clear dose-response relationship between wood dust exposure, symptoms and asthma 
may additionally be explained by a healthy worker effect (HWE). The HWE has been well described 
as a source of confounding among occupational epidemiological studies, particularly cross-sectional 
studies, where symptomatic or ‘unhealthy’ workers may be pre-selected out of higher exposure jobs 
or be relocated or removed from high exposure jobs as a result of ill-health (146, 149). In the current 
study, workers with WR wheeze had small but significantly less time exposed to VDGF, and similar 
trends were seen for WRRS and WR cough, supporting earlier symptom onset in workers at risk for 
occupational asthma (146). There was a non-significant trend towards younger age and fewer years 
in woodworking among workers in the highest exposure group in the current study. This may reflect 
recent entry to, or premature exit from, the workplace, providing further evidence for a possible 
HWE. Overall, workers had spent an average of eight years exposed to wood dust with a further 19 
years within the woodworking industry. Although OA can occur after many years exposure to an 
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occupational allergen, it is more common in the first years of exposure (11). The long tenure of the 
workers in the current study is further evidence for a HWE, where susceptible workers with fewer 
years’ exposure may have become symptomatic and exited the workplace prematurely. Cohort 
studies are required to further examine the HWE phenomenon among woodworkers, especially at 
lower exposure levels.  
3.4.5 Atopy modifies disease risk in woodworkers but specific sensitisation to wood dust 
is uncommon 
Atopic woodworkers were at significantly increased risk of WRRS, CAS, asthma, and airway 
inflammation in the current study. Risk ratios for CAS were 2.07 (95% CI 1.07 – 4.03), for WRRS 3.31 
(1.29 – 8.48), and for asthma 4.30 (1.87 – 9.88) in atopic versus non-atopic workers. In addition, 
atopic workers were at an increased risk of significant eosinophilic airway inflammation using 
BTS/SIGN criteria: risk ratio for FENO >40ppb was 2.58 (1.07-6.19) in atopic versus non-atopic 
workers. In contrast, atopy did not increase the risk for airflow obstruction, or modify relationships 
between exposure and FEV1 or FVC in linear regression models.  
 
The modifying effect of atopy in asthma risk among woodworkers has been described previously. In 
the current study workers were exposed to a variety of wood species, with the majority using a 
mixture of hard and soft woods. Atopic workers exposed to pine have been found to be at increased 
risk for asthma symptoms and airway hyperresponsiveness across exposure groups when compared 
with non-atopic workers (100). In contrast, studies in WRC asthma have suggested no modifying 
effect of atopy (150). However, although atopy increases the risk of OA, no direct causal link for OA 
among atopic individuals has been established (9). Prevalence of atopy in industrialised nations may 
be as high as 40%, with false positive rates as high as 20%, making pre-employment screening 
problematic for all workers (151). Only a small proportion of atopic workers will go on to develop 
disease, and there is currently no way to identify such individuals. As with any screening programme, 
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there must be benefit to the individual, and those benefits must be balanced with costs to society 
(35). Since pre-employment screening on the basis of atopy is unlikely to offer advantages to 
individual workers and is likely to be costly and possibly misleading, pre-selection of workers away 
from woodworking on the basis of atopic status should not be recommended. Further studies 
exploring gene-environment interactions in the causation of OA will help to define risk factors for 
developing disease and may help to inform surveillance for susceptible individuals at high risk of 
occupational diseases. 
 
Rates of SIgE sensitisation in the current study were less than 1%. Low IgE sensitisation rates have 
been reported among woodworkers, suggesting that sensitisation among woodworkers is not 
measurable with SIgE, that tests are not accurate enough, or that disease occurs through a non-IgE 
mechanism (77, 152). It is possible the sensitivity of the panel tests used was reduced as workers 
were exposed to a number of different wood species in varying quantities. However, even where 
bespoke tests to a specific allergen have been used in patients with confirmed OA, specific 
sensitisation rates have been low suggesting at least some patients do not raise an IgE response 
(109). Where positive SIgE results are present they may be helpful in supporting a diagnosis of wood 
dust OA, but the current findings suggest that negative tests are not helpful in identifying 
woodworkers at risk of, or suffering from, OA.   
3.4.6 Eosinophilic airway inflammation in woodworkers 
Overall, airway inflammation was common among the study population, with almost a fifth of 
workers having a FENO above 40ppb, the cut-point suggested by BTS/SIGN for significant eosinophilic 
airway inflammation (4). In the current study, mean FENO was 27.59 ppb (95% CI 24.18 – 31.00 ppb), 
and median FENO was 18.71 ppb with a 95th percentile of 85.44 ppb. In comparison, Torén et. al. 
reported a lower median FENO 18.2 ppb with a 95th percentile of 41.3 ppb from their population-
based study of European adults (153). Furthermore, the ATS/ERS guideline suggests a FENO above 
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25ppb is ‘predictive of eosinophilic airway inflammation, and that predictive values for FENO are 
higher than spirometry and peak flow and similar to bronchial challenge testing’ (46). Eighty (36%) of 
our study population had a FENO above 25 ppb, suggesting a significant number of workers with 
airway inflammation, even accounting for a false positive rate of 20% (154). The higher rates of 
eosinophilic airway inflammation observed in woodworkers may be a consequence of exposure to 
wood dust, may represent early allergic airways disease, or be a combination of the two.  Only one 
previous study has examined FENO in WRC workers with OA, finding no relationship with positive SIC 
(72). However, this is the first workplace study to examine FENO in a population of exposed 
woodworkers. Better understanding of the role of FENO in exposed, but not necessarily diseased, 
woodworkers will help to determine its use as a diagnostic and screening tool for OA in future.  
 
Interestingly, over half the workers with symptoms (either WRRS or CAS) and airway inflammation 
had no asthma diagnosis, suggesting a number of workers may have had undiagnosed airways 
disease. NICE have previously reported levels above 40 ppb as having a sensitivity of 78.6 - 88.3% 
and specificity of 82.6 - 89.5% for predicting asthma in symptomatic individuals (48). Furthermore, 
among symptomatic workers FENO provided additional information than spirometry alone. More 
symptomatic workers had airway inflammation than airflow obstruction (18% versus 8%), and there 
was very little overlap between airway inflammation and airflow obstruction suggesting the two 
tests provide information on distinct groups. Although some workers may have had falsely positive 
FENO, some may also have had early allergic airway disease. FENO has been demonstrated to identify 
at-risk groups of occupationally exposed apprentices, even when spirometry is normal (41, 124). The 
development of obstructive lung function is a late sign in OA and, when present, may be irreversible 
(14). Identifying individuals with OA early in their disease process is vital to ensuring good health 
outcomes for affected workers (11). This finding suggests there may be individuals identified by high 
FENO who are not picked up by spirometry and supports further exploration of FENO as a tool for 
identifying OA in wood-dust exposed workers.  
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Few studies have examined whether FENO is related to increasing exposure in workplace settings. In 
woodworkers, exposure was associated with an increased risk of eosinophilic airway inflammation, 
albeit without a clear dose-response. Risk ratios for FENO >40ppb were significantly raised in the low 
versus lowest exposed (3.43, 1.06-11.15), with positive, but non-significant effects seen in higher 
exposure groups. Since rates of both current and ever smoking, age, and atopy were not significantly 
different between exposure quartiles, this difference may be further explained by the HWE. 
Consensus is lacking to show FENO is useful in occupational settings (155). However, the current 
study demonstrates FENO to be as reproducible as spirometry with a similar number of people able 
to perform the required manoeuvre. Cohort studies are needed in order to examine how FENO 
relates to allergen exposures over time, and better understand its utility in a programme of health 
surveillance. 
3.4.7 Lung function in British woodworkers 
No significant differences were found in lung function across exposure groups. Although post-
bronchodilator spirometry was not performed, the 4% prevalence of obstructive lung disease 
(FEV1/FVC <LLN) reported here is lower than the European prevalence range of 9-26% recently 
reported by Blanco et al (156). In contrast, rates of current smoking among woodworkers were 26%, 
comparable to the recent national average for men (157). The current study population was younger 
than those included in the COPD prevalence studies, which may account for the lower rates of 
airflow obstruction. Interestingly, positive associations with wood dust exposure were found for 
both FEV1 and FVC, reflecting findings elsewhere (106, 107). The reduced prevalence of airflow 
obstruction and positive associations with FEV1 and wood dust exposure is likely to be a further 
example of a healthy worker effect.  
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The most significant effect on lung function in the current study was the use of RPE, an effect even 
more remarkable considering the relatively low exposures recorded. Workers using RPE had an FEV1 
240mls higher than those who did not (unstandardised β=240.36mls, 95% CI 68.59-412.12). Properly 
used RPE is an important part of the hierarchy of controls, and can help to reduce individual 
exposures after appropriate risk assessment and elimination has taken place (23). Conversely, RPE 
may not be available in workplaces with poorer health and safety practices; workers may not use it 
due to lack of education about its importance or beliefs about its effects; or it may not be tolerated 
in people with pre-existing respiratory disease where symptoms make its use more difficult (158). 
Further studies are needed to explore in more detail how and why RPE is used in workplaces, its 
impact on personal exposure, and its influence on long-term lung function decline in woodworkers.  
3.4.8 Summary 
Current asthma symptoms are common among woodworkers at levels of wood dust exposure 
significantly lower than the current UK WEL, raising the possibility of an allergic, rather than irritant, 
mechanism. Among woodworkers, atopy was the most significant predictor of current asthma 
symptoms, asthma, and airway inflammation. Rates of SIgE sensitisation to wood dust were very 
low, suggesting specific sensitisation in woodworkers is not measurable by routinely available IgE 
tests, and allergy in such populations may not be IgE mediated. Eosinophilic airway inflammation 
was common among the study population and provided additional information on asthma risk to 
spirometry alone in symptomatic workers. Workers in higher exposure categories tended to be at 
increased risk of airway inflammation and asthma, although a clear dose-response was not 
observed. A significant proportion of symptomatic workers with airway inflammation reported no 
asthma diagnosis, suggesting a possible role for the measurement of eosinophilic airway 
inflammation in health surveillance. Further exploration of the utility of FENO in LMW exposure 
environments is required to better understand how eosinophilic airway inflammation relates to 


















4 Respiratory symptoms, airway inflammation, and asthma in British 
foundry workers 
 Background 
4.1.1 Definition and history of the foundry process 
The casting of metal items dates back thousands of years. The earliest records of copper castings 
date from ancient Mesopotamia in the period between 4000 and 3000 B.C (159). The addition of tin 
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to create bronze alloys enabled ancient civilisations to cast metals for a wide variety of objects 
including weapons, jewellery and ornaments.  
 
Figure 8: Bronze age spear tip mould, France. Photograph by Rama, Wikimedia Commons, Cc-by-sa-2.0-fr 
[CeCILL (http://www.cecill.info/licences/Licence_CeCILL_V2-en.html) or CC BY-SA 2.0 fr 
(https://creativecommons.org/licenses/by-sa/2.0/fr/deed.en)], from Wikimedia Commons 
Iron castings were first produced in China around 1000 B.C., and by the 1500s iron-smelting 
foundries were common. The foundry industry was rapidly industrialised in the 19th Century 
following the invention of the Bessemer process in Sheffield, which revolutionised the oxidization of 
pig iron and allowed mass production of steel for the first time (160). Today the foundry industry 
employs around 17,000 people in the UK, with an annual turnover of £2.2 billion (161). 
 
Most foundries employ a similar process for casting metal items (Figure 9) (162). Pattern making is 
the first part of the process: patterns for items to be cast are made from wood, metal, wax, or 
plastics. Subsequently, moulds and cores are made. Sand (or greensand) was historically used for 
moulding, but increasingly new moulding materials such as urethane or phenol binder systems are 
employed due to their ease of use and reuse and their improved casting results. A wide variety of 
metals are used for melting and pouring. Castings are then ‘knocked-out’ of their moulds and cooled 
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and mould materials are reclaimed. Finally, finishing processes including fettling, shot blasting, and 
welding may be employed before castings are cleaned and coated ready for use. The foundry 
industry serves sectors including transport, energy, medical, defence, and aerospace, involving a 




Figure 9: Process map showing the main stages of the foundry process 
4.1.2 Exposure to respiratory hazards and asthma risk in foundry work 
Foundry work may involve exposure to a number of respiratory allergens (Figure 10). Urethane resin 
moulding systems can release isocyanates, most commonly methyldiisocyanate (MDI), during 
thermal degradation (163). Isocyanates are among the commonest causes of OA in many 
industrialised countries including Great Britain (26), France (164), Belgium (20), and Canada (21). 
Reported annual incidence in these studies varies between 6 and 15% of all cases of OA. 
Sensitisation to a number of volatile isocyanate species including toluene diisocyanate (TDI), 




Figure 10: Infographic showing the main parts of the foundry process associated with exposure to 
respiratory hazards. Photographs used with permission from the Health and Safety Executive British Survey of 
Foundry workers 2017. 
Alkali-phenolic binder systems containing a phenol-formaldehyde resin are also used in foundries, 
leading to formaldehyde release during the heating process (166). Formaldehyde has been identified 
as an occupational asthmagen in a number of settings including healthcare work (167), manufacture 
of wooden products (168), plastics (169), and clothing (170). Older furan moulds or cores used 
furfuryl alcohol (FFA), which has also been shown to be a respiratory sensitiser (171). Exposure to 
allergenic metals such as nickel sulphate, hexavalent chromium, and cobalt may also occur during 
parts of the finishing process such as shot-blasting or welding, and metal particulate may be present 
in ferrous or non-ferrous foundry particulate (162, 172). 
  
Though isocyanates and formaldehyde are both well-documented in their association with asthma, 
studies in foundry workers are limited in number. Foundry workers with at least one WRRS have 
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been found to have higher rates of histamine reactivity compared with non-exposed workers (173). 
In foundry workers exposed to MDI, workers with higher MDI exposures were more likely to have 
asthma symptoms and had a 50ml cross-shift decrease in FEV1 compared to non-exposed workers 
(174). More recently foundry workers have been found to be at increased risk of OA (defined by an 
onset of asthma symptoms after first foundry exposure, work-related symptoms, and PEF variability 
of at least 20%) versus non-exposed workers (175). Data from cohort studies are scarce: a single 
study of foundry workers, conducted in Scandinavia at lower levels of allergen exposure, 
demonstrated a high prevalence of nasal and ocular symptoms but no significant difference in cross-
shift lung function between the two exposure groups (176).  
 
Additional malignant and non-malignant respiratory diseases are reported in excess in foundry 
workers, who are exposed to hazards other than respiratory allergens. Respirable crystalline silica 
(RCS) exposure is common in foundries, and silica-related disease such as COPD, silicosis, lung cancer 
and tuberculosis is more prevalent in foundry workers (177-179). Cadmium exposure has also been 
reported in foundry workers leading to an increased risk of COPD (180). Lung cancer is more 
prevalent among foundry workers, even after accounting for smoking, attributed to silica, 
polyaromatic hydrocarbon and other carcinogen exposure (181). Additional irritant symptoms may 
be caused by benzene, toluene, carbon monoxide, foundry particulate and fume, as well as extreme 
heat or dryness (162).  
4.1.3 Fractional exhaled nitric oxide in foundry workers 
FENO is increasingly used in the diagnosis and treatment of asthma (48). Its use is attractive in 
occupational settings as an adjunct to spirometry in health surveillance, where it could provide 
additional information to lung function in at-risk workers and help to diagnose workers with asthma 
earlier in their disease process (124). Some studies have shown an increase in airway inflammation 
following exposure to isocyanates (182, 183). Even fewer studies have reported eosinophilic airway 
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inflammation in association with formaldehyde exposure. A case-report of occupational eosinophilic 
bronchitis due to formaldehyde has been published (184), but case-reports for OA due to 
formaldehyde have been less strongly associated with eosinophilic airway inflammation (185, 186). 
Fewer population-based studies looking at airway inflammation in isocyanate or formaldehyde 
workers have been published. One study has reported increasing exposure to foundry dust is 
associated with increasing airway inflammation (187). Only one paper has demonstrated an increase 
in FENO in children following higher domestic exposure to formaldehyde (188).  
 
Although foundry workers may be exposed to a number of well-documented sensitisers such as 
isocyanates and formaldehyde, few studies have previously considered the relationships between 
FENO and allergen exposure in foundry populations. In addition, recent data on respiratory health in 
foundry workers is lacking, with few studies exploring the relationship between foundry exposures 
and asthma symptoms. This study aims to evaluate the prevalence of respiratory symptoms, airway 
inflammation, asthma, and abnormal lung function in foundry workers, and to understand 
relationships between these key variables and allergen exposure. 
 
This study was reviewed and approved by the NHS Health Research Authority National Research 
Ethics Committee: North West – Greater Manchester East (REC reference 12/NW/0048).  
 
 Methods 
Data for foundry workers was collected by CWH between 2011 and 2014. As part of the longitudinal 
project and by way of contribution to the data described here, I: constructed a database; coded, 
cleaned and refined the data; co-developed a job-exposure matrix (JEM); designed and undertook an 
analysis plan; and conducted further recruitment visits to foundries. This represents the first analysis 
of this data, which has not yet been reported elsewhere. 
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4.2.1 Worker recruitment 
British foundries were recruited to a longitudinal study through the Cast Metals Federation (CMF). 
CMF is the main industry body for the UK foundry industry and represents a large group of both 
ferrous and non-ferrous foundries. An occupational hygienist from HSE worked with the CMF to 
identify foundry sites employing processes with a high potential for exposure to respiratory hazards. 
These exposure scenarios included:  
• whether the foundry was ferrous or non-ferrous (specifically with exposure to iron, steel, or 
aluminium);  
• the binder system used to create cores and moulds (greensand, furan, urethane, or alkali 
phenolic); 
•  and whether the foundry was jobbing or automated (162).  
The study was publicised to all attendees at a national health and safety meeting conducted by CMF 
and HSE. Interested worksites were given information regarding the study and followed up with a 
telephone call from the study team (Appendix C). Prior to data collection, the study was explained in 
detail to managers, and sites received a recruitment visit by one of the study team to directly discuss 
the research with employees.  
4.2.2 Power calculation 
A Monte Carlo-based power calculation was performed as part of the longitudinal Health SRP 
examining lung function decline in foundry workers. Individual three-year exposures were simulated 
using a random effects model based on data from Casting Technologies International published in an 
HSE report in 2009 (189). This is a large dataset with over 9000 measurements from 245 foundries: 
mean respirable dust exposure in the dataset was 1.7 mg/m3, with a between-company SD of 0.58 
(log scale) and a within-company SD of 0.95 (log scale). Assuming a normal FEV1 range of 100 ± 20% 
predicted and a within person SD for spirometry of 100ml (190), a cross-sectional sample of 400 and 
a longitudinal sample of 300 people was estimated to be able to detect a loss of 10.5 ml/yr per 
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mg/m3 increase in respirable dust exposure with 80% power using a two-way significance of 5% 
(130). Similar losses in FEV1 have been observed in construction and wood workers at risk of asthma 
(108, 190). 
4.2.3 Study population 
All exposed workers over the age of 16 employed in any part of the foundry process were invited to 
take part. This included workers with indirect exposures such as maintenance or cleaning. Visits 
were conducted during all working shifts to ensure the maximum number of workers were able to 
participate. Workers were excluded if they worked entirely outside the foundry process in an 
unexposed job (for example, in a wholly office-based role).  
4.2.4 Respiratory questionnaire 
Each worker was administered an interviewer-led questionnaire, including detailed information 
about current and previous jobs, change of jobs due to vapours, dusts, gases, or fumes (VDGF) 
exposure, and use of RPE as previously described in section 3.2.4 (Appendix C). Self-reported current 
and past respiratory illnesses such as asthma, COPD, silicosis, and lung cancer were also 
documented.  
4.2.5 FENO and spirometry measurement 
All workers were invited to undergo FENO and spirometry measurement, as described previously in 
section 3.2.5, according to ATS/ERS guidelines (46, 133). 
4.2.6 Exposure assessment of respiratory sensitisers  
A detailed assessment of foundry exposures was undertaken by HSE occupational hygienists. 
Individual methods of measurement and exposures across surveyed sites are reported in detail 
elsewhere (162). In brief, respirable and inhalable ferrous foundry particulate or, in non-ferrous 
foundries, foundry dust (hereafter referred to as foundry particulate or FP); respirable crystalline 
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silica (RCS); volatile organic compounds (VOCs) including FFA and formaldehyde; isocyanates; metal 
dust and fume; and toluene dyes; were measured in surveyed foundries. Air sampling was carried 
out in accordance with the MDHS 14/4 (134). In addition, a full assessment of foundry processes, 
including the use of local exhaust ventilation (LEV) and personal protective equipment (PPE) was also 
undertaken.  
 
Potential respiratory allergens were identified based on publications of respiratory allergy in foundry 
workers. Isocyanates, formaldehyde, FFA, chromium VI (CrVI), cobalt, and nickel sulphate were all 
considered as possible allergens (191). FFA, nickel sulphate, cobalt and CrVI were either not utilised 
in recruited foundries or had levels below the limit of detection, so were not considered significant 
allergens in the current study (162). As such, isocyanates and formaldehyde were treated as the 
main foundry allergens of interest in the current study.  
4.2.7 Foundry-specific job-exposure matrix  
A foundry-specific job-exposure matrix (JEM) was created alongside an HSE statistician and an 
experienced HSE occupational scientist with an interest in foundry work. The JEM incorporated:  
• current exposure to bonding systems containing isocyanate, formaldehyde, or both, as 
determined by the hygiene assessment at each worksite;  
• current foundry process undertaken by each individual worker as reported within the health 
study and evaluated by the hygienist;  
• empirical airborne exposures measurements made at each participating site by HSE 
occupational hygienists.  
Participants worked in one of 12 foundry processes (Table 12). These processes were grouped into 
four common work areas, based on the stage of the foundry process (Figure 9):  
1. moulding (including mould or core making and sand reclamation);  
2. casting (furnace work; melting and pouring of metals);  
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3. finishing (including knockout, fettling, shot blasting and any subsequent welding);  
4. general foundry work (including housekeeping processes such as cleaning and maintenance).  
 
Table 12: List of 12 foundry processes evaluated in the current study, grouped by common work area. 
Moulding Casting Finishing General foundry work* 
Moulding Casting Knockout Foundry work 
Core making 
Furnace work: ferrous 
metals 
Fettling 








   Pattern making 
* Foundry work included cleaning, general maintenance, labouring and other ancillary jobs. 
 
Weighted exposure estimations were used to assign individual exposures to each of the study 
participants (88). Eight-hour TWA measurements for isocyanates and formaldehyde captured data 
from the 12 foundry tasks undertaken by participants (Table 12). Data were not normally distributed 
so were log-transformed for further analysis. For both formaldehyde and isocyanate exposure, task-
specific averages were estimated based on the mean task-specific 8-hr TWA across the eight sites. 
Similarly, site-specific averages were estimated based on the mean site average across all tasks at 
each of the eight participating worksites. Individual exposures were then estimated for both 
isocyanate and formaldehyde using the product of the task-specific average and the site-specific 
average and expressed as a ratio of overall mean exposures. Where the number of workers 
performing a particular task at an individual site was less than five, exposures were assigned using 
the mean exposure for that particular task taken across all work sites.  
Lowest, middle, and highest exposure categories were determined a priori for the study population 
by stratification of isocyanate and formaldehyde exposure into tertiles. First, formaldehyde 
exposures were ranked, with the lowest tertile being lowest exposed, middle tertile medium 
exposed, and highest tertile highest exposed. Individuals who were not exposed to formaldehyde (in 
other words where formaldehyde was not used at that particular worksite) were assigned missing 
values. The same process was repeated for isocyanate exposure, with workers not exposed to 
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isocyanates assigned missing values. A four-by-four contingency table was used to establish tertiles 
of exposure for the whole population (Figure 11). Workers with low-low or low-missing exposures 
were designated the lowest exposed. Workers with medium-low, medium-medium, or medium-
missing exposures became the medium exposure category. Workers with high-medium, high-high, 
or high-missing exposures were included in the highest exposure category. 
 
 
Figure 11: Four-by-four contingency table used to establish an overall exposure category for the 351 foundry 
workers in the study. Workers were exposed either to formaldehyde, isocyanates, or both. 
4.2.8 Definitions 
Respiratory symptoms evaluated included cough, wheeze, breathlessness, and chest tightness. 
Work-related nasal or ocular symptoms, WRRS, CAS, ever, and current asthma were defined as 
previously described in section 3.2.9. Atopy was defined as a self-reported history of eczema, hay 
fever, or asthma. Data previously reported in section 3.3.2 demonstrated a significantly higher TIgE 
in woodworkers with a history of allergy defined by self-report. High FENO was defined as a FENO 
above 40 parts per billion (ppb) and LLN criteria were used for abnormal spirometry, as previously 
described in section 3.2.9.  
4.2.9 Statistical analysis 
Demographic data was presented as means ± SD where data was continuous, and as numbers with 
percentages for categorical data. Univariate analyses were conducted across the three exposure 
tertiles for demographic, exposure, and health data, using independent t-tests, ANOVA and Chi-
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squared testing. Non-normally distributed data were analysed using Mann-Whitney U testing. 
Where FENO and spirometry values did not meet reproducibility criteria they were excluded from 
analysis. FENO data were not normally distributed so expressed as both arithmetic and geometric 
means. 
 
Multiple logistic regression was used to evaluate associations between exposure to respiratory 
sensitisers (formaldehyde and isocyanates) and the six dependent variables of interest: any WRRS; 
CAS; current asthma; FENO >40 ppb; FEV1 <LLN, FVC <LLN; and FEV1/FVC <LLN, as per section 3.2.10. 
The lowest exposure category was used as the reference group. Models were adjusted for age, sex, 
smoking, RPE use, height, and atopy (for FENO models). Respirable FP was included as an obligate 
confounder in models as a function of overall dust exposure across worksites (162). 
 
Linear regression modelling was used to examine relationships between exposure to sensitisers, 
FENO, and spirometry. Since FENO data were not normally distributed, data were log-transformed and 
back transformed into GMR FENO, as described in section 3.2.10. Ratios for FENO were reported 
separately per 1 µg/m3 in isocyanate exposure and per 1mg/m3 increase in formaldehyde exposure, 
in accordance with the standard units of measurement in the UK (24). Models were adjusted for age, 
smoking, sex, height, RPE use, atopy (for FENO), and respirable FP.  
 
Linear regression models were constructed to explore a potential healthy worker effect among 
foundry workers, as described in section 3.2.10. Years of exposure to VDGF were used as the 
dependent variable to account for movement in jobs within and between foundries. Data were 
adjusted for age, ever smoking, atopy, RPE, FP, and height.   
 
Relationships between workers with CAS or WRRS, FENO >40ppb and airflow obstruction (FEV1/FVC 
<LLN) were explored using intersecting Venn diagrams as described in section 3.2.10. Only significant 
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variables were reported. A p value of less than 0.05 was considered statistically significant. All 
statistical analyses were performed using IBM SPSS Statistics v23 (IBM, New York, 2015).  
 Results 
4.3.1 Study population 
Eight foundries agreed to take part in the study, employing a total of 510 workers. Three-hundred-
and-fifty-one workers participated, with a participation rate of 69%. Reasons for non-participation 
included individual workers declining, unavailability due to shift work, and failure to attend the study 
appointment. No demographic data was available on those who declined to participate.  
 
Seven foundries were ferrous with only one non-ferrous foundry included. Exposure to 
formaldehyde binders was more common among the study population. In total, 309 workers were 
potentially exposed to formaldehyde binder systems and 186 were potentially exposed to 
isocyanate binder systems (Table 13). Three foundries (including a total of 165 workers) used only 
alkali-phenolic (formaldehyde containing) binders, two foundries (42 workers) used only urethane 
(isocyanate) binders, and a further three foundries (144 workers) used both binder systems.  
Table 13: Number of workers exposed to either NCO-based, formaldehyde-based, or both NCO and 
formaldehyde-based binder systems by employment in either ferrous or non-ferrous foundries 
 




Both systems used  
Ferrous foundry 
Foundry A: n=29 
Foundry B: n=13 
Foundry E: n=64 
Foundry H: n=93 
Foundry C: n=38 
Foundry D: n=83 
Foundry F: n=23 
Non-ferrous foundry  Foundry G: n=8  
Total N=42 N=165 N=144 
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4.3.2 Allergen exposure in foundry workers 
Mean exposure to formaldehyde across the study population was 0.14 (0.11) mg/m3, median 
exposure was 0.10 mg/m3 with a 5th and 95th centile of 0.02 and 0.16 mg/m3 respectively (Table 14). 
Mean exposure to isocyanates was 1.61 (1.44) microgrammes/m3 (µg/m3), median exposure was 
1.31 µg/m3, with a 5th and 95th centile of 1.10 and 1.52 µg/m3 respectively. 
 
Following exposure stratification, 76 people were in the lowest exposure tertile, 124 in the medium 
exposure tertile, and 151 in the highest exposure tertile (Table 14). Mean exposures for 
formaldehyde and isocyanates were, respectively: 0.05 mg/m3 and 0.12 µg/m3 in the lowest 
exposed; 0.09 mg/m3 and 0.70 µg/m3 in the medium exposed; and 0.24 mg/m3 and 2.90 µg/m3 for 
the highest exposed. For formaldehyde-exposed workers, mean exposures were almost double in 
the medium compared to the lowest exposure group, and exposures in the highest exposure group 
were five times those in the lowest exposure group.  
 
For isocyanate-exposed workers, mean exposures were six-times higher in the medium compared to 
the lowest exposures, and highest exposures were 24 times the lowest exposures. All exposures 
were an order of magnitude below the current UK WEL of 2.5 mg/m3 for formaldehyde and 20 
µg/m3 for isocyanates: maximum formaldehyde exposure reached one-fifth of the WEL and 
maximum isocyanate exposure reached one-third of the WEL. Respirable FP exposures increased 
across tertiles of formaldehyde exposure but were lower in the highest exposure tertile for 
isocyanate exposure. All respirable FP exposures were lower than the current WEL of 4mg/m3. 
 
Table 14: Range of formaldehyde and isocyanate exposures in the lowest, medium, and highest exposure 
groups, with respirable FP exposure in each tertile. The current UK 8-hr TWA WEL for isocyanates is 20 µg/m3, 
and for formaldehyde is 2.5 mg/m3. Respirable FP was measured in mg/m3. 
 Formaldehyde exposed, mg/m3 (SD) Isocyanate exposed, µg/m3 (SD) 
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89 0.05 (0.02) 0-0.07 
1.22 
(1.48) 





129 0.09 (0.03) 0.071 - 0.15 
1.91 
(2.76) 











62 2.90 (0.94) 2.25-6.36 
0.46 
(0.49) 
Total (n=351) 309 0.14 (0.11)   186 1.61 (1.44)   
 
4.3.3 Population demographics 
Table 15 shows the demographic characteristics of the study population across exposure tertiles. Of 
the 351 participants, 99% were men with a mean age of 42.3 (SD 12.4) years and 8.9 (9.9) years 
working in their current role. There were no differences in age, smoking history, sex, and job 
duration across the three exposure categories. Workers in the highest exposure category were more 
likely to use RPE than those in the medium exposure category and had worked longer in the foundry 
industry compared to those in lower exposure groups. As expected, exposure to formaldehyde and 





Table 15: Study characteristics of 351 British foundry workers, stratified by exposure tertile 









Male, n (%) 76 (100) 124 (100) 150 (99) 350 (99) 
Current smokers, n (%) 24 (32) 33 (27) 39 (26) 96 (27) 
Ever smoked more than 
one pack year, n (%) 
40 (53) 60 (48) 78 (52) 178 (51) 
Ethnicity, Caucasian (%) 73 (96) 121 (98) 148 (98) 342 (97) 
Age, years (SD) 42.76 (11.48) 40.99 (12.64) 43.04 (12.69) 42.3 (12.4) 
BMI, kg/m2 (SD) 28.86 (4.38) 28.16 (4.42) 28.10 (4.50) 28.29 (4.44) 
Height, cm (SD) 176.61 (5.94) 175.77 (6.15) 176.55 (6.74) 176.29 (6.36) 
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Exposure 
Moulding, n (%) 13 (4) 31 (9) 56 (16) 100 (28) 
Casting, n (%) 7 (2) 5 (1) 5 (1) 17 (5) 
Finishing, n (%) 35 (10) 37 (11) 28 (8) 100 (28) 
General foundry work, n 
(%) 
21 (6) 51 (15) 62 (18) 134 (38) 
Wears RPE, n (%) 60 (79) 81 (65) 124** (82) 265 (76) 
Time spent in current 
job, years (SD) 
9.45 (10.54) 8.56 (9.63) 8.86 (9.78) 8.9 (9.9) 
Total time worked in 
foundry, years (SD) 
12.33 (11.83) 14.00 (12.19) 16.64 (13.25)* 14.76 (12.66) 
Ever left job due to 
health, n (%) 
0 (0) 2 (2) 1 (1) 3 (1) 
Mean exposure to 
formaldehyde, mg/m3 
(SD) 
0.05 (0.02) 0.09 (0.03) 0.24 (0.11)** 0.14 (0.11) 
Mean exposure to 
isocyanate, µg/m3 (SD) 
0.12 (0.05) 0.70 (0.54) 2.91 (0.94)** 1.61 (1.44) 
Mean exposure to 
respirable FP, mg/m3 
(SD) 
1.20 (1.55) 2.21 (2.99) 2.18 (4.86)** 1.98 (3.73) 
*p <0.05, **p <0.01.  
RPE = respiratory protective equipment. Lowest exposure group = those with low/low or low/missing exposures from JEM. 
Medium exposure group = medium/medium or medium/missing exposures in JEM. Highest exposure group = high/high or 
high/missing exposures in JEM.  
 
Respiratory symptoms, WRRS, CAS, asthma, and atopy across exposure tertiles are presented in 
Table 16. Over a third of workers (40%) reported at least one respiratory symptom. CAS were also 
common, reported by 37%. Prevalence of respiratory symptoms across the whole population varied 
between 12% (chest tightness without cold) to 27% (wheeze). A third (35%) of the study population 
were atopic. Nineteen (5%) of the study population were taking an inhaled corticosteroid, with no 
significant difference across exposure groups. A self-reported diagnosis of asthma was reported by 
14%, with current asthma by ECRHS criteria less prevalent at 9%. Six workers (2%) self-reported a 
diagnosis of COPD. No workers reported a diagnosis of silicosis.  
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Table 16: Respiratory symptoms, work-related respiratory symptoms, atopy, and asthma across the three 
exposure tertiles in 351 British foundry workers 









Atopy, respiratory symptoms and asthma 
Atopy, n (%) 26 (34) 54 (44) 43 (28)* 123 (35) 
Cough, n (%) 20 (26) 31 (25) 29 (19) 80 (23) 
Chest tightness without cold, n (%) 15 (20) 14 (11) 14 (9) 43 (12) 
Wheezing without colds, n (%) 13 (17) 24 (19) 36 (24) 73 (21) 
Shortness of breath, n (%) 17 (22) 22 (18) 17 (11) 56 (16) 
More than one respiratory symptom, n (%) 30 (39) 55 (44) 56 (37) 141 (40) 
Ever diagnosed with asthma, n (%) 12 (16) 15 (12) 23 (15) 50 (14) 
Current steroid inhaler use, n (%) 4 (5) 7 (6) 8 (5) 19 (5) 
Current asthma, n (%) 7 (9) 11 (9) 14 (9) 32 (9) 
Current asthma symptoms, n (%) 33 (43) 48 (39) 47 (31) 128 (37) 
Work-related respiratory symptoms 
Changed job due to breathing problems, n 
(%) 
0 (0) 2 (2) 1 (1) 3 (1) 
Work-related cough, n (%) 14 (18) 15 (12) 16 (11) 45 (13) 
Work-related chest tightness, n (%) 2 (3) 4 (3) 7 (5) 28 (8) 
Work-related wheeze, n (%) 7 (9) 11 (9) 9 (6) 27 (8) 
Work-related breathlessness, n (%) 0 (0) 0 (0) 1 (1) 1 (1) 
Work-related eye irritation, n (%) 14 (18) 17 (14) 20 (13) 51 (15) 
Work-related nasal irritation, n (%) 9 (12) 16 (13) 31 (21) 56 (16) 
WRRS, n (%) 17 (22) 26 (21) 26 (17) 69 (20) 
More than one work-related eye or nasal 
symptom, n (%) 
19 (25) 23 (19) 41 (27) 83 (24) 
*p<0.05, **p<0.01.   
Atopy = history of allergy (rhinitis, eczema or asthma). Lowest exposure group = those with low/low or low/missing 
exposures from JEM. Medium exposure group = medium/medium or medium/missing exposures in JEM. Highest 
exposure group = high/high or high/missing exposures in JEM. 
 
Prevalence of individual WRRS varied from 1% (work-related breathlessness) to 13% (work-related 
cough). Work-related chest tightness and work-related wheeze were reported by 8% respectively. 
Overall, one-fifth (n=69) reported at least one WRRS. Work-related nasal or ocular symptoms were 
reported by 24%. Less than 1% (n=3) of workers reported ever having to change their job due to 
breathing problems.  
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Workers in the highest exposure group were significantly less likely to be atopic than those in the 
medium exposure group (28% versus 44%, p=<0.05, Table 16). Respiratory symptoms including 
cough, chest tightness without cold, wheeze, and breathlessness were all more common among the 
lowest exposed group, but not significantly so. There was no significant difference between any 
work-related symptom, CAS, or asthma between exposure groups. 
 
FENO and spirometry data for the study population are presented in Table 17. Valid FENO readings 
were obtained in 297 workers (85%). One-quarter (n=75) of the study population had a FENO above 
40ppb. Valid spirometry was performed in 313 (89%) participants. Mean percent predicted FEV1, 
FVC, and PEF were 98.58 (13.71), 103.46 (12.29), and 108.42 (17.37) respectively. LLN criteria for 
FEV1 were met in 6% of workers, for FVC in 2%, and for FEV1/FVC in 7%. 
 
GM FENO was significantly higher in the medium exposure group compared to the highest exposure 
group (25.70 versus 16.98 ppb, p<0.01). Workers in the medium exposure group were significantly 
more likely to have a FENO above 40 ppb compared to other groups (34% versus 20% in the lowest 
and 12% in the highest group, p <0.01). Absolute and percent predicted FEV1, FVC, and PEF did not 
differ significantly between groups. However, medium exposed participants were significantly more 
likely to have an FEV1 <LLN versus the lowest exposed.  
 
 
Table 17: FENO and spirometry across the three exposure tertiles in 351 British foundry workers 








Fractional exhaled nitric oxide a 
AM FENO, ppb (SD) 28.7 (30.64) 34.36 (24.30)* 24.25 (21.93) 
29.04 
(25.39) 
GM FENO, ppb (SD) 17.78 (2.81) 25.70 (2.29)** 16.98 (2.51) 
20.42 
(2.51) 
FENO above 40ppb, n (%) 15 (20) 42 (34)** 18 (12) 75 (25) 
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Spirometryb 
Mean FEV1, mls (SD) 3715.8 (680.77) 3749.8 (751.92) 3849.9 (680.49) 
3787.20 
(705.75) 
Mean FVC, mls (SD) 4892.5 (804.65) 4823.4 (794.26) 4856.6 (800.83) 
4852.50 
(797.17) 
Mean PEF, mls (SD) 570.74 (94.74) 591.86 (108.37) 593.38 (93.23) 
592.30 
(98.75) 
Mean % predicted FEV1 
(SD) 
96.49 (12.18) 96.81 (15.95) 100.95 (12.13) 
98.58 
(13.71) 
Mean % predicted FVC 
(SD) 
103.97 (12.60) 102.39 (13.44) 104.06 (11.19) 
103.46 
(12.29) 
Mean % predicted PEF 
(SD) 
108.20 (17.76) 107.63 (18.99) 109.14 (15.89) 
108.42 
(17.37) 
FEV1 < LLN, n (%) 4 (6) 12 (11)* 3 (2) 19 (6) 
FVC < LLN, n (%) 1 (2) 4 (4) 1 (1) 6 (2) 
FEV1/FVC < LLN, n (%) 6 (9) 11 (10) 4 (3) 21 (7) 
*p<0.05, **p<0.01. a: Valid FENO obtained in 297 (85%) workers.  b: Valid spirometry obtained in 313 (89%) 
workers. Lowest exposure group = those with low/low or low/missing exposures from JEM. Medium exposure 
group = medium/medium or medium/missing exposures in JEM. Highest exposure group = high/high or 
high/missing exposures in JEM. 
 
Mean arithmetic mean (AM) FENO was 29.04 (25.39), with mean geometric mean (GM) FENO 20.42 
(2.51). Median FENO was 22.0 ppb and was significantly lower in current versus ex- or never smokers 
(Figure 12). Median FENO in current smokers was 12.50 ppb (5th and 95th centile 1.47 and 72.90 ppb 
respectively) versus 25.67 ppb (5th and 95th centile 6.27 and 83.47 ppb) in ex- or never smokers 
(Mann-Whitney-U for difference <0.01).  
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Figure 12: Median FENO across the study population, stratified by current versus former or never smokers. 
4.3.4 Respiratory symptoms, work-related respiratory symptoms, and asthma across 
exposure groups 
Table 18 shows data from logistic regression models for respiratory symptoms, WRRS, CAS, and 
asthma. There was no clear increase in risk for any respiratory symptom or WRRS across exposure 
tertiles. Workers in the highest exposure tertile were at increased risk of work-related nasal 
symptoms, though this was not significant (OR 2.13, 95% CI 0.93 – 4.87, p 0.07). Ever smoking was 
associated with an increased risk of any respiratory symptom and any upper airway symptom (OR 
for any respiratory symptom 2.28, 1.46 – 3.57, p=0.01 and for any upper airway symptoms 1.66, 
1.05-2.6, p=0.03). Ever smoking was also significantly associated with an increased risk of WRRS (OR 
2.04, 1.17-3.55, p=0.01). Atopic workers were twice as likely to report any upper respiratory 
symptom than non-atopic workers (2.05, 1.27-3.31, p=0.01).  
 
There was a tendency for workers in the highest exposure category to have a lower risk for CAS, 
although this did not reach statistical significance (0.59, 0.33-1.06, p=0.08). Ever smokers were twice 
as likely to report CAS than those who had never smoked (OR 2.22, 1.4-3.51). Risk for either self-
reported or current asthma did not vary significantly across exposure tertiles. In contrast, atopy 
significantly increased the risk for both self-reported (OR 4.31, 2.22-8.36, p <0.01) and current 
 109 
asthma (3.56, 1.62-7.85, p <0.01) compared to non-atopic workers. Respirable FP had no effect on 
any model. 
 
Table 18: Logistic regression models for respiratory symptoms, work-related respiratory symptoms, current 
asthma symptoms, and asthma stratified by exposure tertile. Odds ratios are displayed with 95% confidence 

























 (0.69 – 2.33) 
0.57  
(0.31 – 1.08) 
0.69  
(0.31 – 1.53) 
0.98  
(0.41 – 2.54) 
0.91  
(0.45 – 1.89) 
0.87  
(0.47 – 1.60) 
0.57  
(0.23 – 1.38) 
0.71  




(0.54 – 1.74) 
1.19  
(0.67 – 2.13) 
0.73  
(0.34 – 1.55) 
2.13  
(0.93 – 4.87)^ 
0.76  
(0.38 – 1.53) 
0.59  
(0.33 – 1.06)# 
1.04  
(0.46 – 2.32) 
0.98  
(0.36 – 2.67) 
Atopy yes vs 
no 
1.13  
(0.71 – 1.81) 
2.05  
(1.27 – 3.31)** 
1.33  
(0.71 – 2.46) 
1.54  
(0.82 – 2.90) 
0.8  
(0.45 – 1.44) 
1.15  





(1.62 – 7.85)** 
Ever smoked 
>1 Pack year 





(1.05 – 2.60)* 
1.11  
(0.61 – 2.02) 
1.72  
(0.93 – 3.19)# 
2.04 (1.17 – 
3.55) 
2.22  
(1.4 – 3.51)** 
0.83  
(0.44 – 1.58) 
0.7  




(0.92 – 1.04)  
0.94  
(0.88 – 1.01) 
0.96  
(0.88 – 1.07) 
0.89  
(0.78 – 1.02) 
1.00 (0.93 – 
1.08) 
1.00 (0.94 – 
1.06) 
0.99  
(0.91 – 1.09) 
1.01  
(0.92 – 1.12) 
*p<0.05 **p<0.01 ^p=0.07 #p=0.08.  
WRRS = work-related respiratory symptoms. CAS = current asthma symptoms.  
Models also adjusted for age, BMI and RPE use, only significant predictors shown. Numbers included in models shown in parentheses: in total, 345 workers had 
valid atopy, smoking and exposure data. 
4.3.5 Airway inflammation and spirometry across exposure groups 
Table 19 shows risk ratios for airway inflammation and spirometry across exposure groups. Models 
including FENO were adjusted for current smoking, atopy, age, sex, and RPE use: the addition of ICS 
use to models did not affect the outcome. Medium exposure was associated with an increased risk 
of FENO >40ppb (OR 1.82, 0.87 – 3.82) but this was not statistically significant (Table 19). However, 
increasing exposure to respirable FP was significantly associated with FENO >40ppb (OR 1.09, 1.01-
1.18, p=0.04). Current smokers were at reduced risk of airway inflammation (0.45, 0.22-0.90, 
p<0.05), whereas risk was increased in atopics (OR 1.70, 0.95 – 3.04, p=0.07).  
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Table 19: Odds ratios for categorical FENO and spirometry outcomes of interest, stratified by exposure tertile. 










Medium vs lowest 1.82 (0.87 – 3.82) 2.15 (0.63 – 7.41) 1.38 (0.13 – 15.06) 1.48 (0.48 – 4.56) 
Highest vs lowest 0.63 (0.28 – 1.39) 0.32 (0.07 – 1.55) 0.22 (0.01 – 6.15) 0.28 (0.07 – 1.08)^ 
Atopy yes vs no 1.71 (0.95 – 3.04)^ 1.76 (0.65 – 4.76) 2.68 (0.43 – 16.56 1.71 (0.65 – 4.55) 
Smoking yes vs no 0.45 (0.22 – 0.90)* 1.01 (0.38 – 2.70) - 1.4 (0.53 – 3.74) 
Respirable FFP (mg/m3) 1.09 (1.01 – 1.19)* 1.01 (0.89 – 1.16) 1.13 (0.93 – 1.38) 0.87 (0.69 – 1.11) 
*p=0.05, ^ p = 0.07 
a: Model adjusted for age, current smoking, height, RPE use, atopy, and sex.  
b: Model adjusted for age, ever having smoked more than one pack year, RPE use, atopy, height and sex.  
-  No data generated for FVC due to small numbers in models.  
 
Associations between FEV1<LLN and exposure disappeared in adjusted models (Table 19). No 
significant observations were seen for any of the spirometric outcomes considered and either 
exposure, atopy, smoking, or respirable FP. There was a tendency for medium exposure to be 
associated with an increased risk of low FEV1, FVC, and FEV1/FVC. In contrast, exposure in the 
highest group tended to be associated with a lower risk of abnormal spirometry. Atopy tended to be 
associated with an increased risk of abnormal spirometry. Clear associations between smoking and 
abnormal spirometry were not observed, and no data was generated for FVC <LLN due to small 
numbers of smokers in the model.  
4.3.6 Evidence of a healthy worker effect among foundry workers 
Table 20 shows relationships between respiratory symptoms and asthma and years’ exposure to 
VDGF among British foundry workers. A current asthma diagnosis was associated with increasing 
years’ exposure to VDGF among foundry workers (unstandardised β 0.003, p=0.05). Similarly, work-
related cough and wheeze were associated with increasing years’ exposure to VDGF. In contrast, 
work-related breathlessness was associated with fewer years’ exposure to VDGF.  
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Table 20: Linear regression models for cumulative years’ exposure to VDGF, respiratory symptoms, and 





WR CT WR 
wheeze 

































 *p=0.05, ^p=0.09, #p=0.08 
VDGF = vapours, dusts, gases, and fumes. WRRS = work-related respiratory symptoms. WR cough = work-related cough. 
WR CT = work-related chest tightness. WR SOB = work-related shortness of breath. WR NS = work-related nasal 
symptoms. WR OS = work-related ocular symptoms. CAS = current asthma symptoms.  
 
4.3.7 Associations between continuous measurements of exposure, airway inflammation 
and lung function  
Multiple linear regression models were constructed to examine relationships between exposure to 
either isocyanates or formaldehyde and GMR FENO, percent predicted FEV1, percent predicted FVC, 
and percent predicted PEF (Tables 21 and 22). All models were significant although explained only 
around 5% of variance within the outcome variable (R2 varied between 0.03 and 0.11). Increasing 
isocyanate exposure was positively associated with GMR FENO (Table 21). For each 1µg/m3 increase 
in isocyanate exposure, there was a 11% increase in GMR FENO (GMR 1.11, 95% CI 1.01 – 1.21, 
p<0.05). In contrast, increasing exposure to formaldehyde was not significantly associated with GMR 
FENO (0.89, 0.34 – 2.33, p=0.81, Table 22). Increasing respirable FP exposure was associated with 
small but significant increases in GMR FENO in formaldehyde-exposed workers. Each 1mg/m3 
increase in respirable FP related to a 3% increase in GMR FENO (1.03, 1.00 – 1.06, p<0.01) in workers 
co-exposed to formaldehyde. Similar trends were observed in isocyanate models but were not 
significant. In linear models, smoking was negatively associated with GMR FENO for both 
formaldehyde and isocyanate exposed workers, whereas no significant association was observed for 
atopic workers.  
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Table 21: Linear regression models showing the association between current exposure to isocyanates with 
GMR FENO and % predicted FEV1, FVC, PEF and FEV1/FVC. FENO is reported as geometric mean ratio data with 
95% confidence intervals. For spirometry, unstandardised β coefficients are reported with 95% confidence 
intervals. 
 GMR FENOa %FEV1b %FVCb %PEFb 
Current exposure  
to isocyanates, (μg/m3) 
1.11 (1.01 – 1.21)* 1.77 (0.31-3.23)* 0.65 (-0.72-2.02) 1.93 (1.22-3.73) 
Atopy, 
yes vs no 
1.04 (0.80 - 1.37)    
Smoking,  yes vs no 0.68 (0.53 – 0.89)** -1.99 (-6.16 – 2.18) 0.75 (-3.17-4.67) -2.74 (-7.90-2.42) 
Respirable FFP 
(mg/m3) 
1.06 (0.99 – 1.14) -0.21 (-1.49-1.07) -0.67 (-1.88-0.53) 1.28 (-0.30-2.86) 
R2; p for model 0.11; <0.01 0.03; 0.09 -0.01; 0.65 0.03; 0.05 
a Regression coefficient showing relationship between log10 FENO and current exposure to isocyanates. Models were 
adjusted for age, ever smoking, RPE use, atopic symptoms, and sex. Only reproducible FENO data was included. FENO 
data is back-transformed.  
b Regression coefficients showing relationship between spirometric outcomes of interest and current exposure to 
isocyanates. Models adjusted for age, ever smoking, RPE use, sex, and height. 
 
Table 22: Linear regression models showing the association between current exposure to formaldehyde with 
GMR FENO and % predicted FEV1, FVC, PEF and FEV1/FVC. FENO is reported as geometric mean ratio data with 
95% confidence intervals. For spirometry, unstandardised β coefficients are reported with 95% confidence 
intervals. 
 
Isocyanate exposure was associated with small but significant increases in FEV1 and PEF (Table 21). 
For each 1µg/m3 isocyanate rise there was a 1.77% increase in percent predicted FEV1 (1.77, 0.31-
 FENOa %FEV1b %FVCb %PEFb 
Current exposure to formaldehyde 
(mg/m3) 








 yes vs no 
1.12 (0.99 – 1.40)    
Smoking, 
yes vs no 
0.73 (0.59 – 
0.90)** 
0.56 (-2.79-3.86) 2.17 (-0.87-5.20) -0.75 (-5.0-3.51) 
Respirable FFP (mg/m3) 







R2; p for model 0.07; < 0.01 0.02; 0.06 0.01; 0.28  0.01; 0.25 
a  Regression coefficient showing relationship between log10 FENO and current exposure to isocyanates. Models were 
adjusted for age, ever smoking, RPE use, atopic symptoms, and sex. Only reproducible FENO data was included. FENO 
data is back-transformed.  
b Regression coefficients showing relationship between spirometric outcomes of interest and current exposure to 
isocyanates. Models adjusted for age, ever smoking, RPE use, sex, and height. 
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3.23, p=0.02). Percent predicted PEF increased by 1.93% with each 1µg/m3 increase in isocyanates 
(1.93, 1.22-3.73, p=0.04). No trend was seen for FVC. In formaldehyde models, no significant 
relationships between exposure and the six spirometric outcomes of interest were observed. 
 
Stratified analyses were performed to evaluate whether exposure-response effects were more 
evident in workers with WRRS or current asthma. Stratification by WRRS or current asthma made no 
difference to relationships between FENO and exposure to either isocyanates or formaldehyde, and 
models were not significant. 
4.3.8 Relationships between current asthma symptoms, high FENO and abnormal 
spirometry among the study population 
In order to understand the relationships between airway inflammation (FENO >40ppb) and other 
clinical features of work-related asthma (CAS or WRRS and airflow obstruction), contingency 
analyses were performed. Figure 13 shows intersections between CAS, airway inflammation and 
airflow obstruction among 187 foundry workers. Workers without CAS, airway inflammation or 
airway obstruction were excluded. Of the 128 workers with CAS, 37 (19% of total) also had airway 
inflammation whereas only 12 (6%) had airflow obstruction. There was little overlap between airway 
inflammation and airflow obstruction among symptomatic workers: only five symptomatic workers 
(3%) had both airway inflammation and airflow obstruction. A further two workers had both airway 
inflammation and airflow obstruction but reported no CAS. 
 
Figure 14 shows intersections between 153 participants with WRRS, airway inflammation and 
airflow obstruction. A quarter of workers (n=17, 11%) with WRRS had significant airway 
inflammation. Only three workers (2%) with WRRS had airflow obstruction. Again, little overlap was 
observed between airway inflammation and airflow obstruction among symptomatic workers: of the 
seven workers with both airway inflammation and airflow obstruction, only one (1%) had WRRS. 
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Thus, there were 6 workers with both airflow obstruction and airway inflammation who reported no 
WRRS.  
 
Figure 13: Intersections between the three asthma indices current asthma symptoms, airway inflammation 




Figure 14: Intersections between work-related respiratory symptoms, airway inflammation (defined by FENO 
>40 ppb) and airflow obstruction (defined by FEV1/FVC <LLN) in 153 foundry workers. 
 
Figure 15 shows the proportion of workers diagnosed with asthma who had either CAS+airway 
inflammation or WRRS +airway inflammation. Nearly two-thirds (n=23, 62%) of those with CAS and 
airway inflammation did not have an asthma diagnosis. Two-thirds (n=10, 67%) of those with WRRS 
and airway inflammation did not have an asthma diagnosis. As a composite variable, CAS and airway 
inflammation had a 43.8% (95% CI 26.4 – 62.3%) sensitivity and 92.3% (88.7 - 95.1%) specificity for 
predicting a diagnosis of asthma, with a positive predictive value (PPV) of 37.84% (25.9 - 51.8%) and 
a negative predictive value (NPV) of 93.9 % (91.9 - 95.4%). 
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Figure 15: Proportion of study participants with and without a current asthma diagnosis among workers 
with WRRS and airway inflammation (defined by FENO >40ppb) and CAS and airway inflammation. 
 Discussion 
This cross-sectional study of British foundry workers found isocyanate, but not formaldehyde, 
exposure was associated with small but significant increases in eosinophilic airway inflammation, 
despite low exposures. Overall, foundry workers had high levels of airway inflammation measured 
using FENO, with 25% of the workforce having a FENO exceeding 40ppb. Isocyanate exposure was 
associated with increasing airway inflammation in linear regression models, at levels substantially 
lower than the current UK WEL, even after controlling for common confounders such as smoking or 
atopy. However, evidence for a dose-response across exposure groups was less clear, with medium, 
but not high, exposed workers at increased risk for FENO above 40ppb and FEV1 <LLN compared with 
the lowest exposed group. Using a foundry-specific JEM to attribute exposures, no clear exposure-
response relationship was found between exposure to formaldehyde or isocyanates and risk of CAS, 
WRRS, or self-reported asthma. Unexpectedly, increasing isocyanate exposure was associated with 
an increase in FEV1 and PEF in linear regression models. A significant proportion of symptomatic 
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workers (with either CAS or WRRS) had evidence of airway inflammation, but there was little overlap 
between airway inflammation and airflow obstruction among the study population. Most of these 
workers had no diagnosis of asthma, suggesting FENO may provide additional information to 
spirometry alone when screening at-risk populations for OA.  
4.4.1 Limitations 
Few recent studies have investigated allergic respiratory disease in foundry workers. The current 
study considered the effect of exposure to two respiratory sensitisers – formaldehyde and 
isocyanates – based on the processes and exposures present in the foundries recruited. Other 
potential respiratory sensitisers employed in foundries include, but are not limited to, FFA, cobalt, 
nickel sulphate, chromium VI, stainless steel, and welding fume (192). A detailed exposure 
assessment allowed exclusion of these other sensitisers as either not presently used or detected 
(162). However, this does not account for historical exposure to sensitisers nor exclude their 
occasional use. Past or occasional exposures may contribute to the risk of OA in exposed 
populations, and the magnitude of their effect can be difficult to quantify in observational studies 
(9). 
 
Surprisingly, increasing exposure to FP was associated with small but significant increases in FENO. 
Whilst FP was quantitatively measured, its constituent parts were not examined in detail. A recent 
study has shown foundry particulate to contain fragments of metals such as copper, nickel, chrome, 
tin and zinc (187). Such metal particles are also known to cause occupational asthma. Observed 
increases in FENO may therefore be due to allergen, rather than irritant, exposures.  
 
FP may also contain irritants such as smoke, dust, or caustic substances, that are directly toxic to the 
pulmonary epithelium (162, 193). Increasing airway inflammation has previously been reported 
following exposure to cement dust; the authors suggested that direct epithelial injury rather than an 
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immune-mediated process was causative (194). FENO rises following irritant exposures may falsely 
overestimate the degree of asthmatic airway inflammation in the study population. However, even 
after controlling for FP exposures in regression models, an exposure-response effect for isocyanates 
and FENO remained. Further work is needed to explore the extent to which allergenic or irritant 
components of FP contribute to increasing airway inflammation in foundry workers. 
 
This study differs from recent studies of foundry workers in its exposure assessment and 
assignment. Worksites underwent contemporaneous measurements of a number of respiratory 
allergens by a qualified occupational hygienist. A foundry-specific site-process JEM was utilised to 
assign exposures to workers based on job title, process exposures, and workplace exposures. Even 
using this method, exposure misclassification is possible if individuals were assigned exposures 
based on a small number of measurements for a particular site-process combination. However, any 
misclassification is likely to bias the results towards the null; that is to say, exposures are likely to be 
under- not overestimated meaning any effects observed underestimate any exposure-response 
relationships (142). 
 
A standardized and validated questionnaire was used to determine atopy, respiratory symptoms, 
WRRS, and history of respiratory diseases. However, these questionnaires rely on self-report and 
may be affected by recall bias (195). Using a history of atopic symptoms may overestimate the ‘true’ 
prevalence of atopy among a group of workers. Conversely, where definitions rely on self-report, 
underreporting may underestimate the true incidence of symptoms or disease within a population 
(30). Underreporting of symptoms in workplace studies may underestimate the true symptom or 
disease burden of a population.  
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4.4.2 Exposure assessment in British foundry workers 
Few studies have reported exposures to isocyanates and formaldehyde in foundry workers. In their 
longitudinal study of foundry workers, Löfstedt and colleagues described mean isocyanic acid 
exposures of 18 µg/m3, methylisocyanate exposures of 3.7 µg/m3, and formaldehyde exposures of 
0.05 mg/m3 (192). In the current study, workers were exposed to diisocyanates, predominantly MDI. 
In comparison to the UK WEL, isocyanate exposures were approximately one-twelfth the 20 µg/m3 8 
hr-TWA and formaldehyde exposures were one-eighteenth the 2.5 mg/m3 8-hr TWA. The current 
study was powered to detect evidence of disease at respirable dust levels close to the UK WEL, 
requiring 400 workers in the cross-sectional arm in order to achieve adequate power to detect an 
effect. As such, the power to detect evidence of disease among workers may have been reduced. 
The observation of lower exposures among foundry workers could be related to selection bias 
among participating worksites with better exposure controls. However, it is an encouraging sign and 
suggests use of adequate control measures in order to reduce the risk of exposure to respiratory 
hazards.   
 
Although exposure levels were below the WEL, symptoms have been reported in foundry workers 
even at low exposure levels. A Swedish longitudinal study showed increased cough, nasal and ocular 
symptoms in exposed versus non-exposed workers at levels of formaldehyde exposure lower than in 
the current study (176). Furthermore, studies of isocyanate-exposed foundry workers have 
suggested that respiratory symptoms and asthma may occur at exposure levels significantly lower 
than the UK WEL, and a previous British study reported symptoms where isocyanate exposures were 
undetectable (173). There is no safe exposure threshold for respiratory sensitisers, and susceptible 
individuals may develop disease even at very low exposures. Current guidance aims, therefore, to 
achieve levels of exposure that are as low as reasonably practicable, in order to minimise the risk to 
entire workforce. This is one of the first studies to model foundry exposures in detail and evaluate 
their relationship with allergic respiratory disease. The longitudinal arm of this research programme 
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will generate valuable information on how allergen exposure affects asthma risk in foundry workers 
over time, even at low exposures.  
4.4.3 Respiratory symptoms and asthma in British foundry workers 
Symptom prevalence was lower in the current study compared to a previous study of British foundry 
workers. Cherry and colleagues reported symptom prevalence of 33% for WRRS, 9% for work-related 
wheeze, 15% for work-related cough, 16% for work-related chest tightness, and 8% for work-related 
breathlessness among workers with a mean age of 43.9 years, of whom 33% were current smokers 
(173). Mean age among foundry workers in the current study was similar (42.3 years) with slightly 
lower rates of current smoking (27%). We found overall rates of WRRS of 20%: 8% for work-related 
wheeze, 13% for work-related cough, 8% for work-related chest tightness, and 1% for work-related 
breathlessness. This comparative analysis suggests a reduction in WRRS among foundry workers 
over time, particularly in work-related breathlessness and chest tightness. This may be explained by 
a reduction in foundry allergen exposures over the last 15 years and suggests an improvement in 
respiratory symptoms among foundry workers. 
 
There was no clear relationship between medium or higher exposures and risk of respiratory 
symptoms or asthma. In fact, higher exposures tended to be associated with a lower risk of current 
asthma symptoms, with borderline significance (OR 0.59 in highest versus lowest exposure, 95% CI 
0.33-1.06, p=0.08). Few studies have attempted to evaluate risk of respiratory symptoms and 
asthma across a spectrum of foundry exposures; most have focussed on comparing exposed to non-
exposed groups. Kuo et. al. reported no difference in symptom prevalence among foundry workers 
where exposures varied with job description, although did report higher symptom prevalence 
among smokers (196). In contrast, Löfstedt et. al. reported a higher risk of nasal symptoms with 
increasing exposure gradient in foundry workers exposed to isocyanates and formaldehyde when 
compared with controls (176). In the current study workers in the highest exposed category were 
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significantly more likely to use RPE, which may have attenuated any exposure-response. 
Furthermore, workers may not perceive, may underreport, or may not experience respiratory 
symptoms for a variety of reasons that may attenuate any exposure-response relationships (30). 
Examining symptoms in changing exposure environments, and over time, may reveal clearer 
evidence of an exposure-response relationship.  
 
There was some suggestion of a remaining ‘healthy worker’ population in the current study, with 
workers in the highest exposure group tending to have a lower risk of respiratory symptoms and 
asthma than those in the lowest exposure group. In specific regression analyses, workers with a 
current asthma diagnosis and had significantly more years’ exposure to foundry work, although the 
magnitude of effect was small. This contrasts with what may be expected with a healthy worker 
survivor effect, where one sees a reduction in asthma risk with increasing years’ exposure reflecting 
individuals’ early departure from, or lack of recruitment to, the workforce. The short latency of OA 
means the healthy worker effect is often difficult to detect in cross-sectional studies, and there is no 
single measure of healthy worker effect bias in asthma (146, 197). The study was unable to capture 
recent movement of workers from a high to a low exposure environment, and only identified three 
workers who previously left a job for health reasons (the ‘healthy worker effect’) (146). Longitudinal 
studies of foundry workers are required to examine whether respiratory disease is associated with 
premature exit or relocation within the foundry industry.  
4.4.4 Impact of smoking and atopy on respiratory symptoms and asthma in foundry 
workers 
Both smoking and atopy impacted respiratory symptoms and asthma in foundry workers. Ever 
smokers were at increased risk of CAS (OR 2.22, 95% CI 1.4-3.51), any respiratory symptom (OR 2.28, 
95% CI 1.46 – 3.57) and upper airway symptoms (1.66, 1.05-2.6) compared with never smokers. 
However, no increased risk was seen among ever smokers for WRRS, self-reported or current 
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asthma. Foundry workers are well-documented to be at increased risk of COPD (179, 180). This may 
explain the increase in symptoms among smokers in the absence of a clear association to work or 
asthma. However, lung function among the current population was within normal limits, and rates 
of obstructive airways disease were low. In addition, workers may not recognise or report work-
relatedness to their symptoms, which would point to more variability in their condition and a 
potential diagnosis of allergic airways disease (198). Longitudinal study of these symptomatic 
foundry workers will help understand whether these symptoms are explained by early airways 
disease.  
 
 In contrast, workers with atopy were four times more likely to self-report asthma (4.31, 2.22-8.36) 
and three times more likely to fulfil ECRHS asthma criteria (3.56, 1.62-7.85), but significant 
relationships between atopy and either WRRS or CAS were not observed. Atopy has been shown to 
increase the risk of isocyanate OA in a case-referent study of British foundry workers, with a more 
modest increase in OA risk observed for smokers (199). Atopy is well recognised to increase OA risk 
in workers exposed to HMW and some LMW agents, although the mechanisms through which atopy 
modifies OA risk in LMW-exposed workers is unclear (9, 10). The relationship between smoking and 
asthma is less well established. Some studies report exposure to pollutants such as cigarette smoke 
may alter asthma phenotype and treatment efficacy, but fewer studies have shown a direct causal 
link (20, 200). In the current study over a quarter of the population were current smokers and over 
half had ever smoked. Further examination of how exposure to smoke and other pollutants augment 
asthma risk is important in helping to reduce the future risk of asthma in foundry workers.  
4.4.5 Relationships between spirometry and foundry exposures 
Among our study population, FEV1, FVC, and PEF were similar to the expected percentage predicted 
values. Mean percent predicted FEV1, FVC, and PEF did not differ significantly across exposure 
groups, and in adjusted regression models no significant associations between exposure and 
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categorical spirometric outcomes were observed. Foundry workers have previously been shown to 
have significantly poorer predicted FEV1 compared to lesser or non-exposed controls (201). RPE use 
was more prevalent among those with higher exposures (82% versus 65% in medium exposed, 
p<0.01). This may explain the absence of abnormal lung function in higher exposed groups and 
supports its use in such populations.  
 
Increasing µg/m3 isocyanate exposure was associated with small but significant increases in percent 
predicted FEV1 in linear regression models (unstandardised β 1.77%, 0.31-3.23). This was an 
unexpected finding, and contradicts previous research showing foundry workers are at increased risk 
for obstructive airways disease even after accounting for smoking (202). A healthy worker hire effect 
or healthy worker survivor effect could explain this aberrant finding. Workers in the current study 
had spent an average of 14.76 (12.66) years in the foundry industry, and the highest exposure group 
had significantly more years of service than the lowest (16.64 versus 12.33 years, p <0.05). Self-
reported job change due to workplace exposures was very low in the population and did not differ 
between exposure groups. This suggests a relatively stable workforce, with those with higher 
exposures staying longer in the job. This is particularly important in foundry work, where hazards 
such as molten metal are immediate and obvious, and the working environment can be hostile. 
Individuals who are unable to work in foundry environments are likely to leave the workplace early, 
with those who remain more able to manage the working conditions. This healthy worker survival 
effect may attenuate any differences between lung function seen at different exposure levels.  
4.4.6 Relationships between airway inflammation and foundry exposures 
The current study found increasing exposure to isocyanates was associated with increasing airway 
inflammation. GMR FENO increased by 11% (GMR 1.11, 1.01 – 1.21) per µg/m3 rise in isocyanate 
exposure. A previous study of car spray painters found no significant relationship between 
increasing isocyanate exposure and FENO using either continuous or dichotomized endpoints but 
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reported a strong relationship between FENO and risk of BHR (203). FENO has been shown to rise 
following positive SIC to isocyanates, rising at 8 hours and peaking around 24 hours post-exposure 
(182). Furthermore, the same study reported significant FENO increases in non-asthmatics exposed to 
isocyanates with, but not without, BHR. This suggests that FENO might be useful not only in 
identifying incident asthma in isocyanate exposed workers, but also in detecting workers with 
asymptomatic BHR at risk of becoming asthmatic, even at levels of exposure lower than the UK WEL.  
 
In contrast, the current study found no clear relationship between airway inflammation and 
increasing formaldehyde exposure. Associations between formaldehyde exposure and FENO have not 
been widely reported. Previous studies into formaldehyde OA have failed to demonstrate an 
association with eosinophilic inflammation, with the authors suggesting formaldehyde may reduce 
thresholds for other exposures provoking asthmatic symptoms at lower exposure levels rather than 
directly inducing inflammation (185). A proportion of LMW-OA is thought to be non-eosinophilic 
(19); therefore, exposures may drive non-eosinophilic inflammation or other cause symptoms by 
other mechanisms (5). The potency of an occupational allergen may also influence its ability to 
induce airway inflammation, and statistical models that predict the hazard associated with LMW 
exposures suggest isocyanates have a stronger asthmatic potential than aldehydes (204). 
 
This study supports an association between increasing FP exposure and airway inflammation using a 
categorical endpoint. Among foundry workers there was a 9% increased risk of FENO above 40ppb 
with each mg/m3 increase in FP. Furthermore, in linear models we found respirable FP was 
associated with small but significant increases in GMR FENO. One study has previously explored 
relationships between dust exposure and airway inflammation in foundry workers, reporting 
increased nitric oxide levels in workers with higher cumulative exposures to RCS and foundry 
particulate. The authors concluded that FP exposure may induce pulmonary inflammation, 
measurable through FENO (187). Previous hygiene studies have shown FP to contain allergenic 
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substances including metal particles (205). Increasing airway inflammation in association with FP 
exposure may therefore be related to allergen rather than irritant exposure. Furthermore, high 
general exposure to vapours, dusts, gases and fumes has previously been associated with higher 
sensitiser exposure, suggesting that non-sensitisers may be useful as a surrogate for general hygiene 
measures at worksites (88). 
4.4.7 Fractional exhaled nitric oxide as a health surveillance tool in foundry workers 
Among symptomatic foundry workers, the current study found differences in the proportion of 
symptomatic workers with airway inflammation or airflow obstruction. A fifth (19%) of foundry 
workers with CAS also had airway inflammation, whereas only 6% had both CAS and airflow 
obstruction. Similar relationships were observed for foundry workers with WRRS; 11% also had 
airway inflammation, whereas only 2% had WRRS and airflow obstruction. Among asymptomatic 
workers, intersections between airway inflammation and airflow obstruction were limited. This 
suggests that airway inflammation and airflow obstruction identify discrete groups of symptomatic 
foundry workers, and the addition of measures of airway inflammation such as FENO may be useful in 
screening workers at risk of OA. A fall in FEV1 is a late sign in OA, and early identification of workers 
with the condition is vital in improving both clinical and employment outcomes (11, 14). FENO could 
be useful in detecting early airway inflammation in symptomatic workers, prior to the onset of 
obstructive spirometry, and further investigation of this is warranted. 
 
A number of external factors may affect FENO as a potential tool for health surveillance. Atopy and 
smoking are well known to moderate FENO (46). We found foundry workers with atopy to be at 
significantly increased risk of having a FENO above 40 ppb (OR 1.95, 1.11-3.42, p=0.02) and smokers 
to be at significantly reduced risk (0.47, 0.27-0.83, p=0.01). The longitudinal arm of the current study 
will provide further detail about the extent to which atopy and smoking influence the development 
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of airway inflammation and asthma in British foundry workers, and how this might be accounted for 
in future health surveillance programmes. 
 
Foundry workers are largely exposed to LMW allergens. The role of FENO in LMW exposures is 
particularly debated, with a lack of consensus on its use in either SIC or workplace studies (126, 155). 
In contrast, there is more evidence supporting a relationship between FENO and exposure to HMW 
agents (40). Comparing the current findings to evidence from HMW environments may help to 
understand the extent to which the molecular weight of exposure can influence airway 
inflammation; and whether relationships between airway inflammation, airflow obstruction, and 
symptoms are more significant in HMW exposure environments. 
4.4.8 Summary 
This study of isocyanate and formaldehyde exposed foundry workers has demonstrated that though 
current asthma symptoms are common, they are not clearly related to exposure. However, airway 
inflammation appears to be related to increasing isocyanate exposure, even after controlling for 
common confounders. Further study is needed to examine how airway inflammation relates to 
other asthma indices over time, and to better understand the role of FENO in different exposure 
environments.  
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5 Respiratory symptoms, airway inflammation, and lung function in 
laboratory animal workers 
 Introduction 
5.1.1 Laboratory animal allergy 
Laboratory animal workers are exposed to HMW allergenic animal proteins such as dander, urine, or 
skin (206). Sensitisation to such proteins, measurable by SIgE or SPT, is present in nine per cent of 
laboratory animal workers and is strongly associated with the development of laboratory animal 
allergy (LAA) and OA (207). LAA is defined as either occupational rhinitis (OR), OA, or anaphylaxis 
caused by exposure to laboratory animal allergens and has been reported in up to 10% of exposed 
workers (207). LAA remains a common cause of OR and OA in the UK (26). 
 
Allergen exposure is a key risk factor for the development of LAA. Both duration and intensity of 
exposure to laboratory animal allergens have been shown to significantly increase LAA risk. This 
includes the number of hours’ exposure, as well as the number of animals handled at any one time 
(208). Recent changes in research practice, animal husbandry, and health and safety legislation have 
altered how animal research is approached, leading to a reduction in the duration and intensity of 
allergen exposure (209). Genetically modified mice models are now preferred for in vivo work, with 
animals increasingly housed in individually ventilated cages (IVCs) to prevent experimental 
contamination and infection of animals by airborne microbes (207). New legislative requirements 
necessitate individuals working in animal facilities to be registered with the UK Home Office, with 
workers undergoing training in animal welfare in order to achieve registration (210). Health and 
safety practices have been improved in facilities in order to prevent cross-contamination of infection 
between animals and to comply with the three Rs - replacement, reduction and refinement - of 
animal experimentation (211). However, most studies of LAA were undertaken prior to these 
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changes in working, with few studies examining the risk of sensitisation and LAA following their 
introduction. 
5.1.2 Fractional exhaled nitric oxide in laboratory animal workers 
Fractional exhaled nitric oxide (FENO) has been shown to be higher in people with LAA compared to 
asymptomatic exposed controls: stepwise increases in FENO have been demonstrated across groups 
of exposed workers, workers with early LAA (OR and sensitisation) and workers with OA (44). 
Sensitised laboratory animal workers have been shown to have significantly higher FENO than 
sensitised controls, despite no differences in spirometry between groups (212). A study of laboratory 
animal workers with work-related symptoms reported increases in FENO following increasing allergen 
exposure in sensitised individuals (213).  
 
Relationships between HMW exposures, such as animal allergens, and eosinophilic airway 
inflammation are more established than for LMW exposures. Mechanisms for OA in HMW-exposed 
workers are well described, frequently related to Th-2 driven inflammation, associated eosinophilia, 
and SIgE (10). Data from SIC studies support a rise in FENO following exposure to HMW, but not 
LMW, allergens (40). Longitudinal data from workers exposed to flour supports the use of FENO in 
predicting incident BHR, suggesting it may be useful tool in screening for at-risk populations for OA 
in these settings (41, 214).  
5.1.3 Study rationale 
Data reported in this thesis has shown increasing airway inflammation, measured using FENO, with 
exposure to LMW agents including isocyanates and wood. However, a consistent dose-response 
effect has not been found. No recent studies have examined the relationship between airway 
inflammation and laboratory animal exposures in workers at risk of LAA. This study aims to 
understand relationships between exposure to laboratory animal allergens and work-related 
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symptoms, sensitisation, asthma, airway inflammation, and lung function in a subset of laboratory 
animal workers taking part in the SPIRAL (Safe Practice in Reducing Allergy in Laboratories) study 
(215). Further, it aims to understand whether associations between exposure and airway 
inflammation were present in this group, and whether these associations were influenced by 
sensitisation. 
 
An NHS REC committee approved this study (reference 13/NI/0208). 
 Methods 
Data on laboratory animal workers was collected as part of the Safe Practices in Reducing Allergy in 
Laboratories (SPIRAL) study, led by Dr Johanna Feary from the National Heart and Lung Institute, 
Imperial College London, and is reproduced here with Dr Feary’s kind permission. The existing study 
protocol was amended to include measurement of lung function and ethical approval was agreed. 
Data presented here was collected alongside Dr Feary and Bernadette Fitzgerald across eight site 
visits over a two-year period.  
5.2.1 Power calculation 
No recent studies have examined LAA in Britain since the increasing introduction of mice models. 
Therefore, evidence from rat-exposed populations was used. In their study of rat-exposed laboratory 
animal workers, Cullinan et. al. reported 37% of workers had work-related chest symptoms at GM 
exposure to rat urinary allergen of 1.26 μg/m3 (95% CI 0.86 - 1.85) (216). At the same exposure, 
there was an increased risk of respiratory symptoms with an OR of 3.5 (95% CI 0.7-18.7) versus 
controls. On this basis a power calculation was performed to achieve 80% study power at a two-
sided 5% significance level (130). A sample size of 187 participants was estimated to provide 
adequate power, assuming a true underlying symptom prevalence of 25% and a OR of 3.5 between 
the highest and lowest exposed (130).  
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5.2.2 Study population 
SPIRAL was established to determine whether the introduction of IVCs in laboratory animal facilities 
has led to a reduction in LAA populations of exposed workers. SPIRAL was a multicentre study of 750 
laboratory animal workers across seven UK research institutions that ran between July 2014 and 
March 2017 (215). In brief, workers were recruited if they had at least four months of exposure. 
Mice were used most frequently among the participating research institutions. The primary study 
endpoint was sensitisation to mouse proteins in individuals working in IVC-only versus other (mixed 
or open) facilities. Only workers with fewer than three years’ exposure were included in the primary 
analysis. All workers over 18, employed at participating worksites and exposed to laboratory animals 
were included. Individuals were excluded if they had ever worked with animals at an institution 
other than their current research facility.  
 
As part of this thesis a subgroup of SPIRAL participants were recruited. Laboratory animal workers 
participating in SPIRAL were recruited over a 12-month period between November 2015 and 
October 2016 (Appendix D). All SPIRAL participants recruited within the study window were invited 
to undergo FENO and spirometry testing in addition to the standard SPIRAL testing. SPIRAL 
participants were consented for the additional tests and FENO and lung function were performed on 
the same day as the other study examinations.  
5.2.3 Questionnaire and allergy testing 
As part of the SPIRAL study protocol, participants undertook an online questionnaire detailing their 
work environment (open cages, mixed, or IVC-only), job histories, and current and past animal 
exposures (Appendix D). Work-related ocular, nasal or respiratory (chest-tightness, difficulty 
breathing, wheezing or whistling in chest) symptoms were self-reported. Respiratory symptoms 
occurring on exposure to any animals, and also to specific animal species, were documented. 
Individuals self-reported hay fever symptoms and current or previous diagnosis of asthma.  
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Standard immunological testing included in SPIRAL included SPT to common aeroallergens including 
grass pollen, Dermatophagoides pteronyssius (house dust mite), cat, and dog, and specific SPTs to 
mouse and rat epithelium. A negative saline and positive histamine control were used 
(Allergopharma, Diagenics, Milton Keynes, UK and Stallergenes, London, UK). SPTs were timed at 15 
minutes and then allergen was removed from the skin. Visible wheals were copied and recorded in 
the study file.  
5.2.4 FENO and spirometry 
In addition to the standard SPIRAL protocol, participants underwent FENO and lung function testing, 
as described previously in section 3.2.5, according to ATS/ERS guidelines (46, 133).  
5.2.5 Exposure assessment  
Background and personal exposure to the primary mouse allergen Mus-m-1 was determined in IVC-
only versus open or mixed facilities (215). In brief, inhalable particulate was collected from selected 
individuals working in either IVC-only or open facilities and analysed using a commercial enzyme-
linked immunosorbent assay (ELISA). Background measures were collected using static samplers. 
Both background and personal Mus-m-1 levels were significantly lower in IVC-only facilities: 
background geometric mean (GM) Mus-m-1 was 0.04 ng/m3 in IVC-only versus 0.53 ng/m3 in open 
or mixed facilities, and personal GM Mus-m-1 was 1.00 ng/m3 versus 8.35 ng/m3 in open or mixed 
facilities .  
 
Most workers with LAA will develop symptoms within three years of starting work, and the risk is 
highest in the first two years (217). Thus, the primary analysis in SPIRAL was limited to participants 
with less than three years’ exposure. Individual exposures were not modelled in the SPIRAL study 
and are therefore not included in the current analysis. 
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5.2.6 Definitions 
Work-related nasal symptoms (WRNS), work-related ocular symptoms (WROS) and WRRS were 
defined respectively as nasal, ocular, or respiratory symptoms worsening on exposure to animals in 
the workplace or improving when away from work at weekends or on holidays. Current asthma was 
defined as self-reported asthma within the last 12 months.  
 
Individuals were considered atopic if they had positive SPTs to any common aeroallergen, defined as 
a saline adjusted wheal diameter equal or greater than 2mm. Specific sensitisation to mouse or rat 
was defined by a positive SPT to mouse or rat epithelium if a saline adjusted wheal size was equal to 
or greater to 2mm (215). A self-reported doctor diagnosis of LAA was used to define the LAA group. 
A high FENO was defined as a mean FENO exceeding 40ppb and spirometry was considered abnormal 
if FEV1, FVC, PEF or FEV1/FVC fell below their age, ethnicity, and height adjusted LLN value, as 
previously described in section 3.2.9.  
5.2.7 Data analysis 
Univariate analyses were conducted using independent student’s t-tests for continuous and chi-
squared analyses for categorical data. Continuous data were expressed as mean ± SD with 
categorical data expressed numerically with associated percentages. FENO data did not meet 
normality criteria so were log transformed and data expressed as GM and GSD for averages and as 
GMR in regression models, as described in section 3.2.10.  
 
Binary logistic regression models were constructed to examine associations between years of 
exposure and the key categorical variables of interest: work-related symptoms; current asthma; 
specific sensitisation to mouse or rat epithelium; FENO above 40ppb; and FEV1, FVC or PEF less than 
LLN. A three-year exposure threshold was used, and workers with less than three years’ exposure 
were used as the control group. Relationships between years’ exposure, FENO and spirometry were 
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also explored using multiple linear regression, with log FENO and percent predicted spirometry being 
the key dependent variables. Regression models were constructed and controlled for as previously 
reported in section 3.2.10. FENO data was further analysed by presence or absence of work-related 
symptoms (WRS) (44).  
 
Linear regression models were constructed to explore a potential healthy worker effect among 
laboratory animal workers, as described in section 3.2.10. Years of exposure to laboratory animals in 
worker’s current job were used as the dependent variable, with work-related symptoms, CAS, and 
current asthma as independent variables. Data were adjusted for age, sex, atopy, height, and ever 
smoking.   
 
Odds ratios and unstandardised  values with associated 95% confidence intervals (CI) were 
reported, with two-way significance taken at the 5% level. 
 
Stratified analyses were conducted to explore differences between workers with and without 
specific sensitisation (213). Finally, intersections between groups of workers with respiratory 
symptoms, airway inflammation, and airflow obstruction were examined using contingency analyses 
and Venn diagrams as previously described in section 3.2.10. All statistical analyses were conducted 
using SPSS (141).  
 Results 
5.3.1 Study population 
One hundred and fifty-five people were recruited to SPIRAL during the 12-month study window, of 
whom 153 (99%) took part in the current study (Table 23). The two non-participants declined lung 
function testing. Mean age of the study group was 29.21 (SD 7.96) years; just over half (n=89, 58%) 
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were female and a sixth (n=25, 16%) had ever smoked more than one pack year. Twenty (13%) 
participants were current smokers. Mean BMI was 24.28 (SD 4.4) kg/m2. There were no significant 
differences in sex, age, smoking habits, BMI, or current job title between the two groups.  
 
Table 23: Demographics of the study population stratified by duration of exposure to laboratory animals 
Demographics 
Less than three years’ exposure 
(n=66) 




Age, years (SD) 28.00 (7.70) 30.13 (8.08) 29.21 (7.96) 
Sex, f (%) 43 (65) 46 (53) 89 (58) 
Current smoker, n (%) 9 (14) 11 (13) 20 (13) 
Ever smoked > 1 pack yr, n 
(%) 
11 (17) 14 (16) 25 (16) 
BMI, kg/m2 (SD) 23.87 (4.45) 24. 56 (4.49) 24.28 (4.40) 
Height, cm (SD) 168.92 (9.15) 169.28 (9.10) 169.12 (9.09) 
 
The exposure characteristics of the study population are shown in Table 24. The majority of 
participants were scientists (n=124, 81%). On average, participants had spent 5.22 (SD 5.08) years in 
their current job. All participants worked with mice; 62 workers (41%) were also exposed to rats. 
Sixty-six workers (43%) had been exposed to laboratory animals for three years or less. Workers with 
more than three years’ exposure were more likely to work in an IVC-only facility (31% versus 17%, p 
<0.05). Participants with more than three years’ exposure to laboratory animals had worked 
significantly longer in their current job compared to those with less than three years’ exposure (7.40 
versus 2.35 years, p<0.01). Scientists and laboratory technicians were equally represented between 





Table 24: Exposure characteristics of the study population stratified by duration of exposure to laboratory 
animals 
Exposure 
Less than three years’ 
exposure  
(n=66) 





Technician, n (%) 5 (8) 16 (18) 21 (14) 
Scientist, n (%) 58 (88) 66 (76) 124 (81) 
Office, n (%) 3 (5) 4 (5) 7 (5) 
Maintenance, n (%) 0 (0) 1 (1) 1 (1) 
Currently works in IVC-only facility, n 
(%) 
11 (17) 27 (31)* 38 (25) 
Only ever worked in IVC-only facility, 
n (%) 
6 (9) 16 (18) 22 (14) 
Mice in animal facility, n (%) 66 (100) 87 (100) 153 (100) 
Rats in animal facility, n (%) 22 (14) 40 (46) 62 (41) 
Number of years in current job, years 
(SD) 
2.35 (0.67) 7.40 (5.85)** 5.22 (5.08) 
*p<0.05, **p<0.01. IVC = individually ventilated cages.  
 
The health characteristics of the study population are shown in Table 25. Upper airway symptoms 
were the most frequently reported complaint. Twenty-three percent of workers reported nasal 
symptoms and 17% reported ocular symptoms; WRNS were reported by 16% and WROS by 13%. 
Respiratory symptoms on exposure to pets were reported by 16%; however, WRRS were uncommon 
reported by only 3%.  
 
SPTs were refused or not interpretable due to dermatographia in three workers (2%). Atopy was 
common, with 41% of participants having a positive SPT to at least one common aeroallergen. 
Specific sensitisation was less common; 13% had a positive SPT to mouse or rat epithelium. Current 
hay fever symptoms were reported by 29% of the study group. Atopic symptoms correlated well to 





Table 25: Health characteristics of the study population, stratified by more or less than three years’ 
exposure to laboratory animal allergens. 
Health 
Less than three years’ 
exposure  
(n=66) 





Nasal symptoms, n (%) 14 (21) 21 (24) 35 (23) 
WRNS, n (%) 9 (14) 16 (18) 25 (16) 
Ocular symptoms, n (%) 10 (15) 16 (18) 26 (17) 
WROS, n (%) 7 (11) 13 (15) 20 (13) 
Respiratory  symptoms, n (%) 10 (20) 9 (13) 19 (16) 
WRRS, n (%) 3 (5) 2 (2) 5 (3) 
Any work-related symptom, 
n (%) 
11 (17) 18 (21) 29 (19) 
Hayfever last 12 months, n 
(%) 
20 (30) 25 (29) 45 (29) 
Atopic, n (%) 27 (42) 36 (42) 63 (41) 
+ve SPT mouse/rat, n (%) 6 (9) 14 (16) 20 (13) 
Current inhaled steroid use, n 
(%) 
1 (2) 2 (2) 3 (2) 
Self-reported LAA, n (%) 4 (6) 4 (5) 8 (5) 
Childhood asthma, n (%) 6 (9) 5 (6) 11 (7) 
Current asthma, n (%) 2 (3) 2 (2) 4 (3) 
AM FENO, ppb (SD) 19.49 (19.30) 31.14 (32.56)** 26.20 (28.23) 
GM FENO, ppb (GSD) 13.83 (2.32) 22.18 (2.25)** 18.15 (2.35) 
FENO >40ppb, n (%) 5 (9) 17 (20) 22 (15) 
Mean % predicted FEV1 (SD)b 101.97 (12.78) 98.68 (9.87) 100.17 (11.36) 
Mean  % predicted FVC (SD) 106.22 (12.88) 102.24 (9.43)* 104.05 (11.27) 
Mean % predicted PEF (SD) 108.52 (17.57) 109.15 (14.31) 108.86 (15.82) 
Mean FEV1, litres (SD) 3.63 (0.91) 3.39 (0.68)^ 3.50 (0.80) 
Mean FVC, litres (SD) 4.44 (1.16) 4.11 (0.84) 4.26 (1.00) 
Mean PEF, litres (SD) 527.77 (133.90) 519.76 (120.58) 522.35(122.32) 
FEV1 <LLN, n (%) 3 (2) 1 (1) 4 (3) 
FVC <LLN, n (%) 1 (2) 1 (1) 2 (2) 
PEF <LLN, n (%) 1 (2) 1 (1) 2 (2) 
FEV1/FVC <LLN, n (%) 2 (3) 1 (1) 3 (2) 
*p<0.05, **p<0.01.  
WRNS= work-related nasal symptoms. WROS = work-related ocular symptoms. WRRS = work-related respiratory 




Figure 16: Presence or absence of atopy (defined by SPT positivity to a common aeroallergen) in workers 
with and without atopic symptoms 
Seven percent of the study group reported childhood asthma. Prevalence of current asthma was 
low: only 4 (3%) workers self-reported a diagnosis. A further three workers (2%) were taking inhaled 
steroids none of whom reported a current diagnosis of asthma. Eight workers (5%) self-reported a 
diagnosis of LAA. There were no significant differences in prevalence of upper or lower respiratory 
symptoms, atopy, hayfever, or self-reported asthma or LAA between the two exposure groups.  
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Valid FENO measurements were obtained in 135 (91%) workers. One worker was unable to perform 
FENO due to recent dental surgery and a further 13 were unable to perform a reproducible test. Valid 
spirometry was performed in 135 (88%) participants: the remaining 16 (12%) were unable to 
perform a reproducible test. AM FENO was 26.20 (SD 28.23) ppb and GM FENO was 18.15 (GSD 2.35) 
ppb. Nineteen (14%) workers had a FENO above 40ppb. Mean percentage predicted FEV1, FVC and 
PEF were all above 100% and few workers met LLN criteria for spirometry, with only 3% having an 
FEV1 <LLN, 2% having an FVC <LLN, and 2% with an FEV1/FVC <LLN.  
 
FENO was significantly higher in workers with more than three years’ exposure. GM FENO was 22.18 
(GSD 2.25) ppb compared with 13.83 (2.32) in those with fewer than three years’ exposure (p<0.01). 
Prevalence of FENO > 40 ppb was higher in workers with more than three years’ exposure, but this 
was not statistically significant (18% versus 9%, p=0.13).  
 
Percent predicted FVC was significantly lower among workers with more than three years’ exposure 
(102% versus 106%, p <0.05). FEV1 was within normal limits in both exposure groups and no 
significant difference was seen between FEV1 between the two groups. The overall prevalence of 
abnormal spirometry using LLN criteria was low, and there was no significant difference in 
categorical spirometry outcomes between the two exposure groups in univariate analyses.  
5.3.2 Associations between years’ exposure and respiratory symptoms, atopy, and 
laboratory animal allergy  
Associations between exposure and nasal, ocular, respiratory, and work-related symptoms were 
explored using logistic regression (Table 26). Non-significant relationships were observed between 
all symptom outcomes and exposure to laboratory animals of more than three years’ duration. A 
non-significantly increased risk for both nasal (OR 1.07, 95% CI 0.48 – 2.41) and ocular (1.20, 0.48 – 
2.97) symptoms was seen in workers with more than three years’ exposure, whereas risk tended to 
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be reduced for respiratory symptoms (0.26, 0.05 – 1.48). A similar trend was observed for work-
related symptoms, with non-significantly increased odds of WRNS (1.25, 0.49 - 3.19) and WROS 
(1.40, 0.50 – 3.87) and reduced risk of WRRS (0.43, 0.07 - 2.81) seen in workers with more than 
three years’ exposure.  
 
Atopic workers were at significantly increased risk of nasal and ocular symptoms compared to non-
atopic workers (OR 2.47 and 2.92 respectively, Table 26). Similarly, risk for WRNS (2.66, 95% CI 1.05-
6.79) and WROS (2.75, 0.99-7.59) was significantly increased in atopic workers. Risk for both 
respiratory symptoms and WRRS was higher in atopic workers although confidence intervals were 
wide, and data did not reach statistical significance.  
 
Table 26: Relationships (odds ratios and 95% confidence intervals) between more than three years exposure 
to laboratory animals and nasal, ocular, respiratory, and work-related symptoms. All models were controlled 
for sex, atopy, ever smoking and BMI. 
Upper and lower airway symptoms Nasal symptoms Ocular symptoms Respiratory symptoms 
> 3 years’ exposure (yes=1) 1.07 (0.48 – 2.41) 
1.20  
(0.48 – 2.97) 
0.26  
(0.05 – 1.48) 
Atopic (yes=1) 2.47 (1.10 – 5.57)* 
2.92  
(1.17 – 7.28)* 
3.44  
(0.59 - 19.97) 
Work-related symptoms WRNS WROS WRRS 
> 3 years’ exposure (yes=1) 
1.25  
(0.49 - 3.19) 
1.40  
(0.50 – 3.87) 
0.43  
(0.07 - 2.81) 
Atopic (yes=1) 
2.66  
(1.05 – 6.79)* 
2.75  
(0.99 – 7.59)* 
2.00  
(0.29 - 13.58) 
Data presented as odds ratios and 95% confidence intervals. > 3 years exposure = more than three years exposure to 
laboratory animals. Atopy defined by positive skin prick tests to more than one common aeroallergen. WRNS = work-
related nasal symptoms. WROS = work-related ocular symptoms. WRRS = work-related respiratory symptoms. *p<0.05, 
**p<0.01 
 
Atopic workers were over seven times more likely to have specific sensitisation than non-atopic 
workers (OR 7.79, 95% CI 2.29-26.83, Table 27), although confidence intervals were wide. In 
addition, atopic workers tended to be more likely to self-report LAA, although this just missed 
statistical significance (8.45, 0.95 – 75.07, p=0.06). Interestingly, ever smoking was associated with a 
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reduced risk of specific sensitisation (0.09, 0.01 - 0.92), whereas BMI was associated with an 
increased risk (1.18, 1.05 - 1.32).  
 
More than three years’ exposure was not significantly associated with increased risk of asthma, 
sensitisation, or self-reported LAA (Table 27). Workers with more than three years’ exposure had a 
non-significantly increased risk of specific sensitisation (1.81, 95% CI 0.61 – 5.62). In contrast, risk of 
self-reported LAA (0.51, 0.10 – 2.49) and of current asthma (0.35, 0.03 – 4.39) tended to be lower in 
workers with more than three years’ exposure.  
 
Table 27: Associations (odds ratios and 95% confidence intervals) between asthma, sensitisation and self-
reported laboratory animal allergy with years exposure, atopy, and smoking status. All models were 
controlled for atopy, ever smoking, BMI, and gender with significant cofactors reported. 
 Childhood asthma Current asthma 
> 3 years’ exposure (yes=1) 0.29 (0.07 - 1.27) 0.35 (0.03 – 4.39) 
Atopic (yes=1) 1.40 (0.34 – 5.87) 2.56 (0.20 – 32.27) 
Ever smoked (yes=1) 0.65 (0.07 – 6.14) 10.70 (0.77 – 149.32) 
 Specific sensitisation Self-reported LAA 
> 3 years’ exposure (yes=1) 1.85 (0.61 – 5.62) 0.51 (0.10 – 2.49) 
Atopic (yes=1) 7.79 (2.26 – 26.83)** 8.45 (0.95 – 75.07) 
Ever smoked (yes=1) 0.09 (0.01 - 0.92)* 0.70 (0.07 – 7.64) 
BMI, mg/m2 1.18 (1.05 – 1.32)** 1.03 (0.85 – 1.26) 0.75 
Data presented as odds ratios and 95% confidence intervals. > 3 years exposure = more than three years exposure to 
laboratory animals. Atopy defined by positive skin prick tests to more than one common aeroallergen. Ever smoked = 
ever smoked more than one pack year history. *p<0.05, **p<0.01 
 
5.3.3 The Healthy Worker Effect in laboratory animal workers 
Table 28 shows data from linear regression analyses exploring the healthy worker effect in 
laboratory animal workers. No significant associations were seen between years’ exposure to 
laboratory animals and any of the independent variables studied. Overall magnitude of associations 
was small for all variables studied.  
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Table 28: Linear regression models for years’ exposure to laboratory animals, respiratory symptoms, and 






































*self-reported years exposure to laboratory animals in current job. 
 WR nasal = work-related nasal symptoms. WR eyes = work-related ocular symptoms. WRRS = work-related respiratory 
symptoms. Any WRS = any work-related symptom.  
 
5.3.4 Airway inflammation in workers exposed to laboratory animal allergens 
Linear regression models were constructed to examine the relationship between log FENO and the 
dichotomised exposure variable of more or less than three years’ exposure to laboratory animals 
(Table 29). In workers with more than three years’ exposure, GMR FENO was 63% (95% CI 1.21 – 2.10) 
higher than in workers with less than three years’ exposure. To look for an effect at earlier stages of 
exposure, the analysis was restricted using more or less than two years’ exposure. Similar 
associations were observed between GMR FENO and years exposure, with workers with more than 
two years’ exposure having a GMR FENO 51% (1.01-2.13) higher than those with less than two years’ 
exposure.  
 
When FENO was dichotomised in logistic regression models, significant relationships were also 
observed with years’ exposure (Table 29). More than three years’ exposure was associated with an 
increased risk of FENO >40ppb (OR 2.87, 0.83 – 9.93, p=0.09). When using a two-year exposure 
threshold, this association was stronger (OR 7.75, 0.93 – 64.88, p=0.06), although confidence 
intervals were wide.  
 
Interestingly, no clear associations between current smoking and FENO were seen. Both GMR FENO 
and risk of FENO >40ppb were lower in smokers, but neither association was significant (Table 29). 
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Similarly, neither GMR FENO nor FENO >40ppb were significantly associated with atopy in workers 
exposed to laboratory animal allergens.  
 
Table 29: Adjusted GMR FENO (unstandardised β and 95% confidence intervals) and FENO >40ppb (odds ratios 
and 95% CI) between groups with more than three and more than two years’ exposure to laboratory 
animals. Models were adjusted for sex, ever and current smoking, height, and atopy. 
 GMR FE NO (n=127) FENO > 40 ppb (n=127) 
> 3 years’ exposure (yes=1) 1.63 (1.21 - 2.10)** 2.87 (0.83 – 9.93) 
> 2 years’ exposure (yes=1) 1.51 (1.07 - 2.13)* 7.75 (0.93 – 64.88) 
Atopic (yes=1) 1.13 (0.83 – 1.52) 0.68 (0.22 - 2.11) 
Smoker (yes=1) 0.96 (0.62 – 1.50) 0.80 (0.15 – 4.40) 
GMR FENO data presented as back transformed log10 FENO values in units of measurement (unstandardised β and 
associated 95% confidence interval). FENO >40ppb data presented as odds ratios and 95% confidence intervals. > 3 years 
exposure = more than three years exposure to laboratory animals. Atopy defined by positive skin prick tests to more 
than one common aeroallergen. Smoker = currently smokes cigarettes. *p<0.05, **p<0.01 
 
There were no significant differences in either GM or AM FENO among workers with and without 
WRS (Table 30). Similarly, no difference in the prevalence of FENO >40ppb was found between the 
two groups.  
 
Table 30: FENO by presence or absence of any work-related symptom* 
 WRS (n=28) No WRS (n=111) P value 
AM FENO, ppb (SD) 25.94 (20.64) 26.26 (29.92) 0.29 
GM FENO, ppb (SD) 20.26 (2.10) 17.65 (2.41) 0.25 
FENO >40ppb, n (%) 4 (14) 15 (14) 0.92 
*Any work-related symptom = any work-related respiratory, nasal, or ocular symptoms 
 
5.3.5 Association between exposure and spirometry in laboratory animal workers 
Small but significant reductions in percent predicted FEV1 and FVC were observed in workers with 
more than three years exposure to laboratory animals (Table 31). Percent predicted FEV1 was 3.9% 
lower in workers with more versus less than three years exposure (unstandardised β -3.90%, 95% CI 
-7.82 - - 0.02). Percent predicted FVC was 4.4% lower in workers with more versus less than three 
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years exposure (β -4.41, -8.12 - -0.70). Similarly, absolute FEV1 and FVC were significantly lower in 
workers with more than three years exposure, with FEV1 333 mls lower and FVC 453mls lower in 
workers with more than three years exposure compared to those with less than three years 
exposure (for FEV1 β = -333.48, -579.113 - -87.84; for FVC β = -453.30, -763.18 - -143.42). No effect 
was seen for PEF.  
 
When years’ exposure was used as a continuous variable in linear models, no significant associations 
were observed between increasing exposure duration and FEV1 or FVC. However, increasing years’ 
exposure tended to be negatively associated with both absolute and percent predicted FEV1 and FVC 
(Table 31).  
 
Table 31: Adjusted linear regression models showing associations between more than years exposure to 
laboratory animals as categorical (more or less than three years) and continuous predictors for absolute and 
percent predicted FEV1, FVC, and PEF. Unstandardised β and 95% confidence intervals in parentheses. Al 
models adjusted for age, gender, smoking and atopy. 
 FEV1, mls 
(n=128) 
FVC, mls  
(n=128) 
PEF, mls  
(n=128) 
> 3 years’ exposure (yes=1) -333.48  
(-579.11 - -87.84)** 
-453.30  
(-763.18 - -143.42)** 
-33.41  
(-71.94 - 5.13) 
Exposure, years  -15.99  
(-38.98 – 7.00) 
-17.29  
(-46.49 - 11.90) 
-0.32  
(-3.89 - 3.25) 
 % predicted FEV1 (n=128) % predicted FVC  
(n=128) 
% predicted PEF (n=128) 
> 3 years’ exposure (yes=1) -3.90  
(-7.82 - - 0.02)* 
-4.41  
(-8.12 - -0.70)* 
-1.16  
(-6.66 - 4.35) 
Exposure, years -0.25  
(-0.61 - 0.11) 
-0.20  
(--0.55 - 0.14) 
0.10  
(-0.40 - 0.61) 
Atopy defined by positive skin prick tests to more than one common aeroallergen. Smoker = currently smokes 
cigarettes. *p<0.05, **p<0.01 
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5.3.6 Relationship between specific sensitisation and nasal, ocular and respiratory 
symptoms 
To explore the degree in which specific sensitisation influenced outcomes, univariate analyses and 
regression models were stratified by specific sensitisation to mouse or rat epithelium. The 20 people 
specifically sensitised had significantly higher BMI and had worked longer in their current job. 
Technicians were over-represented in the sensitised group (30%, versus 12% in the non-sensitised 
group, p <0.01).  
 
Regression models were constructed to examine associations between specific sensitisation, 
symptoms, and airway inflammation (Table 32). Sensitised workers were 11 times more likely to 
report nasal symptoms (OR 11.52, 95% CI 3.62-36.31), nine times more likely to report ocular 
symptoms (OR 9.60, 2.98-30.96), and 14 times more likely to report respiratory symptoms (14.49, 
2.36-89.04) compared to non-sensitised workers.  
 
Table 32: Odds ratios (and associated 95% confidence intervals) from logistic regression models showing 










Specific sensitisation (sensitised 
= 1) 
11.52 (3.62-36.31)** 9.60 (2.98-30.96)** 14.49 (2.36-89.04)** 
 WRNS (n=141) WROS (n=141) WRRS (n=141) 
Specific sensitisation (sensitised 
= 1) 
17.41 (5.18-58.52)** 16.75 (4.64-60.54)** 37.94 (3.47-414.77)** 
  FENO >40 ppb (n=127) LAA (n=141)  
Specific sensitisation  
(sensitised = 1) 
3.36 (0.94 – 12.02) 14.95 (2.35 – 95.32)**  
Controlled for age, current smoking, height, sex, and years of current exposure. No other predictors were significant.  
WRNS = work-related nasal symptoms. WROS = work-related ocular symptoms. WRRS = work-related respiratory 
symptoms. *p<0.05, **p<0.01 
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Similar associations were observed for work-related symptoms. Sensitised workers tended to have a 
higher risk of significant airway inflammation versus non-sensitised workers: OR for FENO >40ppb was 
3.36 (0.94-12.02, p=0.06) among sensitised participants. Specific sensitisation was strongly 
associated with risk for LAA (OR 14.95, 2.34 – 95.32, p <0.01). 
5.3.7 Intersections between airway inflammation, airflow obstruction and respiratory 
symptoms 
In order to evaluate the interactions between respiratory symptoms, airway inflammation (FENO 
>40ppb) and obstructive spirometry (FEV1/FVC <LLN), an intersecting Venn diagram was constructed 
(Figure 17). A total of 41 participants were included in the analysis: 19 with any respiratory 
symptoms, 22 with airway inflammation, and three with airflow obstruction. There was little 
association between the three groups. Only two (5% of total) participants with respiratory 
symptoms had evidence of airway inflammation. Only one symptomatic worker had airflow 
obstruction. No workers with airway inflammation also had airflow obstruction. 
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Figure 17: Venn diagram showing intersections between groups with either respiratory symptoms, airway 
inflammation or obstructive spirometry. In total 41 workers participants were included in the analysis.  
Similarly, little association was observed between those with WRRS, airway inflammation, or airflow 
obstruction (Figure 18). Twenty-eight participants were included in the set analysis: five with WRRS, 
22 with airway inflammation and three with airflow obstruction. Two (7%) of participants with WRRS 




Figure 18: Intersecting Venn diagram showing relationships between participants with work-related 
respiratory symptoms, airway inflammation, and airflow obstruction (FEV1/FVC <LLN). 
 Discussion 
This study has demonstrated that more than three years’ exposure to laboratory animal allergens is 
associated with significantly higher GMR FENO and lower percent predicted FEV1 and FVC. Risk of 
symptoms was highest in laboratory animal workers who were sensitised to mice. In contrast, no 
clear associations were seen between increasing duration of exposure and self-reported respiratory 
symptoms, asthma, or LAA. Among laboratory animal workers, atopy is a significant modifier of nasal 
and ocular symptoms, with atopic workers significantly more likely to report both work-related nasal 
and work-related ocular symptoms.  
5.4.1 Limitations 
Since case-referent studies have shown the majority of individuals who develop symptoms and 
sensitisation in LAA are most likely to do so within the first three years of exposure, the primary 
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analysis in SPIRAL was limited to those with less than three years’ exposure to laboratory animal 
allergens (215). Exposure to laboratory animal allergens was measured through static and personal 
monitoring, but individual exposures were not assigned to the study cohort for analysis. This made it 
difficult to model allergen exposure along with measures of airway inflammation or spirometry in 
this study.  
 
Cross-sectional studies are at risk of exposure misclassification as they may fail to capture individuals 
moving from a high to low exposure environment, or retiring from the industry altogether (142). 
Similarly, it may be difficult to accurately account for historical exposures in a cross-sectional study. 
Since both duration and intensity of exposure to laboratory animal allergens are known to be 
important in the development of LAA, misidentifying historical exposures is important when 
considering current risk of disease (208). However, years of employment has previously been shown 
to be a marker of risk for LAA and its use has been reported elsewhere (218, 219). 
 
The main aim of SPIRAL was to determine whether work in IVC-only facilities and associated 
exposure reduction has led to a reduction in laboratory animal allergy. Individuals with previous 
exposures to laboratory animal allergens in other facilities were excluded from the primary analysis 
in SPIRAL. Many researchers will spend time in multiple facilities during their doctoral and post-
doctoral training; excluding those with previous animal exposures could have led to exclusion of 
some older workers with higher historical exposures, thus attenuating any exposure-response 
observed (207). This is reflected in the findings of the current study where we compared workers 
with more rather than less than three years’ exposure and found that workers with more than three 
years’ exposure had increased airway inflammation and poorer age-adjusted spirometry.  
 
The present analysis of a subset of participants from SPIRAL may have introduced selection bias. It is 
possible that the limited 12-month sampling frame led to sampling differences in workplace 
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exposures. Indeed, the prevalence of workers employed in IVC-only facilities reported in the current 
study was lower than across the whole SPIRAL cohort, at 14% versus 28%. However, rates of work-
related respiratory symptoms, specific sensitisation, and LAA were broadly similar in the current 
study compared with SPIRAL, suggesting this subset is representative of the whole sample (215). It 
was not feasible to extend lung function and FENO testing to the larger group of SPIRAL participants, 
but future examination of measures of airway inflammation and lung function in laboratory animal 
workers, particularly those with lower exposures, will help to understand how useful these tools are 
in detecting LAA or OA in these populations.  
 
The majority of participants in the current study were scientists rather than laboratory technicians. 
Scientists have a more limited role in animal husbandry and culling and therefore exposures among 
this group may be lower than in other laboratory animal workers (207). Furthermore, the gender, 
smoking habits, and educational status of scientists differed significantly from technicians in our 
study, with scientists being more likely to be women, less likely to smoke, and having higher 
educational attainment. These factors may have influenced FENO measurements, which are known to 
be modified by gender and smoking (47).  
 
The current study was powered to detect significance in odds ratios at a mean level of exposure of 
1.26 μg/m3. However, exposures in SPIRAL were lower than this which may have underpowered the 
current results. However, exposure measurements were made on a convenience basis and did 
necessarily include high-exposure tasks, for example cleaning IVC filters or cages (209). Data was 
sparse for some of the outcomes of interest, for example for specific sensitisation or current asthma. 
This lack of data reflects findings from the whole SPIRAL cohort where formal diagnoses of LAA were 
rare. However, despite difficulties in comparing groups due to small numbers, the overall reduction 
in prevalence of LAA, relative to previous studies, is likely to reflect reductions in exposure in animal 
units (215). 
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5.4.2 Work-related symptoms, allergy and sensitisation are related to atopy but not to 
duration of allergen exposure   
Prevalence of work-related symptoms in the current study was low, with only 3% of the study 
population reporting any WRRS. Furthermore, only 3% of the current study population reported a 
current diagnosis of asthma, and only 5% self-reported LAA. Previous studies of laboratory animal 
workers have demonstrated a higher prevalence of work-related symptoms and asthma. Cullinan et 
al. reported work-related symptoms in 29% of their cohort (218). In their study of 225 laboratory 
animal workers, Kruize et al. reported rates of work-related rhinitis in 14% and work-related asthma 
in 8% (220). This suggests the introduction of IVCs and subsequent reduction in exposure to 
laboratory animal allergen has led to a reduction in WRRS and asthma prevalence.  
 
No significant relationships between increasing years’ exposure to laboratory animal allergens and 
upper, lower, or work-related respiratory symptoms were identified in the current study. Work-
related nasal and ocular symptoms were more common among those with over three years’ 
exposure to laboratory animals, whereas work-related respiratory symptoms tended to be less 
common, although neither finding reached statistical significance. In addition, linear regression 
models demonstrated no clear association between years’ exposure to laboratory animals and 
respiratory symptomrs or asthma. Since most cases of LAA occur within the first three years’ 
exposure, a higher prevalence of work-related symptoms or asthma may be expected in those with 
shorter exposures. Workers with less than three years’ exposure were more likely to have worked in 
mixed facilities and had spent a shorter time in their current job. Individuals who develop symptoms 
or sensitisation early after exposure to laboratory animal allergens may leave the workplace, leading 
to a healthy worker survivor effect among the current study population (146). A healthy worker hire 
effect may also pre-select workers with allergic tendencies or asthma out of employment (197). 
Furthermore, other factors are thought to be important in the development of LAA. Stable moderate 
exposures and variable high-level exposures are associated with distinct immunological responses in 
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laboratory animal workers, with evidence to support an attenuation of LAA at higher exposures 
(221). This may explain the absence of an association between years’ exposure and either 
respiratory or work-related respiratory symptoms observed in the present study.  
Similarly, asthma and LAA were not associated with exposure in logistic regression models. The 
current study population had spent an average of 5.22 years exposed to laboratory animals. Since 
symptoms of LAA most commonly occur within the first three years of exposure, the relative 
absence of LAA among our study population could be explained by a survivor effect. Improvements 
in working conditions and a reduction in exposure to laboratory allergen have been described over 
the last decade, and a recent cohort study has demonstrated declining rates of LAA over the last 15 
years (222). Detecting significant changes in disease prevalence across small exposure thresholds is 
challenging and larger studies of exposed populations are needed to more accurately characterise 
exposure thresholds that cause clinically apparent disease.  
 
Atopy was significantly associated with upper airway symptoms, respiratory symptoms and 
sensitisation among laboratory animal workers. Atopic workers were more likely to report both 
work-related and non-work-related nasal and ocular symptoms compared to non-atopic workers. 
Similarly, atopic workers were significantly more likely to be sensitised to mouse or rat than non-
atopics (OR 7.79, 95% CI 2.26 – 26.83). This finding reflects previously reported evidence that atopy 
is a significant risk factor for nasal, ocular, respiratory and work-related symptoms in laboratory 
animal workers (9, 216) Atopy was associated with around a three-fold risk increase for ocular, 
nasal, or respiratory symptoms in controlled analyses. However, significant interactions between 
atopy and years’ exposure were not identified, findings that have been supported elsewhere (216). 
Atopic workers with HMW exposures have been reported to be at increased risk of OA compared to 
non-atopic workers (9). However, individual risk of developing LAA varies significantly and these 
findings do not support workforce selection on the basis of atopic status (207). When considering 
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risk reduction for LAA emphasis should be placed on modifiable risk factors, the most important of 
which is allergen exposure. 
5.4.3 Specific sensitisation is a key risk factor for symptoms and LAA 
The current findings suggest specific sensitisation to mouse epithelium is strongly associated with 
nasal, ocular, and respiratory symptoms, as well as LAA. Risk of work-related nasal, ocular, and 
respiratory symptoms was significantly higher in sensitised workers. Similarly, risk for LAA was 
higher among sensitised workers, although confidence intervals were wide. Previous studies have 
demonstrated a strong relationship between specific sensitisation and both work-related symptoms 
and the development of LAA (216, 217). However, there was no clear association between specific 
sensitisation and asthma in the current study. No sensitised workers self-reported a current 
diagnosis of asthma despite a number of sensitised individuals reporting work-related symptoms 
who were also taking asthma inhalers. The pressures of undertaking research in which animal 
models are a requisite part may make it impossible for PhD students or scientists to report 
symptoms. Although the study was confidential, there may have been reporting bias in the current 
study. Individuals may under-report symptoms if they do not recognise that they are work-related or 
because they are concerned about symptoms negatively influencing their job (15). This 
demonstrates the importance of testing other than symptom questionnaires in the screening for 
LAA. 
5.4.4 Airway inflammation is related to longer duration of exposure in laboratory animal 
workers 
The current study suggests longer exposure is associated with increasing airway inflammation even 
after considering known confounders such as atopy, smoking, and sex. GMR FENO was 63% higher in 
workers with more versus less than three years’ exposure to laboratory animals (GMR FENO 1.63ppb, 
95% CI 1.21 - 2.10, p<0.01). These findings suggest that increasing duration of exposure to 
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laboratory animal allergens is associated with increasing airway inflammation. A number of studies 
have looked at FENO in laboratory animal workers. Adisesh and colleagues reported a mean exhaled 
NO of 6.08 (95% CI 4.58–8.07) ppb in asymptomatic laboratory animal workers versus 12.53 (6.50–
24.14) ppb in those with early LAA (workers who were sensitised and with work-related symptoms) 
(44). This reflects the current findings, where the risk of FENO >40ppb was higher among sensitised 
workers. Hewitt and colleagues reported GM FENO of 17.7ppb in the whole study population and 
significantly higher FENO in two sensitised workers (213). Overall, FENO in the current study was 
similar at 18.15 (GSD 2.35) ppb, with GM FENO in sensitised workers 20.52 (GSD 2.84) ppb. This 
suggests FENO levels have not changed significantly over a decade, in spite of significant 
improvements in exposure and an apparent reduction in symptoms and asthma prevalence.  
 
We found no difference in FENO among participants with work-related symptoms. Furthermore, set 
analysis showed little overlap between airway inflammation, lung function, or respiratory symptoms. 
This contrasts to data reported previously in this thesis, where there was more overlap between 
respiratory symptoms and airway inflammation in wood and foundry workers. This is surprising 
given the relationship between HMW exposures (such as laboratory animal allergens) and 
eosinophilic airway inflammation is better established (40). A study comparing airway inflammation 
in apprentice bakers and hairdressers reported higher levels of physician-diagnosed asthma in 
bakers (with HMW exposures) with high FENO compared with hairdressers (124). The same study 
reported little overlap between airway inflammation and airflow obstruction. Evaluating airway 
inflammation from both LMW and HMW exposure environments should help to understand the 
determinants of FENO in these settings, as well as further explore its use as a screening tool in 
workplace environments.  
 
Cohort evidence has suggested a significant increase in FENO in sensitised laboratory animal workers 
after six and 12 months exposure, with the difference disappearing at 24 months (219). Palmberg et 
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al. reported similar overall levels of exhaled NO in their longitudinal study of newly exposed 
workers, though reported a significant difference in exhaled NO only among sensitised workers at six 
and 12, but not 24, months. GM FENO among those with more than three years’ exposure was 
significantly higher than those with fewer than three years’ exposure (22.18 versus 13.83 ppb, 
p<0.01). Although the current study was unable to prospectively evaluate FENO in the current study, 
longitudinal studies would be useful to enhance understanding of how FENO changes over time in 
laboratory animal workers.  
 
Interestingly, no association between smoking or atopy and FENO was found among laboratory 
animal workers. This is surprising as multiple studies have demonstrated both to be important 
modifiers of FENO, with airway inflammation increasing in atopic individuals and decreasing in 
current smokers (46). Rates of current smoking were low in the current study, at only 13%. In 
contrast, prevalence of atopy was high, with 42% of workers having at least one positive SPT to 
common aeroallergens. The association between HMW exposures (such as laboratory animals) and 
Th-2 predominant inflammation in OA is better established than for LMW exposures (9). Atopy may 
therefore have been expected to play a more significant role in modifying airway inflammation in 
laboratory animal workers. The absence of such associations may reflect the low overall exposures 
within the study and support the continued use of IVCs in the prevention of LAA.  
5.4.5 Lung function and increasing exposure to laboratory animals 
Individuals with longer exposure to laboratory animals had poorer absolute and percent predicted 
FEV1, even after controlling for age, sex, and smoking habits. Overall percent predicted FEV1 was 
normal, reflecting the young age of the study population. However, a lower FEV1 in those with 
longer tenure may reflect excess FEV1 decline in a population with prolonged or heavier exposure to 
laboratory animal allergens (219). Excess FEV1 decline is a feature of OA with ongoing exposures, and 
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its identification is a key part of health surveillance in order to recognise disease early and reduce or 
remove exposures appropriately (11).  
 
In addition, increasing years of exposure was associated with poorer percent predicted and absolute 
FVC. Although we excluded spirometry that failed to meet acceptability criteria, the FVC is more 
susceptible to technical variation than the FEV1, which may have contributed to the observed 
reduction in both FEV1 and FVC (133). While the main exposures of interest in the current study 
were animal allergens (primarily Mus-m-1), laboratory workers may also be exposed to other agents 
harmful to the respiratory tract, either as agents required for animal husbandry (for example 
cleaning agents or antibiotics) or as part of the research they are undertaking (223). Such agents 
could attenuate FVC as well as FEV1, leading to a reduction in both parameters, as observed in the 
present study.  
 
There was little association between low FEV1 and either respiratory symptoms or airway 
inflammation in the current study. Only 2% of the current study population had an FEV1/FVC LLN, 
likely due to a number of factors including young age (mean age 29.21 years), low smoking 
prevalence, and good physical health (mean BMI 24.28 kg/m2).  However, it might be expected those 
with airway obstruction would have respiratory symptoms. Asymptomatic airflow obstruction can 
occur in healthy populations and relates to increased exercise-induced dyspnoea and dynamic 
hyperinflation (224) Such groups require closer follow-up, as airflow obstruction, irrespective of 
cause, is associated with impaired future health and functional status (225). 
5.4.6 Summary 
The current study supports a relationship between increasing years’ exposure to laboratory animal 
allergens and increasing airway inflammation, reduced FEV1 and FVC, but not with an increase in 
respiratory symptoms or LAA. The finding of lower exposures and disease prevalence is likely to 
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reflect an overall reduction in LAA associated with reduced exposures secondary to the introduction 
of IVC-only facilities. Further evidence from SPIRAL will improve understanding of the way in which 
exposure variation and duration influences the development of LAA in light of changes in laboratory 
practise. Larger studies are needed to explore the role of FENO populations of laboratory animal 



















6 Fractional exhaled nitric oxide in allergen-exposed workers 
 Introduction 
6.1.1 Fractional exhaled nitric oxide in the diagnosis of occupational asthma 
Fractional exhaled nitric oxide (FENO) is a simple, non-invasive measure of eosinophilic airway 
inflammation used in the diagnosis of asthma (4). In OA, rises in FENO have been reported following 
positive SIC to both HMW and LMW agents: levels peak at between 24 and 48 hours and show 
correlation with rises in sputum eosinophilia (182, 183, 226). Increases in FENO have been reported 
following positive SIC to latex (227), flour (228), animal dander (229), and isocyanates (230). 
Challenge studies have suggested such increases are more marked among individuals with 
low/normal baseline FENO and a late bronchial response (183). Recent guidance has recommended 
FENO as an aid to identifying positive SICs for OA where sputum cytology is unavailable (155). 
However, evidence from challenge studies remains conflicting, with some studies reporting an 
increase in FENO only following HMW exposures (126). 
6.1.2 Fractional exhaled nitric oxide in screening for OA 
In Britain, health surveillance is mandatory for workers at risk of OA (29). Respiratory questionnaires, 
spirometry, and where appropriate, specific sensitisation are commonly used tools for evaluating 
asthma in those at risk (35). However, sensitivity and specificity of both questionnaires and 
spirometry is low, particularly in early disease (9). Early diagnosis is crucial in OA in order to prevent 
disease progression and developing more accurate health surveillance programmes is important to 
improve disease outcomes, prevent job losses, and reduce the economic burden of OA (28). Since 
FENO is inexpensive, easy to perform, portable, and increasingly available, it is an attractive potential 
tool for health surveillance in OA. In their study of bakers and hairdressers, Bohadana et al. 
demonstrated little overlap between apprentices with high FENO or airway obstruction, suggesting 
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the two tests provide distinct information on OA risk in such groups (124). In a follow-up study, 
Tossa et al. demonstrated increases in FENO were significantly associated with incident BHR, with a 
two-fold increase in risk of developing BHR per log ppb increase in FENO (41).  
 
In screening studies, FENO has been associated with increased asthma incidence in spice factory 
workers (231), bakery workers (42), laboratory animal workers (44), lifeguards (232), and aluminium 
workers (233). FENO has also been used to monitor efficacy of exposure reduction, with sustained 
reductions demonstrated among farmers following educational interventions to reduce workplace 
exposures (113). However, relatively few studies have looked at relationships between quantitative 
measures of exposure and FENO (43, 45, 234). Evidence from other exposure environments is lacking, 
particularly with reference to known modifiers such as gender, height, cigarette smoking, atopy, age, 
and ICS use. No studies have explored the modifying effects of atopy or smoking in woodworkers, 
foundry workers, or laboratory animal workers.  
 
First, this study explores the determinants of FENO in a population of workers exposed to either 
HMW or LMW allergens, in particular the degree of influence of smoking and atopy. Second, it 
evaluates relationships between FENO and other indicators of OA including current asthma 
symptoms, work-related respiratory symptoms, and obstructive spirometry. Finally, it aims to 
understand the degree to which allergen exposure determines FENO, using quantitative allergen 
exposures. 
 Methods 
6.2.1 Study population 
In brief, foundry, wood, and laboratory animal workers were recruited over a period of four years (as 
described in detail in sections 3.2, 4.2, and 5.2). Foundry and wood workers were recruited as part of 
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HSE’s SRP. A subset of workers participating in the SPIRAL study comprised the laboratory animal 
worker group. Workers in all studies were included if they were currently working in an exposed 
environment and were over 16. Individuals who were entirely office-based were excluded.  
6.2.2 Questionnaire 
All workers underwent a validated questionnaire as described in sections 3.2, 4.2, and 5.2 
(Appendices B, C and D). Questionnaires detailed demographic information, smoking history, and 
allergic status; job history; nasal, ocular and respiratory symptoms, and their work-relatedness; and 
current or past respiratory diagnoses.  
6.2.3 Fractional exhaled nitric oxide and spirometry  
FENO and spirometry measurements are described in detail in chapters 3.2, 4.2, and 5.2. In brief, FENO 
was performed before spirometry wherever possible, and following a minimum of 24 hours’ 
exposure in the workplace, according to ATS/ERS standards (46). Subsequently, spirometry was 
performed sitting and without a nose clip, according to ATS/ERS standards (133). 
6.2.4 Atopy and sensitisation assessment 
Consenting woodworkers underwent serum IgE analysis for TIgE and SIgE to hard and soft wood as 
described in section 3.2.6. Foundry workers reported current allergy symptoms (hayfever, rhinitis, or 
asthma) as described in section 4.2.8. SPRIAL participants underwent SPTs for common 
aeroallergens (house dust mite, grass, cat, dog) as well as specific SPTs for mouse epithelium as 
described in section 5.2.3. In wood and laboratory animal studies, total IgE and SPT positivity 
respectively were associated with a significantly increased likelihood of an allergy diagnosis.  
6.2.5 Definitions 
Work-related nasal symptoms (WRNS), WROS, and WRRS were those that worsened at work or 
improved away from work or on holiday. Additionally, WRS were defined as those workers with 
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either WRNS or WRRS. CAS, ever, and current asthma were defined using ECRHS criteria, as 
described in section 3.2.9.  
 
Workers were considered atopic if they had either: at least one positive SPT to a common 
aeroallergen (laboratory animal workers), a TIgE above 100 kU/L (wood workers) or reported allergic 
symptoms such as hayfever and rhinitis within the last 12 months (foundry workers). Current and 
ever smokers were identified by smoking history and pack years.  
 
A FENO of at least 40ppb was considered high, and LLN criteria were used to define abnormal 
spirometry, as described in section 3.2.9.  
6.2.6 Data analysis 
Only workers with technically acceptable FENO data and who had complete atopy and smoking 
information were included in the final analysis. Workers who reported a current respiratory tract 
infection were excluded (46). FENO data were not normally distributed so were log transformed and 
then back-transformed into units of measurement, presented as GM and GSD for descriptive data, 
and GMR in linear regression models, as previously described in chapter 3.2.10 (45, 139). 
 
Demographic data were compared with univariate analyses and presented as means ± SD or 
proportions for categorical variables. Univariate analyses were conducted to explore relationships 
between FENO and known determinants including atopy, current smoking, sex, age, ICS use, height, 
and asthma diagnosis. Relationships between key determinants were further explored using 
adjusted linear and logistic regression analyses. Four groups of workers were created based on 




Multiple linear regression was used to examine associations between FENO and WRS, CAS, current 
asthma, abnormal spirometry, and HMW or LMW allergen exposure. Multiple logistic regression was 
used to explore relationships between FENO above 40ppb with WRS, CAS, current asthma, abnormal 
spirometry, and HMW or LMW allergen exposure.  
 
In order to explore relationships between FENO and commonly used health surveillance tools, FENO 
was combined with other diagnostic features of asthma to create composite asthma indices and 
evaluated against other features of OA (100). Composite asthma indices included: CAS and FENO 
above 40ppb; CAS and FEV1 < LLN; and CAS and FEV1/FVC < LLN. Logistic regression models were 
constructed to explore their association with other features of OA such as WROS, WRNS, WRRS, self-
reported asthma, and exposure to LMW or HMW allergens. All models were controlled for age, sex, 
atopy, height, and current smoking. Degree of agreement between airway inflammation (FENO 
>40ppb) and obstructive spirometry (FEV1/FVC <LLN) was assessed in symptomatic individuals using 
intersecting Venn diagrams, as previously described in section 3.2.10. 
 
In order to explore the effect of exposure on FENO, data were pooled and stratified by exposure to 
either HMW or LMW allergens. Laboratory animal workers formed the HMW exposure group and 
foundry and wood workers the LMW exposure group. To evaluate the effect of quantitative 
exposure measures on FENO, a ‘higher’ versus ‘lower’ exposure group was created. Exposure 
assessment differed between HMW and LMW groups. SPIRAL used a three-year exposure threshold 
to determine the primary analysis cohort, whereas in the wood and foundry studies analyses were 
stratified by quantified allergen exposures. Thus, analysis of FENO data in ‘higher’ versus ‘lower’ 
exposure environments was restricted to LMW-exposed workers only. Woodworkers in the highest 
quartile of exposure (section 3.3.1), or foundry workers in the highest tertile of exposure (section 
4.3.3), formed the ‘higher’ exposure group. The remaining participants formed the ‘lower’ exposure 
category. 
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All statistical analyses were conducted using SPSS statistical software, v23 (141). 
 Results 
6.3.1 Study population 
The baseline study group included 773 participants: 351 foundry workers; 269 wood workers; and 
153 laboratory animal workers (Figure 19). Thirteen workers refused FENO measurement or were 
unavailable during assessment. A further 100 (13%) were excluded as they were unable to perform a 
reproducible result or reported symptoms of a current respiratory tract infection. Smoking or atopy 
data was incomplete in five workers. The final study population comprised 655 workers.  
 
Figure 19: Flow diagram showing participants included from foundry, wood, and laboratory animal studies. 
RTI = respiratory tract infection 
Subjects excluded from analysis were more likely to be LMW exposed, were older than the study 
population (43.98 versus 38.96 years, p <0.01), and were significantly more likely to be male (93% 
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versus 86%, p <0.05). There were no significant differences in smoking status, atopy, clinical 
symptoms, or asthma among the excluded versus the included groups.  
6.3.2 Study demographics 
The population demographics are shown in Table 33. Average worker age was 38.96 (SD 12.53) 
years. The majority (n=565, 86%) were male, with a mean 7.43 (7.80) years spent working in their 
current job. Overall, symptoms were common, with rates of nasal, eye and respiratory symptoms 
varying between 22 – 40%, rates of work-related symptoms ranging between 13-16%, and CAS 
reported by 33%. One-third of workers were atopic, with one-sixth self-reporting ever asthma and 
one-tenth fulfilling criteria for current asthma. GM FENO was 17.80 (GSD 2.48). Forty percent of the 
population had a FENO >25 ppb and 20% had a FENO >40ppb. 
 
Rates of smoking and atopy varied significantly between the three groups. Laboratory animal 
workers were less likely to smoke: rates of current smoking among laboratory animal workers were 
13% versus 24% and 30% in wood and foundry workers respectively (p for trend <0.01). However, 
atopy was commoner among laboratory animal workers compared to wood and foundry workers 
(41% versus 25% and 36% respectively, p for trend <0.01). Laboratory animal workers differed from 
wood and foundry workers being younger in age, more likely to be female, and having a lower BMI 
and height (Table 30). Laboratory animal workers were also less likely to use RPE at work and had 
spent a shorter time employed in their current job. Laboratory animal workers were less likely to 
have work-related symptoms or CAS and were less likely to have current asthma. Rates of asthma 
were very low in laboratory animal workers at 1%. 
 
There was no difference between AM or GM FENO between the three groups. However, more 
foundry workers had a FENO above 40ppb (25% versus 18% and 13% in wood and laboratory animal 
workers respectively, p for trend <0.05). Similarly, foundry workers were more likely to have a FENO 
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above 25 ppb. There was no difference in percent predicted FEV1, FVC, or PEF between the three 
groups.  










Age, years (SD) 41.23 (12.23) 41.91 (12.23) 28.75 (7.47)** 38.96 (12.53) 
Sex, m (%) 218 (97) 294 (99) 53 (40)** 565 (86) 
Current smoker, y (%) 54 (24) 89 (30) 18 (13)** 161 (25) 
BMI, height m2/weight in 
kg (SD) 
26.88 (4.88) 28.25 (4.49) 23.83 (4.27)** 26.91 (4.87) 
Height, cm (SD) 176.17 (8.26) 176.13 (6.47) 168.48 (8.89)** 174.64 (8.21) 
Exposure 
Currently uses RPE, y (%) 172 (76) 216 (73) 64 (47)** 452 (69) 
Time exposed in current 
job, years (SD) 
7.53 (6.87) 8.41 (9.23) 5.13 (4.82)* 7.43 (7.80) 
Health 
Any WRUAS, n (%) 56 (25) 73 (25) 27 (20) 156 (24) 
WRRS, n (%) 23 (10) 60 (20) 5 (4)** 88 (13) 
Any WRS, n (%) 52 (23) 86 (29) 25 (19)* 163 (25) 
CAS, n (%) 108 (48) 134 (45) 21 (16)** 263 (40) 
Atopy, n (%) 57 (25)** 107 (36) 55 (41) 219 (33) 
Inhaled steroid use, n (%) 19 (8) 22 (8) 4 (3) 45 (7) 
Current asthma, n (%) 31 (14) 34 (12) 1 (1)** 66 (10) 
AM FENO, ppb (SD) 27.18 (27.80) 29.33 (27.38) 25.85 (28.02) 27.87 (27.65) 
GM FENO, ppb (GSD) 18.38 (2.47) 20.14 (2.55) 18.03 (2.32) 19.08 (2.48) 
FENO >25 ppb, n (%) 80 (36) 135 (46)* 47 (35) 262 (40) 
FENO > 40 ppb, n (%) 41 (18) 73 (25)* 18 (13) 132 (20) 
Percent predicted FEV1 
(SD) 
100.17 (13.03) 98.27 (13.47) 100.42 (10.96) 99.35 (12.88) 
Percent predicted FVC 
(SD) 
102.98 (14.58) 103.38 (12.22) 104.31 (10.81) 
103.42 
(12.84) 
Percent predicted PEF 
(SD) 
108.49 (16.79) 107.86 (18.29) 108.87 (15.35) 
108.28 
(17.20) 
*p <0.05, **p <0.01  
RPE = respiratory protective equipment. WUAS = work-related upper airway symptom (nasal or ocular symptoms). 
WRRS = work-related respiratory symptoms. WRS = work-related nasal or respiratory symptoms. CAS = current asthma 
symptoms defined by wheezing, nocturnal chest tightness, breathlessness on exertion, at rest, or at night, or asthma 
medication use within the last 12 months as per ECRHS. Atopy defined by total IgE >100kU/L or symptoms within 12 
months among LMW workers and positive SPTs to common aeroallergens in HMW workers. Current asthma was 
defined using ECRHS criteria of CAS plus a current or ever asthma diagnosis.  
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6.3.3 Determinants of FENO in the study population 
Univariate relationships between FENO and known modifiers including sex, atopy, smoking, height, 
ICS use, and current asthma are shown in Table 34. Sex, atopy, and current smoking were 
significantly associated with both GM FENO and FENO >40ppb. FENO was higher among men, atopics, 
and non-smokers. Height was positively correlated with FENO. FENO was higher among current 
asthmatics compared with non-asthmatics. ICS use was associated with a significantly increased GM 
FENO and risk of FENO >40ppb, with a similar magnitude of effect to a diagnosis of asthma. 
Contingency table analysis revealed ICS prescription to be highly correlated to a current asthma 
diagnosis: 85% of individuals taking asthma inhalers fulfilled ECRHS criteria for a current asthma 
diagnosis, whereas 95% of those not taking an inhaler failed to meet diagnostic criteria (p<0.01). 















Table 34: Relationships between key modifiers including sex, age, atopy, smoking, height, inhaled 
corticosteroid use, and current asthma with geometric mean FENO and FENO >40ppb. 
 GM FENO, ppb (GSD) (n=655) FENO >40ppb, n (%) (n=655) 
Sex 
Male (n=565) 19.66 (2.51) 125 (22) 
Female (n=90) 15.81 (2.25) 7 (8) 
P value <0.05 <0.01 
Age, years 
 Pearson’s’ r = 0.045  
P value 0.255  
Atopy 
Yes (n=219) 23.08 (2.66) 62 (28) 
No (n=436) 17.33 (2.35) 70 (16) 
P value <0.01 <0.01 
Current smoker 
Yes (n=161) 11.98 (2.28) 17 (10) 
No (n=494) 22.20 (2.29) 115 (23) 
P value <0.01 <0.01 
Height 
 Pearson’s’ r = 0.10  
P value <0.01  
ICS use 
Yes (n=45) 28.51 (2.48) 15 (48) 
No (n=610) 18.69 (2.47) 117 (19) 
P value 0.01 <0.01 
Current asthma 
Yes (n=66) 24.53 (2.38) 24 (36) 
No (n=589) 18.55 (2.49) 108 (18) 
P value <0.05 <0.01 
 
Adjusted linear and logistic regression analyses were performed to further explore the determinants 
of FENO (Table 35). In linear models, smoking had the most influence on FENO with current smoking 
reducing GMR FENO by almost half (GMR FENO 0.53, 95% CI 0.45 -0.62). Atopy increased GMR FENO by 
approximately a quarter (1.28, 1.11 - 1.47). Non-significant associations were observed for sex. In 
logistic models, current smoking, sex, and atopy were associated with a FENO >40ppb. Among current 
smokers, risk of significant airway inflammation was less than half that of non-smokers (OR 0.35, 
95% CI 0.20 – 0.61). Risk was significantly lower in female versus male workers (0.40, 0.16 – 0.96) 
whereas for atopic workers (1.87, 1.26 – 2.82) it was significantly increased. Relationships for height 
were not significant in adjusted models. Adjusted R2 for both models was 0.12.  
 167 
 
Table 35: Adjusted multiple linear and logistic relationships between GMR FENO and FENO >40ppb and sex, 
atopy, and current smoking. 
 GMR FENO, ppb FENO >40ppb P value 
Female sex (female =1) 0.83 (0.66 - 1.04) 0.40 (0.16 – 0.96) 
GMR FENO p=0.11 
FENO >40 ppb = <0.05 
Atopic (atopic =1) 1.28 (1.11 - 1.47) 1.85 (1.22 – 2.79) 
GMR FENO p<0.01 
FENO >40 ppb p<0.01 
Current smoker (yes =1) 0.53 (0.45 -0.62) 0.35 (0.20 – 0.62) 
GMR FENO p<0.01 
FENO >40 ppb p<0.01 
R2 0.12 0.12  
 
6.3.4 Modifiers of airway inflammation stratified by atopy and smoking 
Multiple linear and logistic regression models were constructed to explore associations between 
airway inflammation and clinical parameters including CAS, WRS, WRRS, current asthma, and 
spirometry across the study population (Table 36). Since rates of specific sensitisation were very low 
among workers exposed to LMW allergens (<1% in this study), no further analyses considering 
specific sensitisation were performed. As ICS use was closely related to current asthma diagnosis 
and was not significant in models, it was not included as an obligate confounder. All models were 
controlled for sex, age, smoking, height, and atopy.  
 
Eosinophilic airway inflammation was associated with a diagnosis of current asthma among the 
whole study population (OR for FENO >40ppb 2.12, 95% CI 1.19 – 3.78). The association for GMR FENO 
was also significant (GMR FENO 1.26, 95% CI 1.01 – 1.58). No significant relationships were observed 
between FENO and any of CAS, WRS, WROS or WRRS. There were no significant associations observed 
between either GMR FENO or FENO >40ppb and percent predicted FEV1, FVC, or PEF.  
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Table 36: Linear and logistic associations between FENO and respiratory symptoms, asthma, and spirometry 
across the study population. Models were adjusted for sex, atopy, and smoking. 
 GMR FENO FENO >40ppb P value 
CAS (yes=1) 1.02 (0.89 - 1.17) 1.12 (0.74 – 1.68) 
GMR FENO p=0.78 
FENO >40ppb = 0.60 
WROS or WRNS (yes=1) 0.97 (0.84 - 1.14) 0.68 (0.42 – 1.11) 
GMR FENO p=0.75 
FENO >40ppb p=0.12 
WRRS (yes=1) 1.12 (0.93 - 1.36) 1.09 (0.62 – 1.91) 
GMR FENO p=0.24 
FENO >40ppb p=0.78 
WRS (yes=1) 1.02 (0.88 - 1.19) 0.77 (0.48 – 1.24) 
GMR FENO p=0.79 
FENO >40ppb p=0.28 
Current asthma (yes=1) 1.26 (1.01 – 1.58) 2.12 (1.19 – 3.78) 
GMR FENO p=0.04 
FENO >40 ppb p=0.01 
%FEV1 1.00 (0.99 - 1.01) 0.99 (0.97 – 1.01) 
GMR FENO p=0.59 
FENO >40ppb p=0.45 
%FVC 1.00 (0.99 - 1.01) 1.00 (0.99 – 1.02) 
GMR FENO p=0.88 
FENO >40ppb p =0.98 
%PEF 1.00 (0.99 - 1.01) 1.00 (0.99 – 1.01) 
GMR FENO p = 0.73 
FENO >40ppb p=0.89 
WROS = work-related ocular symptoms. WRNS = work-related nasal symptoms. CAS = current asthma symptoms. WRRS 
= work-related respiratory symptoms. WRS = work-related nasal or respiratory symptoms. FEV1 = forced expiratory 
volume in 1 second. FVC = forced vital capacity. PEF = peak expiratory flow. 
 
To further investigate associations between FENO and features of asthma, data were stratified by 
atopy and smoking (Figure 20, Tables 37-40). Relationships were analysed for: atopic smokers (n=49, 
Table 37); atopic non-smokers (n=170, Table 38); non-atopic smokers (n=112, Table 39); and non-
atopic non-smokers (n=324, Table 40).  
 
FENO was most strongly associated with current asthma among non-smoking groups. Among atopic 
non-smokers, a current asthma diagnosis was associated with an increased risk of FENO >40ppb (OR 
for FENO >40ppb 2.70, 1.17 – 6.26) and a higher GMR FENO (1.37, 0.94 – 1.99). Current asthma also 
increased the likelihood of high FENO among non-atopic non-smokers: OR for FENO >40ppb among 
non-atopic non-smokers was 2.64 (0.92 – 7.63, Table 40).  
 
Among smokers, WRS rather than asthma were significantly associated with airway inflammation 
(Table 39). In non-atopic smokers, WRRS were significantly associated with both an increase in GMR 
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FENO (1.94, 1.24 – 3.04) and risk of FENO >40ppb (OR 4.44, 1.16 – 16.99). Similar associations were 
also seen for WRS and GMR FENO in the same group. In atopic smokers, risk of FENO >40ppb tended 
to be higher in those with WRRS (Table 37). 
 
Table 37: Associations between FENO and respiratory symptoms, work-related symptoms and current 
asthma in 49 atopic smokers. Models were controlled for sex. 
 Atopic smokers (n=49) 
 GMR FENO FENO >40ppb P value 
CAS (yes=1) 
0.71  
(0.40 – 1.28)  
0.41  
(0.08 – 2.14)  
GMR FENO =0.25 
FENO >40ppb = 0.29 
WROS or WRNS (yes=1) 
1.21  
(0.63 – 2.32)  
2.44  
(0.45 – 13.26)  
GMR FENO =0.57 
FENO >40ppb = 0.30 
WRRS (yes=1) 
1.08  
(0.47 – 2.5)  
2.32  
(0.35 – 15.43)  
GMR FENO p=0.85 
FENO >40ppb = 0.38 
WRS (yes=1) 
0.72  
(0.38 – 1.39)  
1.11  
(1.82 – 6.78)  
GMR FENO p=0.33 
FENO >40ppb = 0.91 
Current asthma (yes=1) 
0.85  
(0.41 – 1.78)  
0.46  
(0.05 – 4.39)  
GMR FENO p=0.66 
FENO >40ppb = 0.50 
WROS = work-related ocular symptoms. WRNS = work-related nasal symptoms. CAS = current asthma symptoms. WRRS 
= work-related respiratory symptoms. WRS = work-related nasal or respiratory symptoms. 
 
Table 38: Associations between FENO and respiratory symptoms, work-related symptoms and current 
asthma in 170 atopic non-smokers. Models were controlled for sex. 
 Atopic non-smokers (n=170) 
 GMR FENO FENO >40ppb P value 
CAS (yes=1) 1.07 (0.81 – 1.41) 0.97 (0.50 – 1.90) 
GMR FENO = 0.65 
FENO >40ppb = 0.94 
WROS or WRNS (yes=1) 0.75 (0.56 – 1.01) 0.49 (0.23 – 1.06) 
GMR FENO =0.06 
FENO >40ppb = 0.07 
WRRS (yes=1) 0.85 (0.57 -1.26) 0.47 (0.16 – 1.36) 
GMR FENO = 0.41 
FENO >40ppb =0.16 
WRS (yes=1) 0.85 (0.63 – 1.15) 0.60 (0.27 – 1.30) 
GMR FENO = 0.29 
FENO >40ppb= 0.19 
Current asthma (yes=1) 1.37 (0.94 – 1.99) 2.70 (1.17 – 6.26) 
GMR FENO = 0.10 
FENO >40ppb = 0.02 
WROS = work-related ocular symptoms. WRNS = work-related nasal symptoms. CAS = current asthma symptoms. WRRS 
= work-related respiratory symptoms. WRS = work-related nasal or respiratory symptoms. 
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Table 39: Associations between FENO and respiratory symptoms, work-related symptoms and current 
asthma in 112 non-atopic smokers. Models were controlled for sex. 
 Non-atopic smokers (n=112) 
 GMR FENO FENO >40ppb P value 
CAS (yes=1) 0.96 (0.65 – 1.41) 1.91 (0.46 – 7.79) 
GMR FENO = 0.83 
FENO >40ppb = 0.37 
WROS or WRNS (yes=1) 1.30 (0.84 – 2.01) 0.73 (0.15 – 3.67) 
GMR FENO =0.24 
FENO >40ppb = 0.73 
WRRS (yes=1) 1.94 (1.24 – 3.04) 4.44 (1.16 – 16.99) 
GMR FENO <0.01 
FENO >40ppb =0.03 
WRS (yes=1) 1.67 (1.11 – 2.51) 2.63 (0.71 – 9.81) 
GMR FENO = 0.01 
FENO >40ppb= 0.15 
Current asthma (yes=1) 1.50 (0.82 – 2.72)  0.88 (0.10 – 7.61) 
GMR FENO = 0.19 
FENO >40ppb = 0.91 
WROS = work-related ocular symptoms. WRNS = work-related nasal symptoms. CAS = current asthma symptoms. WRRS 
= work-related respiratory symptoms. WRS = work-related nasal or respiratory symptoms. 
 
Table 40: Associations between FENO and respiratory symptoms, work-related symptoms and current 
asthma in 324 non-atopic non-smokers. Models were controlled for sex. 
 Non-atopic non-smokers (n=324) 
 GMR FENO FENO >40ppb P value 
CAS (yes=1) 1.10 (0.92 – 1.32) 1.33 (0.73 – 2.41) 
GMR FENO = 0.28 
FENO >40ppb = 0.35 
WROS or WRNS (yes=1) 1.01 (0.83 – 1.24) 0.75 (0.36 – 1.58) 
GMR FENO =0.89 
FENO >40ppb = 0.73 
WRRS (yes=1) 1.02 (0.78 – 1.33) 1.09 (0.45 – 2.64) 
GMR FENO =0.87 
FENO >40ppb =0.86 
WRS (yes=1) 1.02 (0.84 – 1.24) 0.67 (0.32 – 1.41) 
GMR FENO = 0.86 
FENO >40ppb= 0.30 
Current asthma (yes=1) 1.19 (0.82 – 1.73) 2.64 (0.92 – 7.63) 
GMR FENO = 0.36 
FENO >40ppb = 0.07 
WROS = work-related ocular symptoms. WRNS = work-related nasal symptoms. CAS = current asthma symptoms. WRRS 




Figure 20: Box and whisker plot showing odds ratios (95% confidence intervals) for FENO >40ppb in workers 
with current asthma symptoms, work-related respiratory symptoms, and current asthma, stratified by atopy 
and smoking. 
6.3.5 Association of airway inflammation with grouped asthma variables 
Table 41 shows the prevalence of work-related symptoms and asthma split by asthma indices - CAS 
plus airway inflammation (FENO >40ppb) or CAS plus abnormal spirometry (FEV1<LLN, or 
FEV1/FVC<LLN). Nasal or ocular symptoms, WRS, and WRRS were more common among workers 
with CAS and FENO>40ppb compared to those without. Asthma was significantly more prevalent in 
workers with either CAS and an FEV1<LLN and CAS and FEV1/FVC <LLN versus those without. Asthma 
prevalence was 42% in those with CAS and FENO >40ppb versus 32% in those with CAS and FEV1 <LLN 
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and 35% in those with CAS and FEV1/FVC <LLN. The majority of workers in all three groups were 
exposed to LMW allergens.  
 
Table 41: Prevalence of work-related symptoms, respiratory symptoms, asthma, and exposure type in 
workers with a combination of current asthma symptoms and either airway inflammation (FENO >40ppb), an 
FEV1 <LLN, or FEV1/FVC <LLN. 
 CAS+FENO >40ppb, n=57 CAS+FEV1 <LLN, n=19 CAS+FEV1/FVC <LLN, n=26 
WROS or WRNS, n (%) 17 (30) 4 (21) 5 (19) 
WRS, n (%) 25 (44) 3 (16) 5 (19) 
WRRS, n (%) 19 (33) 2 (11) 4 (15) 
Ever asthma, n (%) 24 (42) 6 (32) 9 (35) 
Current asthma, n (%) 24 (42) 6 (32) 9 (35) 
LMW exposed, n (%) 55 (97) 18 (95) 24 (92) 
WROS = work-related ocular symptoms. WRNS = work-related nasal symptoms. CAS = current asthma symptoms. WRRS 
= work-related respiratory symptoms. WRS = work-related nasal or respiratory symptoms 
 
Associations between the three composite asthma variables and work-related symptoms, asthma 
diagnosis, and exposure were explored using multiple logistic regression (Table 42). All models were 
adjusted for current smoking, sex and atopy. Workers with CAS and FENO >40ppb were at increased 
risk of WRS (OR 2.54, 95% CI 1.44 – 4.48) or WRRS (3.75. 2.01 – 7.00). Similarly, workers with CAS 
and high FENO were at increased risk for both ever (4.44, 2.43 – 8.12) and current (8.28, 4.33 – 15.86) 
asthma. Workers with CAS and FENO >40ppb were significantly more likely to be LMW exposed (5.71, 
1.14 – 28.61). The presence of CAS and FEV1 <LLN was associated with a significantly increased risk 
of current asthma (3.34, 1.17 – 9.56). CAS and an FEV1/FVC <LLN was significantly associated with an 




Table 42: Odds ratios for work-related symptoms and asthma across groups of workers with current asthma 
symptoms plus either FENO>40ppb, FEV1<LLN or FEV1/FVC<LLN. All models controlled for sex, atopy and 
smoking. Data presented as odds ratios and associated 95% confidence intervals in parentheses. 
 
CAS and FENO 
>40ppb, n=57 
P value 
CAS and FEV1 
<LLN, n=19 
P value 
CAS and FEV1/FVC 
<LLN, n=26 
P value 
WROS or WRNS 
(yes=1) 
1.25  
(0.68 – 2.31) 
0.47 
0.75  
(0.24 – 2.31) 
0.62 
0.69  




(1.44 – 4.48) 
<0.01 
0.51 ( 
0.15 – 1.79) 
0.30 
0.64  




(2.01 – 7.00) 
<0.01 
0.66  
(0.15 – 2.96) 
0.59 
0.97  





(2.43 – 8.12) 
<0.01 
2.24  
(0.80 – 6.28) 
0.12 
3.16  





(4.33 – 15.86) 
<0.01 
3.34  
(1.17 – 9.56) 
0.02 
4.48  





(1.14 – 28.61) 
0.03 
6.32  
(0.43 – 92.89) 
0.18 
4.77  
(0.50 – 45.27) 
0.17 
^ = versus HMW exposed workers. WROS = work-related ocular symptoms. WRNS = work-related nasal symptoms. CAS 
= current asthma symptoms. WRRS = work-related respiratory symptoms. WRS = work-related nasal or respiratory 
symptoms 
 
The degree of agreement between airway inflammation and obstructive spirometry among workers 
with CAS was assessed using contingency analysis and presented using an intersecting Venn diagram 
(Figure 21). Two-hundred-and-sixty-three (40%) workers had CAS, 132 workers (20%) had high FENO 
and 35 (5%) had an FEV1/FVC <LLN.  
 
Among participants with CAS there was little overlap between those with airway inflammation and 
those with obstructive spirometry. Fifty-two (15%) had airway inflammation, whereas only 21 (6%) 
had obstructive spirometry. Only five (1%) symptomatic workers had both a high FENO and 
obstructive spirometry. There was no significant difference in prevalence of airway inflammation 
between workers with and without CAS (Chi-square for difference 0.10, p=0.75).  
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Figure 21: Venn diagram showing contingency table analysis of workers with current asthma symptoms and 
either FENO >40ppb or FEV1/FVC <LLN. 
Relationships between WRRS, airway inflammation and obstructive spirometry were explored using 
contingency analyses (Figure 22). A similar lack of overlap was found between airway inflammation 
and obstructive spirometry in workers with WRRS: only 1 symptomatic worker (1%) had both airway 
inflammation and obstructive spirometry. Airway inflammation was found in 18 (8%) of those with 




Figure 22: Intersecting Venn diagram showing relationships between WRRS, airway inflammation and 
obstructive spirometry. 
Most workers with CAS and airway inflammation did not have a diagnosis of asthma (Figure 23). 
Among the 52 symptomatic workers with airway inflammation, 24 (46%) self-reported an asthma 
diagnosis whereas the remaining 28 (54%) did not. Among 21 symptomatic workers with obstructive 
spirometry, nine (43%) self-reported asthma whereas the remaining 12 (57%) did not. Among five 
workers with CAS, airway inflammation and obstructive spirometry, two (40%) had no current 





Figure 23: Prevalence of self-reported asthma diagnosis among workers with current asthma symptoms and 
either airway inflammation or obstructive spirometry. Fifty-two workers had a high FENO, 21 workers had 
obstructive lung function, and 5 workers had both. 
6.3.6 Effects of exposure on FENO 
In order to further characterise the effect of exposure on airway inflammation, relationships 
between key modifiers of FENO (atopy, smoking, sex and current asthma) were stratified by exposure 
to either HMW or LMW allergens (Table 43). Overall, associations between key modifiers remained 
for LMW exposures but were less strong for HMW exposures. Current asthma was significantly 
associated with both GMR FENO and FENO above 40ppb in LMW but not HMW-exposed workers. 
Smoking was strongly associated with both GMR FENO and FENO >40ppb in LMW but not HMW-
exposed workers, although analyses for FENO >40ppb were limited among HMW-exposed workers 
due to low smoking rates. Female sex was associated with significantly lower GMR FENO in HMW-













relationship was not significant. Atopy was significantly associated with increased GMR FENO and risk 
of FENO >40ppb among workers exposed to LMW but not HMW agents.  
 
Table 43: Relationships between smoking, sex, atopy and asthma with airway inflammation, stratified by 
exposure to HMW or LMW allergens. 
  GMR FENO FENO >40ppb P value 
HMW, n=135 
Female sex, yes 0.74 (0.56 - 1.01) 0.26 (0.09 – 0.76) 
GMR FENO p=0.06 
FENO >40pp, p=0.01 
Atopic, yes 1.08 (0.80 - 1.50) 0.79 (0.28 – 2.28) 
GMR FENO P=0.61 
FENO >40pp p=0.79 
Current smoker, yes 0.98 (0.64 – 1.50) 0.89 (0.18 – 4.47) 
GMR FENO p=0.94 
FENO >40ppb = 0.67 
Current asthma, yes 0.90 (0.17 – 4.93) 0.56 (0.01 – 1.02) 
GMR FENO p=0.91 
FENO >40pp p=1.0 
LMW, n=520 
Female sex, yes 0.58 (0.31 - 1.04) 0.42 (0.05 – 3.53) 
GMR FENO p=0.07 
FENO >40 ppb, p=0.42 
Atopic, yes 1.35 (1.15 - 1.58) 2.45 (1.59 – 3.79) 
GMR FENO p <0.01 
FENO >40 ppb, p <0.01 
Current smoker, yes 0.49 (0.41 - 0.57) 0.34 (0.19 – 0.61) 
GMR FENO p <0.01 
FENO >40 ppb, p <0.01 
Current asthma, yes 1.27 (1.01 – 1.59) 1.88 (1.04 - 3.39) 
GMR FENO p=0.04 
FENO >40pp p= 0.04 
 
Associations between FENO and work-related symptoms, CAS, and asthma were examined by 
exposure group and stratified by atopy and smoking. Analyses were limited among HMW workers 
due to small numbers of smokers and the low prevalence of asthma, therefore they were stratified 
by LMW exposure only (Table 44). Among LMW-exposed workers, observations were comparable to 
the whole population analyses. The strongest associations were seen for non-smokers, where 
current asthma was associated with a risk of FENO >40ppb in both atopic non-smokers (OR 2.82, 1.18 
– 6.77) and non-atopic non-smokers (2.60, 0.90 – 7.53). Among smokers, significant associations 
between current asthma and FENO were not found. In contrast, smoking groups with work-related 
symptoms tended to be at increased risk of airway inflammation, although relationships were not 
significant (OR for WRRS in non-atopic smokers 3.47, 0.85 – 14.22). No significant relationships were 
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observed among atopic smokers between any of the key independent symptom or asthma variables 
and FENO >40ppb. 
 






















(0.04 – 1.66) 
0.16 
1.07  
(0.52 – 1.20) 
0.85 
1.56  
(0.37 – 6.59) 
0.55 
1.36  





(0.27 – 11.86) 
0.55 
0.43  
(0.19 – 1.00) 
0.05 
0.38  
(0.05 – 3.15) 
0.37 
0.82  




(0.10 – 11.32) 
0.95 
0.42  














(0.22 – 1.19) 
0.12 
2.15  
(0.54 – 8.65) 
0.28 
0.72  





(0.05 – 5.00) 
0.56 
2.82  
(1.18 – 6.77) 
0.02 
0.97  
(0.11 – 8.47) 
0.98 
2.60  
(0.90 – 7.53) 
0.08 
WROS = work-related ocular symptoms. WRNS = work-related nasal symptoms. CAS = current asthma symptoms. WRRS 
= work-related respiratory symptoms. WRS = work-related nasal or respiratory symptoms 
 
Finally, evidence for a dose-response effect for exposure was sought using stratified analysis. No 
quantified exposure measurements were available for HMW-exposed workers, so analyses were 
limited to the 520 LMW-exposed workers (Table 45). One hundred and fourteen workers were 
higher exposed – either in the highest tertile of foundry exposure or highest quartile of wood dust 
exposure. GM FENO was significantly lower in the higher exposed at 16.75 versus 20.83 ppb (p=0.01). 
FENO >40ppb was less prevalent in the higher exposed. In adjusted linear regression models, the 
higher exposed had a lower GMR FENO (GMR FENO 0.84, 95% CI 0.72 – 0.98) versus the lower exposed 
(Table 46). In logistic regression models, risk of FENO >40ppb was lower in the higher exposed (OR 





Table 45: Univariate analyses of FENO among LMW-exposed workers, by higher or lower exposure. 
 Higher exposed (n=114) Lower exposed (n=406) P value 
AM FENO, ppb (SD) 24.69 (26.14) 30.28 (28.10) 0.03 
GM FENO, ppb (SD) 16.75 (2.53) 20.83 (2.49) 0.01 
FENO >40ppb, n (%) 28 (16) 86 (25) 0.02 
 The higher exposed group included woodworkers in the highest exposure quartile and foundry workers in the highest 
exposure tertile. 
 
Table 46: Linear and logistic regression models for airway inflammation among 520 LMW-exposed workers, 
stratified by higher versus lower exposure. 114 workers were higher exposed, and 406 were lower exposed. 
 GMR FENO FENO >40ppb P value 
Higher exposed (lower exposed = 1) 0.84 (0.72 – 0.98) 0.61 (0.37 – 0.99) 
GMR FENO p=0.03 
FENO >40 ppb = 0.05 
Models were adjusted for age, sex, smoking, atopy, height, asthma, and RPE use. 
 
 Discussion 
This study is the first of its kind investigating airway inflammation, alongside qualitative exposure 
measurements, in a large group of wood, foundry, and laboratory animal workers. After controlling 
for key confounders, both GMR FENO and FENO >40ppb were significantly associated with current 
asthma in the overall population, but in stratified analyses associations remained significant only for 
non-smokers. Associations between markers of OA, such as WRRS or an asthma diagnosis, were 
stronger among symptomatic workers with eosinophilic airway inflammation (FENO >40ppb) versus 
symptomatic workers with obstructive spirometry. There was little overlap between these groups, 
and over 50% of symptomatic workers with either airway inflammation or airflow obstruction had 
no asthma diagnosis. This finding suggests measuring eosinophilic airway inflammation provides 
additional information to spirometry in symptomatic workers and supports a possible role for FENO in 
screening for OA.  
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6.4.1 Limitations 
Both smoking and atopy significantly modified eosinophilic airway inflammation in the current study. 
Therefore, differences in the definition of atopy and smoking may have influenced associations 
between FENO and other outcomes of interest. The majority of participants in the current study had a 
diagnosis of atopy based on either total IgE or skin prick testing (235). Symptoms were used to 
determine atopy in foundry workers who underwent neither blood nor skin tests, as in other cross-
sectional studies examining relationships between occupational exposures and OA (236). Data from 
each occupational group was collected according to pre-agreed study designs and approved by an 
ethics committee, and therefore it was impossible to alter this retrospectively. Relying on 
individuals’ ability to recall atopic symptoms may have introduced reporting bias into the current 
study (30). Although the prevalence of atopy differed among the three occupational groups 
included, rates were comparable to those reported in a 2010 systematic review of the UK 
population, where prevalence in the five included studies ranged from 19 to 54% (151). This 
suggests a large under- or overestimation of atopy was not present. Furthermore, data previously 
presented in this thesis (sections 3.3.1 and 5.3.1) supports a strong relationship between atopic 
symptoms and either a total IgE >100 kU/l or positive SPTs. Since symptom data is often the only 
information available for practitioners conducting health surveillance, use of such data may more 
accurately reflect ‘real-world’ experiences, and therefore investigating relationships between atopic 
symptoms and OA is relevant to daily practice.  
 
Furthermore, definitions of smoking may have influenced FENO in the current study. Laboratory 
animal workers reported sporadic smoking habits, some identifying as current but irregular smokers. 
The use of current rather than ever smoking in models may have underestimated the effect of 
smoking in the population, particularly in spirometry models where historic smoking is more 
relevant to the development of airflow obstruction. However, current smoking is known to influence 
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FENO more strongly than ever smoking (46), and its use in models exploring eosinophilic airway 
inflammation is likely to be more appropriate.  
 
Significant demographic differences existed between the three occupational groups. Laboratory 
animal workers were approximately 10 years younger than wood or foundry workers, were 
approximately 10cm shorter, around 50% were female compared to very few female wood or 
foundry workers, and only 13% were current smokers. This made comparisons between workers 
exposed to either HMW or LMW allergens very difficult due to the significant influence of such 
demographic factors on airway inflammation. The demographics of the foundry and wood industry 
are typical of those seen in British manufacturing and heavy industry: manual workforces have 
historically been men, with higher smoking rates and greater retention of staff compared with other 
occupations (237). In contrast, the HMW sample in the current study was drawn from academic 
institutions where the majority of the participants (81%) were academics undertaking doctoral or 
post-doctoral work. Since these sample differences are likely to represent differences at a 
population level rather than sampling bias within the study, matching on a case basis would have 
been impossible. In future, measuring FENO in HMW-exposed workers with more comparable 
demographics to the wood or foundry industry (for example in plant bakery workers) could be useful 
to examine differences in airway inflammation between HMW and LMW-exposed groups (238).   
 
This study was limited in evaluating an exposure-response across the whole study population. 
Methodological differences in exposure assessment among laboratory animal workers made it 
impossible to compare exposure-response relationships across the whole study group. Thus, such 
analyses were restricted to LMW-exposed workers. In the current study, mean exposures among 
wood and foundry workers were lower than the current WEL set by HSE (24). Aligning exposures 
from different work environments is difficult: identifying clinically relevant exposure thresholds is 
often impossible in OA, even for single allergens (9). Furthermore, exposure assessment does not 
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account for individual responses to workplace exposures, or for exposure-reduction measures such 
as use of exhaust ventilation or RPE. Finally, exposure misclassification may occur in cross-sectional 
studies, which cannot accurately capture past exposures and therefore may underestimate historic 
exposures if health and safety practices have improved or individuals with allergy or OA have left the 
workforce due to ill-health. Longitudinal studies with quantitative exposure measures are needed to 
better quantify exposure-response relationships with airway inflammation in workplaces. 
 
FENO release is a marker of Th-2 predominant airway inflammation, in which the eosinophil plays a 
key immunomodulatory role. Th-2 airway inflammation is present in the majority of adults with 
asthma to environmental allergens (5). The majority of OA is associated with Th-2 inflammation 
manifested by a spectrum of specific IgE positivity, sputum eosinophilia, and other biomarker 
increases (10). However, a smaller but significant proportion of OA is non-eosinophilic, with some 
studies reporting prevalence as high as 40% in LMW-exposed populations (19). Neutrophilic or 
paucigranulocytic airway inflammation is not associated with an increased FENO, and symptomatic 
workers with airflow obstruction may have non-eosinophilic asthma (125, 239). However, 
prevalence of obstructive airways disease among symptomatic workers in the current study was low. 
It was not feasible to perform sputum cytology or BAL on participants in the current study, who 
were recruited and surveyed at their places of work. More detailed analysis of symptomatic workers 
using additional markers of airway inflammation, infection, or bronchoconstriction, would be 
interesting in understanding the mechanisms for OA in different exposure environments.  
 
Since the majority of the present study population were exposed to LMW agents (namely 
isocyanates, formaldehyde, and wood dust), it might be expected that non-eosinophilic airway 
inflammation would be more likely. However, the present findings do not support this. Foundry and 
wood workers had a higher GM FENO and a higher proportion had a FENO >40ppb compared to 
laboratory animal workers. In fact, overall GM FENO levels were higher than have been previously 
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reported in workers with non-eosinophilic OA. Anees et al. reported GM FENO of 5.1 (interquartile 
range 3.7 – 6.6) ppb in workers with OA and sputum eosinophils <2%, and 10.4 (5.6–17.4) ppb in 
workers with OA and sputum eosinophilia (240). In contrast, GM FENO in the current study was 
higher at 19.08 (SD 2.48) ppb. Follow-up studies are vital in understanding whether these high levels 
of baseline airway inflammation translate to future respiratory disease.   
 
A strength of this research is its workplace setting. Undertaking research in a workplace provides the 
most realistic environment in which to explore associations between OA and workplace exposures. 
However, quantifying exposures in such research is problematic. For example, though the LMW 
group were primarily exposed to wood dust, isocyanates, and formaldehyde, workers may have 
been exposed to a number of other potential irritants or allergens including foundry dust, welding 
fume, solvents, or glues. Under such circumstances identifying a causative agent for airway 
inflammation may be challenging. In contrast, FENO may be useful as a biomarker of exposure as well 
as disease and be useful as an objective tool to assess exposure and improve workplace controls. 
Cohort and control studies are needed to assess how exposures are related to FENO. Such research 
would be extremely valuable in considering the expansion of the role of FENO as a biomarker of 
exposure as well as of airway inflammation. 
6.4.2 FENO in the diagnosis of occupational asthma  
Sex, atopy, smoking, height, and inhaler use were key determinants of FENO in the current study. 
Even after controlling for confounders, the current study found atopic workers were 80% more likely 
to have a high FENO than non-atopic workers, current smokers were 65% less likely to have a high 
FENO than never smokers, and men were 60% more likely to have a high FENO than women. Smoking 
exerted a greater effect than atopy in linear regression models. Current smoking was associated with 
a 47% lower FENO (GMR 0.53, 95% CI 0.45 -0.61) where atopy was associated with a 28% increase in 
FENO (GMR 1.28, 1.11 - 1.47). The modifying effects of sex, atopy and smoking on FENO are well 
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documented in occupational and non-occupational studies (41, 45-47). Surprisingly, inhaler use was 
associated with an increased, rather than decreased, FENO in the current study. FENO is used to 
identify steroid responsiveness in some asthmatic populations and to monitor ICS use (241). The 
current study did not examine inhaler compliance in detail and therefore did not assess whether 
participants were using their inhaler correctly. Since inhaler use was strongly correlated with asthma 
in the current study, the positive association between inhaler use and FENO may have reflected an 
asthma diagnosis where some individuals were not taking treatment. FENO may therefore provide 
objective evidence of treatment compliance and exacerbation risk in occupational populations, 
which is important in the ongoing management of asthma particularly where populations may still 
be exposed to the causative agent.  
 
The current study supports a relationship between high FENO and current asthma (based on self-
reported disease and CAS or inhaler use), suggesting that FENO is related to asthma in an 
occupational setting. As such, FENO could be a useful tool in diagnosing new-onset asthma in 
workplaces. In particular, FENO may be useful in occupational environments where individuals with 
asthma may have normal spirometry and other tests for asthma such as bronchodilator reversibility, 
bronchial provocation testing or sputum cytology are not available. Since early recognition of 
disease and removal or reduction of exposure is key in OA, the addition of FENO to questionnaires 
and spirometry could highlight populations at higher risk for asthma and prompt more regular 
surveillance or earlier referral to occupational lung disease specialists. This has great potential for 
improving outcomes in OA, where delays in diagnosis are common and associated with poorer 
prognosis (11). 
 
However, when analyses were stratified by smoking and atopy the associations between FENO and 
current asthma remained only in non-smoking groups. Few occupational studies have reported 
associations between asthma and FENO by atopic and smoking status. The findings here reflect those 
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of Jonaid et al. who reported an association between isocyanate exposure and airway inflammation 
only in non-smoking atopic workers (45). Smit et al. described stronger associations between 
wheeze and FENO in non-smoking endotoxin-exposed workers (242). Studies in non-occupational 
cohorts have suggested using reference values for atopic and smoking populations in order to 
identify those with significant changes in FENO (47), but this has yet to be adapted in wider clinical 
practice where a cut-off of 40ppb is more commonly used (4). Interpreting FENO in workers requires 
consideration of their smoking and atopic status, and longitudinal studies are needed to identify 
clinically relevant changes in FENO in occupational settings that could be useful in the diagnosis of 
OA.  
 
In contrast, WRRS were significantly associated with FENO in non-atopic smokers. Among atopic non-
smokers with WRRS, risk of high FENO was four times higher than in those without WRRS (OR 4.44, 
1.16 – 16.99). In their analysis of spice mill workers, Van der Walt et al. reported a five-fold 
increased risk of FENO >50ppb among workers with work-related lower respiratory tract symptoms in 
adjusted regression analyses (43). Smoking is a risk factor for asthma in some occupational studies 
and associations between work-related symptoms and airway inflammation in smoking populations 
may be a sign of early disease (9). Alternatively, airway inflammation in symptomatic smoking 
populations may be suggestive of early COPD (243). Early recognition of symptoms in smokers may 
help encourage smoking cessation and would be advantageous for early diagnosis of airway disease, 
leading to improved health outcomes for the working population (35). 
6.4.3 Relationships between allergen exposure and FENO  
Comparing FENO in HMW versus LMW exposure environments was not the main aim of the current 
study. However, these findings suggest that FENO is associated with asthma in LMW-exposed groups 
even after accounting for smoking and atopy. Although analyses were limited for HMW-exposed 
workers, in LMW-exposed workers GMR FENO was 27% (95% CI 1.01 – 1.59) higher in those with 
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current asthma, and risk of FENO >40ppb was 1.88 (1.04 - 3.39) higher. LMW-exposed workers were 
five times more likely to have CAS and FENO >40ppb versus HMW-exposed workers (OR for CAS and 
FENO >40ppb 5.71, 95% CI 1.14 – 28.61). In contrast, significant relationships between current 
asthma and either GMR FENO or FENO >40ppb were not observed for HMW-exposed workers. 
Previous studies in wood and isocyanate-exposed workers have suggested the role of FENO may be 
limited (72). In studies of SIC for OA, FENO appears to relate more strongly to HMW rather than LMW 
exposures (40). Indeed, evidence has suggested some workers with OA due to LMW exposures do 
not manifest an increase in FENO following a positive challenge. Lemiere et. al. suggested such 
differences could be used to phenotype OA, with LMW-exposed patients having no FENO increases, 
lower rates of atopy, increased nonspecific airway hyperresponsiveness, and higher rates of late 
asthmatic reaction (126). The same study suggested phenotypic differences may be partly related to 
differing underlying mechanisms for OA secondary to HMW or LMW exposures. The applicability of 
this in a workplace population, where the majority of individuals do not have asthma, is not 
established. However, these findings suggest that LMW exposure is associated with an increased risk 
of high FENO and cohort studies are needed to establish how FENO relates to exposure over time, and 
what proportion of individuals with a high FENO will go on to develop clinically relevant disease.  
 
Unusually, atopy was found to be more strongly associated with a high FENO among workers exposed 
to LMW rather than HMW agents. This contrasts with studies where HMW exposure has been more 
strongly associated with high FENO, particularly among atopic workers (42). This finding may reflect 
overrepresentation of LMW workers among the study population, or differing definitions for atopy 
between HMW and LMW workers. Atopy has been shown to be associated with high FENO following 
positive SIC in some workers with LMW OA (244). Since atopy is a constitutional risk factor for FENO 
and therefore unmodifiable, emphasis should be placed on managing modifiable risks such as 
exposure and, as part of a health surveillance programme, smoking.  
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Analyses comparing quantitative exposure assessment with airway inflammation were limited to 
LMW-exposed groups. However, no evidence for an exposure-response effect was found. In fact, 
workers in the higher exposure group had both lower GMR FENO and a lower risk of FENO >40ppb 
compared with workers in the lower exposure groups. Few studies have evaluated risk of airway 
inflammation using quantitative exposure measurements, with inconsistent findings. Van der Walt 
et. al. reported significant 24-hour increases in FENO in spice workers with medium, but not high, 
particulate exposure (43). Increasing isocyanate exposure has been associated with rises in FENO in 
atopic non-smokers (45). Nasal NO has been shown to increase with rising ozone exposures in 
bleachery workers (234). The absence of a clear exposure-response effect in the current study may 
be due to a number of reasons: FENO measurements were made at a single time point, but rises are 
known to peak 24 to 48 hours from initial exposure (155); exposures in wood and foundry workers 
were lower than the current UK WEL, and may not have been sufficient to produce a clinically 
relevant rise in FENO (42); and the absence of such an exposure-response may be further evidence of 
a healthy worker effect (146). 
6.4.4 FENO as a health surveillance tool  
The current study suggests that FENO may have a role in identifying a different population of workers 
at risk for asthma when compared with spirometry. Among workers with symptoms of asthma, 15% 
had evidence of significant airway inflammation whereas only 6% had airflow obstruction. The 
degree of overlap between airway inflammation and airflow obstruction was very low at only 1%. 
The lack of overlap between airway inflammation and airway obstruction reflects previous findings. 
In their study of apprentice hairdressers and bakers, Bohadana et. al. found little overlap between 
FENO and obstructive spirometry (124). Additionally, cohort studies have demonstrated sustained 
decreases in FENO in farmers with confirmed OA but spirometry within the normal range following a 
programme of exposure reduction (113). The presence of airway inflammation in symptomatic 
workers may represent the early signs of clinically apparent asthma (43). FENO may therefore be 
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useful in identifying symptomatic workers before they develop airflow obstruction. This is vital in 
improving outcomes in health surveillance, since established airflow obstruction is associated with 
poorer long-term outcomes in OA (14). 
 
Workers with CAS and airway inflammation were at significantly increased risk of WRS, WRRS, and 
asthma. In contrast, only asthma was associated with CAS and abnormal spirometry in analyses, 
either using FEV1 <LLN alone or using FEV1/FVC <LLN criteria. Work-related nasal or respiratory 
symptoms are used as key referral criteria in health surveillance programmes aimed at identifying 
respiratory diseases that are caused, or exacerbated, by work (11). Furthermore, in workplaces 
where ‘low-level’ health surveillance is used and spirometry not performed, work-related symptoms 
may be the only evidence to support an occupational component where respiratory symptoms exist 
(11). Underreporting of symptoms during health surveillance programmes has been demonstrated, 
with workers having perceived or real fears about divulging work-related symptoms if they believe it 
may threaten their employment (16, 30). Work-related symptoms related better to FENO and CAS 
than to airway obstruction and CAS in the current study. The addition of FENO to a programme of 
health surveillance could help to identify workers who are unwilling or unable to report symptoms in 
order to prompt more active surveillance, evaluation of their work area, or referral to specialist 
services. This could present an important opportunity to improve outcomes in OA among allergen-
exposed workers. 
 
In the current study less than half the symptomatic workers with either airway inflammation or 
airflow obstruction had ever been diagnosed with asthma. Although some symptomatic workers 
may have had a falsely positive FENO (4), or irreversible airways disease such as COPD (13), at least 
some of these patients could have undiagnosed asthma. Longitudinal studies could provide more 
information on the risk of developing asthma in those with symptoms and airway inflammation.  
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6.4.5 Summary 
This large cross-sectional analysis of FENO in wood, foundry, and laboratory animal exposed workers 
shows FENO is strongly associated with self-reported asthma, particularly in non-smokers. Key 
determinants of FENO include atopy, smoking, and sex, and these must be taken into consideration 
when interpreting FENO in occupational studies. There was little association between FENO and 
spirometry in the current study and, in symptomatic workers, FENO was more strongly related to 
features of asthma including work-related symptoms, current asthma symptoms, and a self-reported 
asthma diagnosis. This suggests that FENO provides additional information than spirometry alone in 
allergen-exposed populations at risk of OA. Further studies are needed to understand how the type 
and level of allergen exposure influences FENO in occupational studies, and to describe relevant 














This thesis represents a large cross-sectional study of over 700 workers exposed to occupational 
allergens in the wood, foundry, and laboratory sectors, and captures information on the prevalence 
and associations of respiratory symptoms, asthma, airway inflammation and lung function with 
quantitative allergen exposure. For wood and foundry workers, this represents the first British data 
on asthma prevalence and spirometry for over two decades. Exposures within the wood, foundry, 
and laboratory industries have changed significantly over the last 20 years. This research therefore 
provides important evidence to guide understanding of the current and future risk of asthma in 
these environments.  
 
The population of workers in which fractional exhaled nitric oxide has been measured is among the 
largest in published occupational studies. This is the most recent research studying FENO in wood, 
foundry, and laboratory animal workers. Very few studies have considered the role of FENO in 
allergen-exposed wood and foundry workers, despite persistently high prevalence of OA. 
Approached from a health surveillance perspective, this research demonstrates consistent 
associations between a FENO >40ppb (the threshold used to identify those at high risk of asthma) and 
self-reported asthma in exposed symptomatic workers. In contrast, associations between 
obstructive spirometry and self-reported asthma were weaker, and little evidence for overlap 
between airway inflammation and airflow obstruction in symptomatic wood, foundry, and 
laboratory animal exposed workers was found. Since most health surveillance programmes for OA 
rely on symptoms and spirometry to identify workers at risk, any workers with normal spirometry 
may be missed. Using FENO as part of a health surveillance programme may help to identify workers 
earlier in their disease process, before they develop obstructive spirometry, and therefore could 
improve outcomes in OA.  
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 Exposure-response relationships in wood, foundry, and laboratory animal 
workers.  
Risk for respiratory symptoms and asthma was not clearly related to increasing exposure to wood 
dust, foundry (isocyanates or formaldehyde) or laboratory animal allergens. In fact, both work-
related symptoms and self-reported asthma tended to be less common among higher exposed 
groups. There are a number of possible explanations for these observations. Firstly, the healthy 
worker effect is well described in occupational studies with cross-sectional studies and asthma 
studies particularly liable to its influence (146). This is likely to account for the absence of disease 
among higher exposed workers, particularly in the less sterile working environments of the wood 
and foundry industries. Secondly, exposures in all three industries were lower than those previously 
reported, and significantly lower than the current UK WELs (24). This exposure reduction may also 
explain the observed reduction in symptoms. This is an important finding, as a fundamental principle 
of health and safety legislation and enforcement is identifying and eliminating workplace exposures 
order to reduce disease risk as low as reasonably practicable (23). Though the observed reduction 
could be explained by selection bias of workplace with lower exposures, it also suggests such 
legislation is having some effect. Thirdly, the current work compared higher to lower exposed 
groups, where, although asthma risk was assumed to be lower, it may not have been as low as in 
non-exposed populations. Across the population of wood and foundry workers, respiratory 
symptoms were highly prevalent. This may have limited the effect estimation across exposure 
groups, masking any exposure-response effect (245). Finally, altered dynamics in the exposure-
response relationship may lead to an attenuated response at higher exposures. This phenomenon 
has been previously described for asthma among laboratory animal workers, and forms part of the 
rationale for using immunotherapy for allergic diseases (246, 247). 
 
Similarly, relationships between exposure and abnormal lung function were not consistently seen 
among the populations studied here. Only in laboratory animal workers was increasing years’ 
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exposure related to poorer lung function: quantitative exposures in wood and foundry workers were 
associated with no change or paradoxical increases in FEV1, FVC, and PEF. The absence of an 
exposure-response effect for lung function in a cross-sectional study is not newly described. Workers 
with poorer baseline lung function are less likely to remain in a job with respiratory irritant or 
allergen exposure, particularly where there is a risk of OA (146). In addition, spirometry is a relatively 
insensitive tool when evaluating exposure-response. In healthy individuals, airway dynamics vary 
over the course of the day and variation in asthmatics may significantly exceed that of normal 
airways. Spirometry is not recommended as a tool in assessing day-to-day workplace exposures: its 
use is mainly in longitudinally identifying excess lung function decline (9). As historical allergen 
exposures reduce with improved health and safety measures, the sensitivity and specificity of 
spirometry may reduce also. Developing a role for other objective measures of airway disease, such 
as FENO, may therefore be beneficial. 
 Developing the role of fractional exhaled nitric oxide as a screening tool for 
OA 
Screening for OA entails a number of difficulties. Most health surveillance relies on information from 
questionnaires plus spirometry and/or sensitisation testing. Symptom questionnaires lack sensitivity 
and specificity and rely on self-report. Workers may underreport symptoms for a variety of reasons, 
meaning they are missed at health surveillance (16, 30). Spirometry is the primary objective test 
used to monitor lung function in populations at risk of OA. It too has issues with sensitivity and 
specificity and there is a lack of consensus as to a significant FEV1 decline that may highlight an 
individual needing enhanced health surveillance or referral to specialist care (35). Furthermore, 
obstructive lung function (defined with either percent predicted or LLN values) is a late sign in OA, 
and its use as a prompt for case identification may lead to poorer disease outcomes due to late 
exposure remediation, delayed referral, and/or delayed treatment of affected individuals (14, 248). 
Specific sensitisation is not available or not useful in many workers at risk of OA, particularly those 
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with LMW exposures (35). Since outcomes for OA in the UK remain suboptimal (28), there is 
considerable scope to improve efforts to prevent, understand, and screen for the condition. 
However, the use of FENO as a potential tool for monitoring or diagnosing OA remains controversial. 
There is a paucity of evidence to support the use of FENO in workplace settings and its use in the 
diagnosis of OA in SIC is debated (40). This study presents a significant contribution to understanding 
how FENO may be useful in such settings and supports the hypothesis that FENO is a useful screening 
tool for OA.  
 
Evidence presented in this thesis suggests FENO has three potential uses in occupational settings 
(Figure 24). Firstly, there is evidence that there is scope for its use as a diagnostic tool: in the whole-
population analysis, both GMR FENO and FENO >40ppb were strongly related to a diagnosis of asthma, 
particularly in symptomatic workers. Secondly, there is indication it may be of value as a screening 
tool: in the whole population analysis, the presence of symptoms and airway inflammation was 
strongly related to work-related symptoms, commonly used for identifying asthma in the workplace. 
Furthermore, there was little overlap between airway inflammation and airflow obstruction in all 
three occupational groups studied, suggesting FENO identifies a group of workers not recognised by 
spirometry alone. Thirdly, it may be possible to use as an exposure assessment tool: in the current 
research isocyanate exposure was associated with small but significant increases in GMR FENO, 
although in the limited overall analysis a clear exposure-response relationship was not found.  These 
areas require further exploration in order to fully understand the potential benefits FENO may bring 
to the management of OA. 
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Figure 24: Schematic showing potential uses for FENO in occupational settings 
7.2.1 Fractional exhaled nitric oxide as a diagnostic tool for OA 
An asthma diagnosis depends on the presence of asthma symptoms such as wheeze, chest tightness, 
cough, or breathlessness. No single investigation used for asthma is 100% diagnostic. As such, all 
investigations are supportive rather than conclusive of a diagnosis, and are most sensitive or specific 
in the presence of asthma symptoms (4). This study found a FENO >40ppb was related to a self-
reported asthma diagnosis, particularly among non-smokers. Significantly, this association was 
stronger in the presence of asthma symptoms. These workers may have undiagnosed asthma. A 
recent study of FENO and spirometry in children in primary care has suggested that a symptoms-
based approach may not be adequate in managing individuals with asthma (249). Recent guidelines 
from the Global Initiative for Asthma suggest high FENO is a risk for future asthma exacerbation (3).  
There is an imperative to diagnose asthma earlier in workers at risk of OA, and FENO may be helpful 
in this effort.  
 
Atopy, smoking, and sex were key modifiers of FENO in the current study. Among LMW-exposed 
workers atopy and smoking played a significant role in modifying FENO: among the overall population 
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associations existed between a self-reported asthma diagnosis and an increasing GMR FENO or risk of 
FENO >40ppb in non-smoking groups, whereas FENO was associated with an increased risk of WRRS in 
non-atopic smokers. In the overall analysis, smoking had a greater magnitude of effect than atopy on 
GMR FENO, whereas the converse was true for FENO >40ppb. This finding emphasises the importance 
of considering determinants of FENO in its interpretation. Both atopy and smoking are well-
documented to alter eosinophilic airway inflammation in both healthy and asthmatic populations, 
and some authors have suggested using modified reference ranges to take this into account (47). 
However, international guidance on FENO suggests it is not practicable to use reference ranges in its 
interpretation due to known multiple confounders and the significant overlap in ‘normal’ FENO 
ranges between healthy and asthmatic populations (46). Clinically relevant cut-points such as a cut 
off >40ppb, signifying significant airway inflammation and possible steroid responsiveness, are 
recommended in the UK (4). Like other physiological tests for asthma, FENO must be interpreted in an 
individual context, considering the presence of current respiratory symptoms and/or a history of 
respiratory disease.  
 
FENO remains most strongly associated with Th-2 high airway disease. Th-2 high asthma is associated 
with eosinophilic airway inflammation. FENO correlates to sputum eosinophilia in both non-
occupational and occupational studies, whilst showing little relationship with neutrophilic airway 
inflammation (125, 250). Not all OA is associated with eosinophilic airway inflammation. 
Approximately 40% may be associated with neutrophilic airway inflammation, and neutrophilic 
airway inflammation in more commonly reported following LMW exposures (19).  
 
Interestingly, though the majority of workers were exposed to LMW allergens in the current 
research, a significant proportion had a FENO >40ppb, a level strongly suggestive of eosinophilic 
airway inflammation (46). In fact, LMW-exposed workers were significantly more likely to have a 
FENO >40ppb than HMW-exposed workers. Other methods assessing airway inflammation such as 
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sputum cell counts, cytokine analysis, or BAL cytology, were not practical in this research where data 
collection was performed in geographically disparate locations and often some distance from 
laboratories where samples needed to be processed. Therefore, corroborating FENO with other 
markers of eosinophilic airway inflammation was not possible, and it was also not possible to rule 
out non-eosinophilic airway inflammation in symptomatic workers with a normal FENO. Interpreting 
FENO in conjunction with clinical symptoms remains key in identifying workers with likely asthma, 
irrespective of the underlying immunopathological mechanism, and the absence of a high FENO in a 
symptomatic worker with allergen exposure should not deter further investigation.  
7.2.2 Fractional exhaled nitric oxide as a screening tool for OA 
This research has consistently shown little overlap between FENO and airflow obstruction in allergen-
exposed workers, suggesting a potential additive role for FENO in screening programmes for OA 
(Figure 25). Furthermore, effect sizes for predicting work-related symptoms or asthma diagnosis in 
symptomatic workers were greater for the combination of CAS and FENO >40ppb than for CAS and 
airflow obstruction using either FEV1<LLN or FEV1/FVC <LLN. Previous studies have reported similar 
results, with minimal overlap between spirometry and FENO observed in apprentice bakers and 
hairdressers (124). One explanation for this is that FENO identifies workers with airway disease earlier 
than spirometry. This is an attractive prospect for screening programmes, where the aim is to 
identify workers as early as possible and to reduce disease-associated morbidity and impact on 
work.  
 
Measures of airway inflammation may also be helpful in monitoring efficacy of health surveillance 
programmes. A sustained reduction in FENO and asthma symptoms has been demonstrated in 
farmers with OA and normal spirometry, following a programme of exposure reduction (251). Thus, 
FENO may be useful in identifying workers with OA in the presence of normal lung function and could 
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Figure 25: Schematic showing how FENO may complement existing health surveillance programmes. There is 
overlap in the information provided by FENO, symptoms and spirometry. 
 
Additionally, spirometry and FENO provide different information on airway status. The former is a 
measure of airflow obstruction, indirectly related to airway inflammation, bronchial 
hyperresponsiveness, and airway remodelling (5). The latter is a direct measure of airway 
inflammation mediated largely through IL-13 and closely related to Th-2 inflammation that often 
predominates in asthma (125). As such the two tests provide complementary, but different, 
information on the likelihood of an asthma diagnosis, as well pointing towards the potential 
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underlying pathophysiology. For FENO in OA, this difference has important implications when 
considering the type of exposures and potential mechanisms for disease. Finally, airflow obstruction 
affects airway dynamics, and may therefore limit the measurable fraction of nitric oxide in exhaled 
breath. One study of the National Health and Nutrition Examination Survey cohort found COPD to be 
associated with higher dust exposures and an increased risk of a FENO below 50ppb, with COPD risks 
at FENO >50ppb reduced (252). 
 
Extending FENO testing into workplaces would require a significant change in current practice for OA 
surveillance. The introduction of additional tests to health surveillance programmes may help to 
improve their efficacy, but efforts to increase the provision of health surveillance for OA in the UK 
are vital in order to best capture those populations at risk and will not be accomplished by the 
introduction of a new test such as FENO alone (35). However, improvement in existing screening 
programmes for OA could make a significant difference to workers at risk. It is therefore vital to 
provide evidence to support the role of FENO in such settings, to inform regulators, policy makers, 
and employers.  
7.2.3 Fractional exhaled nitric oxide a measure of exposure to occupational allergens 
Allergen exposure is considered a key modifiable factor for asthma (5). In OA, workplace exposures 
provide the main opportunity to reduce the risk of disease, and much legislative and organisational 
energy has been focused on achieving this over the last 50 years (9). As such, OA research has often 
considered relationships between exposure and disease markers. One strength of this research is 
the quantitative exposure assessment in the wood and foundry workers, allowing accurate 
evaluation of relationships between exposure and markers of asthma in these groups. To date, only 
a small number of studies have examined exposure-response between occupational asthmagens and 
FENO. Data from this research therefore provides novel information on the relationships between 
quantitative allergen exposure and airway inflammation.  
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This research found a positive association between GMR FENO and isocyanate exposure, and 
between GMR FENO and increasing years’ exposure to laboratory animal allergens. However, no clear 
exposure-response relationship was seen between FENO and wood dust exposure, and when a cut-
point of FENO >40ppb was used clear exposure-response effects were not observed in any of the 
individual occupational groups studied. In fact, in the overall analysis, LMW-exposed workers in the 
higher exposure group had a lower risk of high FENO compared to workers in the lower exposure 
category. Workers with medium, but not high, exposure to spice dust have previously been found to 
be at increased risk of FENO >50ppb (43). Cement workers with increasing years exposure have been 
found to have higher FENO than age-matched controls (253). The current research suggests that 
although increasing exposure to isocyanates may be associated with small increases in GMR FENO, 
evidence for increasing allergen exposure causing clinically significant airway inflammation is lacking. 
Longitudinal studies examining the impact of allergen exposure on long-term risk of airway 
inflammation are important in clarifying whether FENO is useful in monitoring workplace exposures. 
 
A strength of this thesis was its workplace design, allowing assessment of airway inflammation in a 
‘real-world’ exposure environment. However, controlling exposures in such studies is difficult. All 
three exposure populations studied may have had additional allergen or irritant exposures not 
accounted for here. Potential co-exposures included solvents or paints in wood workers; foundry 
particulate, silica dust, or heat in foundry workers; and cleaning agents, animal bedding, or research 
chemicals in laboratory animal workers. Co-exposure to such agents may have played a role in 
observed increases in airway inflammation. Even with more accurate quantification of exposure, the 
cross-sectional design of this research precluded the inference of causation. Although FENO is most 
consistently associated with Th-2 type inflammation, its exact cellular source remains unknown, and 
its use is being increasingly explored in other respiratory diseases including eosinophilic bronchitis, 
COPD, cystic fibrosis, and pulmonary infections (243). In future, FENO may be useful in understanding 
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the occupational contributions of exposure to respiratory conditions other than asthma and could 
be a potentially useful tool in monitoring workplace exposures as well as risk of individual 
respiratory conditions.  
 Using FENO in workplace studies: suggestions for future research 
There are a number of areas in which future research is needed in order to better understand the 
role of FENO in allergen-exposed workers. Firstly, understanding reproducibility and validity of FENO in 
the workplace is crucial in exploring its use as a diagnostic or screening tool. Evidence reported here 
demonstrates that FENO can be performed in different workplaces and is at least as reproducible as 
spirometry. In 760 workers who underwent FENO testing, 93 (12%) were unable to perform a valid 
test compared with 97 (13%) unable to perform valid spirometry. Only one worker reported an issue 
with the test as they had recently had dental surgery so were unable to perform either FENO or 
spirometry measurements. Validation studies of FENO in workplaces, showing within- and between-
worker reproducibility are needed to clarify reproducibility and acceptability criteria. 
 
Secondly, consideration of environmental exhaled nitric oxide is an important potential confounder 
in occupational studies. This was eliminated in the current research by inhaling through the scrubber 
before the test is performed, and devices are calibrated to high levels of ambient NO >200ppb (254). 
However, the impact of higher levels of ambient nitric oxide on FENO is not known. Environmental 
conditions will vary hugely between workplaces, and ambient nitric oxide levels may be very high 
particularly where there is release of gases and fumes (243). The performance of FENO devices should 
be evaluated at different levels of ambient NO to ensure that its use is appropriate across the 
spectrum of occupational environments.  
 
Thirdly, using FENO in a health surveillance programme would require the identification of clinically 
significant increases in airway inflammation. The ATS/ERS guidelines suggest an increase of more 
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than 20% in individuals with a FENO >50ppb or more than 10ppb in individuals with a FENO <50ppb is 
clinically significant, but acknowledge that evidence to support this assertion is weak (46). A number 
of papers have considered the sensitivity and specificity of threshold increases in FENO to predict OA 
following SIC, but few studies have considered threshold increases in FENO in exposed populations at 
risk for OA. In their study of apprentice bakers and hairdressers, Florentin and colleagues reported 
the combination of FENO greater than 8.5 ppb and a positive clinical questionnaire to have a 79% 
sensitivity and 80.5% specificity for diagnosing OA (255). Van der Walt et. al. found medium 
exposure to spice particulate led to rises in FENO of >12% when measured 24 hours from initial 
exposure (43). In their longitudinal study of bakers and hairdressers, Tossa and colleagues reported 
FENO increases of 20% in nonatopic and 16% in atopic workers with incident BHR (41). Due to its 
cross-sectional design this research was unable to identify thresholds at which FENO was able to 
predict WRRS, CAS or asthma. Follow-up of the current study populations will enable better 
understanding of threshold increases in FENO at which WRRS, CAS or asthma may be predicted, and 
provide further information for those considering using FENO to diagnose or monitor asthma in 
allergen-exposed workers.  
 
Finally, understanding how FENO relates to the timing and intensity of allergen exposure is important 
for it to be useful in monitoring asthma and allergen exposure in workers. SIC studies have 
demonstrated that FENO peaks 24 to 48 hours from exposure and levels reduces thereafter (182). 
FENO may therefore be more representative of short- to medium-term exposure, and more research 
is needed to understand how these exposures relate to long-term disease risk of respiratory disease. 
There is a paucity of workplace studies considering the effect of differing timing or magnitude of 
exposure on FENO, for example whether intermittent high-dose exposure exerts a greater effect than 
chronic low-dose exposure. Occupational cohort studies of FENO in different exposure environments 
should be conducted to help improve understanding of how exposures relate to FENO rises, and 
whether these are sustained or short-lived. Randomised controlled trials from more general asthma 
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populations, such as those being conducted to determine whether FENO is useful for monitoring 
steroid responsiveness, will also be useful in better understanding how FENO changes over time. 
 
In summary, this thesis presents new evidence on respiratory symptoms, asthma, and lung function 
in British wood, foundry, and laboratory animal workers. Novel understanding of the use of FENO in 
occupational environments, including its association with symptoms, lung function, and allergen 
exposure, suggests airway inflammation may be a useful additional tool for diagnosing and screening 
OA in workplaces, but evidence for an exposure-response effect is lacking. Defining the role of FENO 
in occupational environments may provide information not just on OA risk, but also on disease 




Appendix A: Additional tables and checklist for systematic review in woodworkers 
1. Checklist – studies assessing risk factors in systematic review of British woodworkers 
This set of criteria should be used for assessing studies aimed at identifying the extent to which characteristics or behaviour of a person, an environmental 
exposure or the characteristics of a disease alter the outcome.  
DESCRIPTIVE INFORMATION ABOUT THE STUDY NOTES DESCRIPTION 
Study identification Include author, title, reference and year of publication 
(if available) and the study time frame 
 
What is the study type? Cohorts, case control (C-CS)  
What risk factors are considered?   
What outcomes are considered? e.g. disease, surgical rates, death  
What other factors affect the outcome? Include potential confounders, demographic 
characteristics 
 
What are the characteristics of the population and 
study setting? 
Personal characteristics e.g. sex; disease 
characteristics of the population.  
 
 204 
Study setting e.g. rural, urban, hospital inpatient or 
outpatient, general practice, community.  
EXAMINATION CRITERIA FOR THE STUDY COMMENTS CODE OPTIONS 
A, B1, B2, C, ? n/a 
Are the study participants well defined in terms of 
time, place and person? 
  
What percentage of individuals or clusters refused to 
participate? 
  
Are outcomes measured in a standard, valid and 
reliable way? 
  
Are risk factors and outcomes measured 
independently (blind) of each other? 
  
Are all important risk factors included in the analysis?   
What percentage of individuals or clusters recruited 
into the study are not included in the analysis? 
  
OVERALL ASSESSMENT OF THE STUDY COMMENTS CODE OPTIONS 
A, B1, B2, C 
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How well (code A, B1, B2, C) was the study done to 
minimise bias? If code B1, B2, or C, what is the likely 
direction in which bias might affect the results? 
  
Include other comments concerning areas for further 
research, applicability of evidence to target 






2. List of all papers included in the systematic review by publication date. 




























controls from same 
Geographical area 
813/136 Softwood Median ID = 0.96 LF 2+ 
A 
No significant difference in longitudinal 
lung function between workers and 
controls 






controls from other 
industries. 
150/150 - - LF 2- 
C 
PEFR in workers with longer tenure 
significantly lower than those with 







As per Jacobsen 
2013. 
1506/195 Softwood, wood 
composites, less 
hardwood  
ID = 0.55 SZ 2++ 
A 
No significant relationship between IgE 
to beech or pine and symptoms or 
asthma. Significantly more IgE positivity 
in high exposure group.  
Boskabady et 





the same residential 
area.  
66/66 - - S; LF 2- 
B2 
S: No significant differences between 
respiratory symptoms in exposed vs 
controls.  
LF: Significantly reduced FEV1, FVC, PEF, 
and mid expiratory flow measurements 
between carpenters and controls.  












obeche, pine, oak, 
sapele 
- S; SZ 2- 
B1 
S: 53% of workers reported respiratory 
symptoms; 40% reported rhinitis; 18% 
reported asthma symptoms.  
SZ: 49% of study group atopic. 7% had 
skin prick test positivity to wood species.  







177 Hard and 
softwood 
WD = 1.6 – 61.4 S 2- 
C 
Ocular symptoms most frequent, 
followed by work-related cough, then 







Wood dust exposed 19 studies  - A 1- 
A 
Pooled RR 1.5 for asthma in 










685/? Rubber tree TD = 4.08 LF 2+ 
B1 
FVC and FEV1/FVC negatively correlated 
with increasing dust exposure 








70 Softwood TD = 0.49 – 18.2 LF 2- 
B2 
Lower LF values in longer exposed – no 
data given 






As per Jacobsen 
2013. 
2032/474 Softwood Baseline ID = 0.9; 
follow up ID = 0.6 
S; A 2+ 
A 
S: significantly increased OR for cough 
(3.8) and chronic bronchitis (6.0) in 
female workers in highest vs lowest 
exposure categories.  
A: OR for ever asthma (3.4) and current 
asthma (6.9) in female workers vs 
controls. For female workers with no 
baseline symptoms OR for asthma 
symptoms = 11.3 








328/328 MDF TD = 2.04 LF 2- 
B1 
LF among furniture workers significantly 










103/94 Rubber tree ID = 0.02 - 2.93 S; A; LF 2+ 
A 
S: No significant difference in adjusted 
OR for different exposure levels 
A: Exposed vs office workers OR for ever 
asthma = 6.1. OR for ever asthma in low 
exposure vs control category = 8.41. No 
effect across other exposure categories.  
LF: Incremental FEV1 and FVC loss 
significantly more in factory workers vs 
controls and in highest vs lowest exposed 
groups.  
Glindmeyer et 








1164 >70% hardwood 
in cabinet and 
furniture facilities.  
ID = 1.45; RD = 0.18 S; LF 2++ 
A 
S: Across industry groups, self-reported 
upper respiratory symptoms ranged from 
45 – 53%, lower respiratory symptoms 
from 25-39%, ever asthma from 8.3 – 
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>90% softwood in 
sawmill and 
plywood 
13%, pneumonia from 9.4 – 29%, and 
COPD from 2 – 4%.  
LF: Negative effect for respirable residual 
particulate matter in milling industry. 
Positive effect for respirable wood solids 
in sawmill/planing. 
No effect on LF in furniture/cabinetry 
and plywood. 




Wet and dry wood 
industries; boat 
building and repair; 
construction. 
All employed Finns 
aged 20 – 59. 




TD = 0.02 – 1.5 A 2++ 
A 
RR 1.5 for both male and female 
woodworkers vs general population.  
No increase in risk described with 
increasing exposures. 






As per Jacobsen 
2013. 
1819/415 Softwood Baseline ID = 0.94; 
follow up ID = 0.6 
LF 2+ 
A 
Negative effect on LF for female 
woodworkers who smoked. Dose 
response relationship observed among 
female workers. 
Meo, 2006 Case control. 
Pakistan 




46/46 Teak - LF 2- 
C 
Significantly reduced FEV1 and FVC in 
woodworkers vs controls.  






Students from the 
same school. 
64/62 Fir - S 2- 
B2 
Ocular symptoms and rhinitis 
significantly more common in 
woodworkers vs controls.  
Meo, 2004 Case control. 
Pakistan 




46/46 Teak - LF 2- 
C 
Significantly reduced PEFR in group with 
≥8 years exposure vs 4-8 years and ≤4 
years.  






Office workers at 
FIOSH 
55/15 MDF ID (gm) = 1.2 - 1.3; 




Nasal symptoms more common in MDF 







As per Jacobsen 
2013. 
 
302/71 Softwood, wood 
composites, less 
hardwood  
ID (gm) = 0.96 A 2++ 
A 
A: Increased OR for current asthma in 
highest vs lowest exposure categories 
(3.3 vs 2.1). Strong association between 
atopic workers and asthma indices.  
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9/10/10 Iroko - SZ 2- 
C 
Negative specific IgE to iroko amongst all 
patients with iroko-induced occupational 
asthma. 








As per Jacobsen 
2013. 
339/142 Softwood, wood 
composites, less 
hardwood  
- SZ 2+ 
B1 
55% of participants atopic. No significant 
difference between pine IgE positivity 










-  S; LF 2- 
C 
S: 79% of workers reported work-related 
symptoms. 805 of board-processers 
reported cough.  
LF: Significant cross-shift reduction in 
FEV1 and FVC in under 30s.  







546/565 Variety of African 
hardwoods, podo, 
cypress, pine.  
ID (gm) = 3.86 S 2+ 
A 
Increased OR for work-related cough, 
sputum, SOB, wheeze. 
OR in lower exposure group vs higher 
exposure group:  
WHZ = 4.6 (1.9 – 11) vs 1.9 (0.5 – 7.3); 







As per Jacobsen 
2013. 
161/91 Softwood, wood 
composites, less 
hardwood  
ID = 1.17 S 2+ 
A 








As per Jacobsen 
2013. 
2033/475 Softwood, wood 
composites, less 
hardwood  
ID = 1.17 S; A; LF 2+ 
A 
S: OR for cough (2.7), wheeze (2.5), and 
chronic bronchitis (6.84) higher in 
women with 2-8 years industry service 
compared to controls.  
A: Self-reported and physician diagnosed 
asthma more common in atopic workers 
and female workers in medium and high 
exposure groups.  
LF: No significant difference observed 
when stratified by exposure. 








48/32 Wood composites - SZ 2- 
C 
High rates of early and late positivity to 
fungal species in exposed workers. 
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13 males of similar 
socioeconomic 
status, 200 historical 
controls.  
114/213 Beech and oak ID = 4.08 – 12.74 S; LF 2+ 
A 
S: No significant difference in symptoms 
observed between exposure groups.  
LF: Excess FEV1 and FVC observed across 
exposure groups compared to controls. 
BHR increased significantly with 
exposures.  








chipping and joinery.  
Maintenance 






and WRC also in 
use.  
ID = 0.5 – 15.33; RD = 
0.03 – 1.01; TF = 3.34 – 
74.06 x 103 cfu/m3; 
BACT = 2.86 – 25.72 
103 cfu/m3; IEND = 
0.74 – 21.08 ng/ m3; 
REND = 0.13 – 2.03 ng/ 
m3; IBDG = 0.33 -4.78 
ng/ m3; RBDG = 0.11 – 
0.85 ng/ m3.  
S 2- 
B1  
Significantly more cough, sputum, 
chronic bronchitis and runny nose in 
joiners vs sawmill/chipmill workers and 
controls. Exposed to dust associated with 
increased bronchitis in joiners. Very 
strong association with ear irritation and 
bronchitis in joiners exposed to BDG. 






Kitchen and cabinet 
manufacture 
Maintenance 
workers from same 
work sites 
 
197/30 As per Alwis et al., 
1999.  
ID = 0.83 – 15.33; RD = 
0.16 – 1.01; END = 
0.74 – 21.08 ng/ m3; 
BDG = 0.33 – 4.63 ng/ 
m3 
S; LF 2+ 
A 
S: Nasal and respiratory symptoms more 
common in exposed vs control 
populations.  
LF: Cross-shift lung function significantly 
worse in joiners vs controls.  







Matched by age and 




10628 - - S; A 2+ 
B1 
S: Exposed control populations reported 
high rates of cough (30%), bronchitis 
(32%), wheeze (40%), chest tightness 
(34%), and nasal congestion (38%).  
A: No significant difference in asthma 
outcomes between cases and controls.  








195/63 Pine, beech. - S; LF. 2+ 
B1 
S: Sputum production more common in 
woodworkers vs spray painters. 
LF: Normal FEV1 and FVC observed 
between workers and controls. 







38 Pine gmWD = 0.3 – 0.9; 
gmTERP = 19 – 123 
mg/m3 
S; LF. 2- 
B2 
 
No significant difference in symptoms 
over work shift.  
Significantly lower than predicted lung 
function in workers even when smokers 
removed from analysis. No change in 
cross shift lung function.  
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School employees.  
39/32 Pine  - S 2- 
B1 
Nasal congestion reported in 35% of 
workers.  







130/112 Pine - S 2- 
B2 
Respiratory symptoms more common in 
shops where poorer control reported.  





Oil field and gas 
workers from same 
geographical area.  
127/165 OSB RD = 0.05 – 0.5; FORM 
= < 0.05 ppm 
S; LF 2- 
B2 
S: Nocturnal shortness of breath, wheeze 
and shortness of breath more common in 
workers vs controls.  
LF: Significant cross-shift lung function 
loss observed in cases vs referents.  






Oil field and gas 
workers from same 
geographical area. 
99 OSB TD = 0.27; FORM = 
0.27ppm 
S; LF 2- 
B2 
S: OR above 5 observed in nocturnal SOB, 
wheeze/chest tightness and asthma 
symptoms between exposed workers 
and controls.  
LF: Significant cross-shift FVC change 
observed in workers vs controls.  









Office workers.  
44/38 Rimu, MDF, tawa, 
kauri, Californian 
redwood.  
Median ID = 3.6; 
median FORM = 0.06 
S; A 2- 
B2 
S: 77% of workers experienced sneezing, 
32% of exposed experienced work-
related cough, 25% experienced work-
related wheeze.  
A: 12% of exposed workers diagnosed 
with asthma 








maintenance staff.  
134/298 Softwood, MDF, 
particleboard 
Wood machinists ID = 




Hardwood dust exposure associated with 










145/152 MDF, pine TD = 3.82 S; LF 2+ 
B2 
S: Cough, sputum, SOB, wheeze and 
winter nasal symptoms significantly more 
common amongst exposed workers vs 
controls.  
LF: FEV1, FVC, FEV1/FVC, FEF and PEF 
significantly lower in furniture workers vs 
controls. Significantly higher percentage 
of exposed workers with longer tenure 







Office workers (civil 
servants).  
45/36 MDF, particle 
board, hardwoods 
MDF group: WD = 0.8 
– 3.8; FORM = 0.17 – 
0.48.  
S; LF 2- 
C 
S: Nasal and ocular symptoms 
significantly more common in MDF 
groups vs referents.  
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Wood dust group: WD 
= 0.7 – 1; FORM -= 
0.08 – 0.17 
LF: FEV1 and FVC significantly worse in 
MDF exposed and wood dust exposed 
relative to controls.  








193/46 Softwood, MDF, 
particleboard 
ID = 3.7 S 2- 
B2 
No significant difference in symptoms 
observed between exposure groups. 











93/93 Plywood RD = 0.6; TD = 5.78; 
FORM = 0.5 – 2.36ppm 
S; LF 2- 
B2 
S: Significantly raised OR for asthma, 
work absence due to chronic cough, 
phlegm, episodic cough/phlegm and 
chronic bronchitis between exposed 
workers and controls. 
LF: No effect observed in baseline lung 
function measurements or between 
exposure groups.  
Alexandersson 







47/20 Chipboard TD = 0.1; RD = 0.1; 
FORM = 0.5 
LF 2- 
B2 
Excess longitudinal decline observed in 
smoking woodworkers. Significant 
improvement in FEV1, FVC, and FEV1/FVC 
observed in non-smokers following 
exposure removal for 4 weeks.  
Beretić-







398 Softwood TD = 0.8 – 40 LF 2- 
B2 
LF: Small but significant decrements in 









office workers.  
78/16 Hardwoods - S; LF 2+ 
B1 
S: Work-related sneezing and ocular 
symptoms significantly more common in 
exposed workers vs controls.  
LF: Cross-shift FEV1, PEFR, and FEF values 







Office workers (civil 
servants). 
 
100/106 - WD = 1-2; FORM = 0.2 
– 0.3 
S; LF 2- 
C 
S: Workers in formaldehyde exposed 
group experienced more nasal, ocular 
and lower respiratory symptoms. Work 
related symptoms similar between 
formaldehyde and wood dust exposed 
groups.  
LF: FEV1 and FVC significantly lower in 
wood/formaldehyde vs control group.  






90/53 Variety of mostly 
European hard 
(e.g. iroko, oak) 
and soft (e.g. 
- LF; SZ 2- 
B2 
LF: FEV1. FVC, FEV1FVC, TLCO and KCO 
significantly lower in exposed 









poplar) wood  
SZ: Low frequencies of skin prick 
positivity to wood species. Low specific 
IgG positivity in exposed vs non-exposed 
group.  








30 Rosewood TD = 4.43 S; LF 2- 
C 
S: 50% or more workers reported 
nasal/throat symptoms or sputum.  
LF: Loss of FEV1/FVC in linear regression 
with cumulative exposure. No effect for 
cross-shift change.  





Hospital staff.  
50/50 - TD = 1.83; RD = 0.29; 
FORM = 0.08 
S; LF 2- 
B1 
S: More than 30% of workers reported 
either cough, sputum, or rhinitis vs 
controls. 5% reported asthma symptoms.  
LF: Negative for cross-shift change in 
FEV1 and FVC; negative for longitudinal 
change in FEV1 and FEF75. 
Wilhelmsson et 






Non- or slightly 
exposed controls.  
 
484/192 Hardwood - S; LF 2- 
C 
S: Nasal symptoms significantly more 
frequent in heavily vs slightly exposed 
group.  
LF: Significantly lower FEV1 and FVC in 
exposed workers.  
Wilhelmsson et 








23/14 Hardwood TD = 0.32 – 4.03 SZ 2- 
B2 
Significantly higher levels of skin prick 
positivity to specific woods in 
symptomatic vs asymptomatic workers. 
Low overall positivity to specific woods.  











TD = 0.69 – 4.93; RD = 
0.03 – 0.66 
LF 2- 
B1 
Negative effect observed for cross-shift 
LF change between high and low 












1157 Hardwood, pine - LF 2+ 
B1 
Lower FEV1/FVC ratios observed within 
high vs low exposure group.  
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b Where exposures were measured in the study, they are expressed as a single value or range depending on the data provided: ID = inhalable dust, RD = respirable dust, TD 
= total dust, WD = wood dust where fraction size has not been specified, FORM = formaldehyde, END = endotoxin, BGD = (1,3)-β-D-glucan, TF = total fungi, BACT = bacteria, 
GNBACT = gram negative bacteria, TERP = terpenes, gm = geometric mean, ppm = parts per million. 
c Where identified as primary study outcome measures: S = symptoms, A = asthma, LF = lung function, SZ = sensitisation 
 215 
Appendix B: Supporting documents used in the study ‘Assessment of respiratory 
ill-health in British woodworkers’ 
1. Health Questionnaire: Assessment of respiratory ill health in the woodworking population  
PERSONAL DETAILS 
Forename(s)  Surname  
DOB  N.I Number  
Company ID   Personal ID  
Home address  GP Details  









 Other  
Gender  Height in cm  Weight in kg  BMI  
OCCUPATIONAL HISTORY 
Current occupation  
         
Current work area  
                   
Time worked in this 
work area 
   Years Months Time worked in this 
industry exposed vapours, 
gases, dusts or fumes 
Years Months 
                                                             
Please list your job history, with your current job first (if more room is needed, use continuation sheet) 
If you have performed different tasks at your current worksite, please consider each a separate job and answer below 
Dates/duration 
(Provide a range 
e.g. 2000-2010 
or time in 
months/years) 











RESPIRATORY PROTECTIVE EQUIPMENT 
Yes No 
1 Do you wear any respiratory protection equipment (RPE) during your shift? If no, go to question 4   
2 How many hours a day do you wear it?  Number of hours 
 
3 If yes, which type do you usually wear from the below list? See picture guide. Next, go to question 5.  Yes No 
Disposable half mask respirators   
Simple cloth or fabric face mask   
Valved disposable half mask respirators   
Disposable welding respirators   
Half mask filter respirators   
Full-face respirators   
Power air purifying   
Air fed helmet   
Self-contained breathing apparatus   
4 If no, why do you not wear RPE?  
Not available
  







Have you ever had to change or leave your job because it affected your breathing? If no, go to question 7 Yes No 
  
6 If yes, what was the job, and when were you employed in that job? Please state here Job 
 
Dates (duration) 
7 Have you ever worked in a job, which exposed you to vapours, gas, dust or fumes (apart from those mentioned 
previously)? If no, go to question 11 
Yes No 
  
8 If yes, what was the job? Please state here.  
9 What was the exposure? For example; wood dust, spray paints, resin 
10 How long were you exposed? Years Months 
11 Have you ever had any of these medical problems diagnosed by a doctor? sYes No 
Asthma    
Rhinitis    
Eczema or dermatitis    
COPD (Chronic bronchitis, chronic pulmonary disease, or emphysema)    
Conjunctivitis/other allergies    
Nasopharyngeal cancer    
Other respiratory problems; if yes, please state 
No
. 
ASTHMA & ATOPY 
  
12 Do you currently have a diagnosis of asthma made by a doctor?   
If no go straight to question 24 
Yes No 
  
13 How long have you been diagnosed with asthma? Years 
 
Months 
14 Have you had an attack of asthma in the last 12 months? If no, go to question 16 Yes No 
  
15 How many asthma attacks have you had in the last 12 months?  
16 Have you been woken up by an attack of asthma in the last 12 months? Yes No 
  
17 During the past four weeks, how much has your asthma interfered with your usual activities (e.g. at work, exercising, at home)? Please 
chose from the options below 
1 – all of the time 2 – most of the time 3 – some of the time  4 – a little of the time 5 - never 
18 Are you currently taking any medicines, including inhalers, aerosols or tablets for asthma? If no, go to question 23 Yes No 
  
19 If yes, are you taking regular inhaled steroids 
Please refer to picture guide 
Name (if known) Dose (if known) 
20 Are you taking a rescue inhaler or nebuliser? Please refer to picture guide.  If no, go 
to question 23 
Name (if known) Dose (if known) 
21 During the past four weeks, how often have you used your rescue inhaler or medicine?  
3 or more times a day Once or twice a day Two or three times a 
week 
Once a week or less Not at all 
22 Compared with work days, how much do you use your inhaler on days off? 
Same   More  Less  
  as 
applicable 
23 Is your asthma the same, better or worse on days off?  
Same   Better   Worse   
  as 
applicable 
24 Have you ever suffered from eczema, hay fever, or other allergies?   





26 Do you smoke?  If yes go to question 28   
27 Have you ever smoked as much as 1 cigarette per day, or 1 cigar per week, or 1oz tobacco a month for as long as a 
year?  
If no go to question 30 
  
28 How many cigarettes (or equivalent e.g. roll ups) do you (did you) smoke per day? Please provide a number (e.g. 10) 
or a range (e.g. 5-10) 
 
 






30 Have you been woken by an attack of coughing at any time in the last 12 months?   
31 Do you usually cough first thing in the morning in winter?    
32 Do you usually cough at other times of the day or night in winter?   
If no, go straight to question 38 
  
33 Do you usually bring up any phlegm from the chest when you cough?    
34 Is this cough the same, better or worse on days off? 
Same   Better   Worse     as applicable 
35 
Is this cough the same, better or worse on holiday?  
Same   Better   Worse     as applicable 
36 Do you cough like this on most days for as much as three months out of a year? Yes No 
  





38 Have you been woken up with a feeling of tightness in your chest at any time in the last 12 months?   
39 Does your chest ever become tight or breathing become difficult? 
If no, go straight to question 45 
  
40 Do you get this chest tightness only with colds? 
If yes, go straight to question 45 
  
41 On the days when you have chest tightness, is it worse at any particular time of the day or night? If yes, please tick 
box(es) below 
   
Morning  Afternoon   Evening  Night  At Work  
42 Is the chest tightness the same, better or worse on days off? 
Same   Better   Worse     as    applicable 
43 Is this chest tightness the same, better or worse on holiday? 
Same   Better   Worse     as    applicable 





45 Have you had wheezing or whistling in your chest at any time in the last 12 months?   
46 Have you been woken up with a wheezing of whistling in your chest in your chest at any time in the last 12 months?   
47 Does your chest ever sound wheezy or whistle?  
If no, go straight to question 56 
  
48 Do you get this only with colds? 
If yes, go straight to question 56 
  
49 Have you been at all breathless when the wheezing noise was present?    
50 Is (was) your breathing absolutely normal in between attacks of wheezing?    




Afternoon   Evening  Night  At Work  
53 Is the wheezing the same, better or worse on days off? 
Same   Better   Worse     as    applicable 
54 Is this wheezing the same, better or worse on holiday?  
Same   Better   Worse     as    applicable 
55 How long have you had this wheeze? Years Months 
No
. 
SHORTNESS OF BREATH 
Yes No 
56 Have you been woken by an attack of shortness of breath at any time in the last 12 months?   
57 Are you disabled from walking by a problem other than heart or lung disease?  
If yes, go straight to question 66 
  
58 At worst are you troubled by shortness of breath or breathing when either hurrying on level ground or walking up a 
slight hill? If no, go straight to question 66 
  





At worst do you have to stop for breath when walking at your own pace on level ground? If no, go straight to 
question 62 
  
61 At worst do you become short of breath while resting?   
62 Is the shortness of breath worse at any particular time of the day or night? If yes, please tick box(es) below   
Morning  Afternoon   Evening  Night  At Work  
63 Is the shortness of breath the same, better or worse on days off? 
Same   Better   Worse     as    applicable 
64 Is the shortness of breath the same, better or worse on holiday?  
Same   Better   Worse     as    applicable 








66 Do you suffer from eye irritation such as pricking, itching, burning, dryness, watering, soreness, or stinging? If no, go 
straight to question 72 
  
67 Is the eye irritation worse at any particular time of the day or night? If yes, please tick box(es) below   
Morning  Afternoon   Evening  Night  At Work  
68 Is the eye irritation the same, better or worse on days off? 
Same   Better   Worse     as    applicable 
69 Is the eye irritation the same, better or worse on holiday?  
Same   Better   Worse     as    applicable 
70 Is the eye irritation worse during any season of the year?  
Spring  Summer  Autumn  Winter  
  as    
applicable 





72 Apart from when you have a cold do you suffer from nasal irritation such as pricking, itching, burning, sneezing, or a 
runny, dry or blocked nose? If no, go straight to question 77 
  
73 Is the nasal irritation worse at any particular time of the day or night? If yes, please tick box(es) below   
Morning  Afternoon   Evening  Night  At Work  
74 Is the nasal irritation the same, better or worse on days off? 
Same   Better   Worse   
  as    
applicable 
75 Is the nasal irritation the same, better or worse on holiday?  
Same   Better   Worse   
  as    
applicable 




PARTICIPATION IN HYGIENE STUDY 
Yes No 
77 Have you taken part in the recent HSE hygiene study? If no, go straight to question 79   





79 Are you currently under a health surveillance programme at your workplace?   
80 If yes, have you had any of the following; please tick box(es) below  
 
Questionnaire  Spirometry  Other (please state) 
 
eNO TEST RESULTS 
Date completed  By whom  
Time work 
commenced 
 Time test recorded  
Time last: Eaten Smoked Used steroid inhaler 
Attempt number Result 
1st attempt  
2nd attempt  
3rd attempt  
eNO test comment 
                                    QUALITY CONTROL FOR eNO  Yes No 
Has the ATS recommendation been fulfilled?   
Is the equipment log up to date with verification and calibration records?   
 
LUNG FUNCTION TEST RESULTS 
Date completed  By whom  
FEV1 (litres) 
 






Lung function test comments 
                                    QUALITY CONTROL FOR LUNG FUNCTION Yes No 
Has the ATS criteria been fulfilled?   
Is the spirometer log up to date with verification and calibration records?   
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2. Consent form for woodwork study 
CONSENT FORM  
 
Study Number: PH06113 
  
Participant Identification Number for this trial:  
 
Title of Project: Assessment of respiratory ill health in the woodworking population of Britain 
 
Name of Researcher:    
  
1. I confirm that I have read and understand the information sheet for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, 
without my medical care or legal rights being affected.  
 
3. I agree to any prior workplace health surveillance being reviewed for the purposes of the study. 
 
 
4. I understand that my results will be looked at by the study team, at the Health & Safety Laboratory.  
 
5. I understand that anonymised results from my workplace may be included in a report to HSE and my employer. 
 
6. I agree to being contacted, along with my GP, in the event of any important abnormality being detected from my tests. 
 
7. I understand that in the event of any other important abnormality being found, this information will only be passed onto 
my GP with my consent 
 




……………………………………  …………………………………  ……………………………………… 
Name of Participant    Date     Signature  
 
…………………………………..  ……………………………………  ……………………………………….. 
Name of Person taking consent   Date    Signature 

















3. Participant information sheet for woodwork study   
Assessment of respiratory ill health in the woodworking population of Britain 
INFORMATION FOR VOLUNTEERS 
 
Your workplace has agreed to take part in a Health and Safety Executive (HSE) research project looking into safe levels of 
exposure to dusts, vapours and fumes in the woodworking industry (a hygiene study). Alongside this study there will be 
health study that you may be asked to be involved in. This leaflet provides more information on the health study.  
 
What is the purpose of this study? 
This study is looking at the health of workers who work in the woodworking industry. This is because we know that wood 
dust and some of the processes of treating wood can cause breathing problems. We are interested in your general health 
and the health of your lungs.  
 
What will be involved if I agree to take part in this study? 
If you agree to take part, we will visit your worksite during your normal working hours, with the agreement of your 
employers. We will ask some simple questions about your work history, any breathing problems you might have, and your 
health at work.  We would also like to look at any old breathing tests you may have had done at work and to review any of 
your past health information your work may have.  
 
We will ask you to carry out 2 simple breathing tests. These are quick and painless test, similar to blowing out candles on a 
birthday cake. The tests are done at GP surgeries and hospitals around the UK, and you may have had one in the past. One 
measures breathing function, and the other is a simple test for asthma.  
We will also ask you to provide a small blood sample that will be taken by the study doctor. This is done in the same way as 
your normal GP does blood tests and may cause some minor discomfort. The test is to help us see who is at risk of 
developing problems from working with wood. If you do not want to give a blood sample, we would still like you to take part 
as the other information you can give is also very useful.  
 
Do I have to take part? 
No, the study is voluntary. You can decline to join the study, and you can withdraw from the study at any time without giving 
any reason.  
 
What are the possible benefits of taking part? 
If your breathing function is reduced, it may be helpful for you and your family doctor (or GP) to know. If your blood tests 
show any signs of allergy then it would be helpful to contact you and your GP about it. We will only contact your GP if you 
agree to it. 
Your workplace will get feedback following participation in the study about the health of the workforce. Your personal 
information will not be shared with anyone outside of the study team. 
 
What are the possible risks of taking part? 
It is possible that you might develop a bruise from the blood tests. 
 
What if there is a problem? 
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In the unlikely event that something does go wrong and you are harmed during the study due to someone’s negligence, you 
may have grounds for compensation against HSE or the NHS but you may have to pay your own legal costs.  
 
Will my taking part be confidential? 
Yes. No one other than the study team will know about this unless you choose to inform them. All information will be 
treated with strict medical confidentiality. If we do think your information should be shared with your GP, this will only be 
done with your agreement.  
 
What will happen to the results of the research study? 
The results of the study will be published in a report for the HSE and in scientific journals. Your own results will not be 
identifiable from any of these publications.  
 
Who is organizing and funding the research? 
The study is being organized by the Centre for Workplace Health. The study is being funded by the Health and Safety 
Executive.  
 
Who has looked at the study to make sure it is safe? 
This study has been reviewed and approved by an NHS Ethics committee. 
 
Contact for further information? 
If you have any concerns or questions about this study, you can contact the staff at the Centre for Workplace Health who 
















4. Employer information for woodworking study 
Assessment of respiratory ill health in the woodworking population of Britain 
INFORMATION FOR EMPLOYERS 
 
Your workplace has agreed to participate in a Health and Safety Executive (HSE) research project looking into safe levels of 
exposure to dusts, fumes and vapours in the woodworking industry (a hygiene study). Alongside this study there will be a 
health study that we would like your employees to participate in. This leaflet provides more information about the health 
study.  
 
What is the purpose of this study? 
This study is part of a larger HSE study looking at improving the health of workers exposed to a range of substances in the 
workplace. Over the past two years, this study has successfully collected data from over 300 foundry workers, and 300 
workers exposed to brick and stone dust. We know that wood workers can also develop breathing problems, and would 
therefore like to include them in the study. We are interested in measuring their health, and linking this to current and 
historical levels of exposure.  
 
What will be involved if my company agrees to take part in this study? 
We will visit your worksite during normal working hours at an agreed time. We will spend a maximum of 30 minutes with 
individual employees who have agreed to take part in the study.  We will ask questions about their general health, work 
history, and current breathing problems, as well as other things that might affect breathing like smoking. We will perform 
simple breathing tests and take a small blood sample. The blood sample will be used to look for signs of allergies, and will 
not be used for any other purpose.   
 
Does my company have to take part? 
No, the study is voluntary. You can decline to join the study, and you can withdraw from the study at any time without giving 
any reason. Your taking part is very important however, as measuring health and hygiene data in your company offers a 
unique opportunity to better understand the effects of wood dust exposure.  
 
What are the possible benefits of taking part? 
The results from your workplace will be fed back to you alongside results from other sites for comparison. These results do 
not contain any personal information that would allow individual people to be identified and your own company results will 
not be identifiable to anyone else. The information provided may assist your company in making improvements in the 
workplace that help protect the health of your workforce in the future. 
If any workers taking part are found to have breathing problems, or a reduction in breathing function, they will be advised to 
consult their GP. We will not do this without that individual’s permission. Finding such problems early is generally good for 
the future health of these workers. 
 
What will happen to the results of the research study? 
The results of the study will be published in a report for the HSE and in scientific journals. Each company will also be 
provided with a copy of the report. 
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Who is organizing and funding the research? 
The study is being organized by the Centre for Workplace Health. The study is being funded by the Health and Safety 
Executive.  
 
Who has looked at the study to make sure it is safe? 
This study has been reviewed and approved by an NHS Ethics committee. 
 
Contact for further information? 
If you have any concerns or questions about this study, you can contact the staff at the Centre for Workplace Health who 
would be happy to help you: 
Email: ruth.wiggans@hsl.gsi.gov.uk or cwh@hsl.gsi.gov.uk                              





















Appendix C: Supporting materials for study ‘health impact assessment and 
surveillance for long-latency diseases: foundry exposed workers’ 







N.I Number  
Company ID number  
 
Personal ID number  
 
Home address 




Height in cm  
 
Weight in kg  BMI  
OCCUPATIONAL HISTORY 
Current occupation  
         
Current work area  
                   
Time worked in this 
work area 
   Years Months Time worked in this industry 
exposed vapours, gases, dusts or 
fumes 
Years Months 
                                                             
Please list any personal protective equipment used: 
Please list job history (if more room is needed, use continuation sheet in appendix 3) 
Dates (e.g. 
2000-2001) 
Type of work (e.g. furnace work ferrous metals, furnace work 
non-ferrous metals, moulding, core making, pattern making, 
casting, knockout, fettling, finishing, supervisor, other) 
Did you wear RPE? If yes what % of 
day did you wear 




    
 
No. RESPIRATORY PROTECTIVE EQUIPMENT Yes No 
1 Do you wear any respiratory protection equipment (RPE) during your shift? If no, go to question 2, if yes go to 
question 3 
  
2 If no, why do you not wear RPE?   
 
3 
If yes, how many hours a day do you wear it?  Number of 
hours 
 
4 If yes, which type do you usually wear from the below list?  Yes No 
Disposable half mask respirators   
Simple cloth or fabric face mask   
Valved disposable half mask respirators   
Disposable welding respirators   
Half mask filter respirators   
Full-face respirators   
Power air purifying   
Air fed helmet   
Self-contained breathing apparatus   
 MEDICAL HISTORY 
No.  HEALTHY UNHEALTHY 
5 How would you assess your recent health condition? Please tick as appropriate   
 
6 
Have you ever had to change or leave your job because it affected your breathing? Yes No 
  
7 If yes, what was the job? Please state here 
 




9 If yes, what was the job? Please state here 
 
10 Have you ever had any of these medical problems diagnosed by a doctor? Date Yes No 
 COPD (Chronic bronchitis, chronic pulmonary disease, or emphysema)    
Silicosis    
Pleurisy    
Tuberculosis    
Lung cancer    
Other respiratory problems; if yes, please state 
Kidney problems    
Arthritis or connective tissue problems; if yes, please state 
No. ASTHMA & ATOPY Yes No 
11 Have you ever had asthma?      
If no go straight to question 16 
  
12 Have you had an attack of asthma in the last 12 months?    
13 Are you currently taking any medicines, including inhalers, aerosols or tablets for asthma?   
14 If yes, are you taking regular inhaled steroids?   
15 Other medicines are taken for asthma; if yes, please state   
16 Have you ever suffered from eczema, hay fever, or other allergies?   
17 Do you have a family history of asthma or allergy?   
No. SMOKING Yes No 
18 Do you smoke?         
If yes go straight to question 20 
  
19 Have you ever smoked as much as 1 cigarette per day, or 1 cigar per week, or 1oz tobacco a month for as long 
as a year?  
If no go straight to question 22 
  
20 How many cigarettes (or equivalent e.g. roll ups) do you (did you) smoke per day?   
 
21 For how many years?  Years Months 
No. COUGH Yes No 
22 Do you usually cough first thing in the morning in winter?    
23 Do you usually cough at other times of the day or night in winter?   
If no, go straight to question 30 
  
24 Do you usually bring up any phlegm from the chest when you cough?    
25 Is this cough the same, better or worse on days off?  
Same   Better   Worse     as applicable 
26 
Is this cough the same, better or worse on holiday?  
Same   Better   Worse     as applicable 
27 Do you cough like this on most days for as much as three months out of a year?   
28 Have you been woken by an attack of coughing at any time in the last 12 months?   
29 How long have you had this cough? Years Months 
No. CHEST TIGHTNESS Yes No 
30 Does your chest ever become tight or breathing become difficult?  
If no, go straight to question 37 
  
31 Do you get this chest tightness only with colds?  
If yes go straight to question 37 
  
32 On the days when you have chest tightness, is it worse at any particular time of the day or night? If yes, please 
tick box(es) below 
   
Morning  Afternoon   Evening  Night  At Work  
33 Have you been woken up with a feeling of tightness in your chest at anytime in the last 12 months?   
34 Is the chest tightness the same, better or worse on days off? 
Same   Better   Worse   
  as    
applicable 
35 Is this chest tightness the same, better or worse on holiday? 
Same   Better   Worse   
  as    
applicable 
36 How long have you had this chest tightness? Years Months 
No. WHEEZE Yes No 
37 Have you had wheezing or whistling in your chest at any time in the last 12 months?    
38 Does your chest ever sound wheezy or whistle?  
If no, go straight to question 46 
  
39 Do you get this only with colds? 
If yes, go straight to question 46 
  
40 Have you been at all breathless when the wheezing noise was present?    
41 Is (was) your breathing absolutely normal in-between attacks of wheezing?    
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42 On the days when you wheeze, is it worse at any particular time of the day or night? If yes, please tick box(es) 
below 




Afternoon   Evening  Night  At Work  
43 Is the wheezing the same, better or worse on days off? 
Same   Better   Worse   
  as    
applicable 
44 Is this wheezing the same, better or worse on holiday?  
Same   Better   Worse   
  as    
applicable 
45 How long have you had this wheeze? Years Months 
No. SHORTNESS OF BREATH Yes No 
46 Are you disabled from walking by a problem other than heart or lung disease?  
If yes, go straight to question 56 
  
47 At worst are you troubled by shortness of breath or breathing when either hurrying on level ground or walking 
up as slight hill? 
If no, go straight to question 56 
  
48 At worst do you get short of breath walking with other people of your own age on level ground?  
If no, go straight to question 56 
  
49 At worst do you have to stop for breath when walking at your own pace on level ground? 
If no, go straight to question 56  
  
50 At worst do you become short of breath while resting? If no, go straight to question 56   
51 Is the shortness of breath worse at any particular time of the day or night? If yes, please tick box(es) below   
Morning  Afternoon   Evening  Night  At Work  
52 Have you been woken by an attack of shortness of breath at any time in the last 12 months?   
53 Is the shortness of breath the same, better or worse on days off? 
Same   Better   Worse   
  as    
applicable 
54 Is the shortness of breath the same, better or worse on holiday?  
Same   Better   Worse   
  as    
applicable 
55 How long have you had this shortness of breath? Years 
 
Months 
No. EYE IRRITATION Yes No 
56 Do you suffer from eye irritation such as pricking, itching, burning, dryness, watering, soreness, or stinging? If 
no, go straight to question 62 
  
57 Is the eye irritation worse at any particular time of the day or night? If yes, please tick box(es) below   
Morning  Afternoon   Evening  Night  At Work  
58 Is the eye irritation the same, better or worse on days off? 
Same   Better   Worse   
  as    
applicable 
59 Is the eye irritation the same, better or worse on holiday?  
Same   Better   Worse   
  as    
applicable 
60 Is the eye irritation worse during any season of the year?  
Spring  Summer  Autumn  Winter  
  as    
applic
able 
61 How long have you had this eye irritation? Years Months 
No. NASAL IRRITATION Yes No 
62 Apart from when you have a cold do you suffer from nasal irritation such as pricking, itching, burning, sneezing, 
or a runny, dry or blocked nose? If no, go straight to question 67 
  
63 Is the nasal irritation worse at any particular time of the day or night? If yes, please tick box(es) below   
Morning  Afternoon   Evening  Night  At Work  
64 Is the nasal irritation the same, better or worse on days off? 
Same   Better   Worse   
  as    
applicable 
65 Is the nasal irritation the same, better or worse on holiday?  
Same   Better   Worse   
  as    
applicable 
66 How long have you had this eye irritation? Years Months 
 
No. WELDING AND METAL WORKING FUME Yes No 
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67 Do you currently work with metals e.g. molten metals, welding, burning?  
If no, go straight to question 72 
  
68 During the last 12 months did you experience any of the following symptoms within the first few hours of starting work?  
Metallic taste   
Fever   
Feelings of flu   
General malaise   
Chills   
Loss of appetite   
Nausea   
Abdominal cramps   
Fatigue   
Yawning   
Difficulty concentrating   
69 If yes to any one; how long does it take after you start being exposed for this to happen in hours? Number of 
hours 
 
70 What base metal were you working with when you got this problem? Please state below 
 
 
71 How many times have you had the problem?  
 
No. PARTICIPATION IN HYGIENE STUDY Yes No 
72 Have you taken part in the recent HSE hygiene study? If no, go straight to question 75   
73 If yes, did you have personal monitoring?   
74 If yes, did you have a urine test?   
No. HEALTH SURVEILLANCE Yes No 
75 Are you currently under a health surveillance programme at your workplace?   
76 If yes, have you had any of the following; please tick box(es) below 
Questionnaire  Spirometry  Chest x-ray  Other (please state) 
 





By whom  
Attempt number Result 
1st attempt  
 





eNO test comments 
As per the American Thoracic Society (ATS) recommendations for exhaled nitric oxide, three satisfactory manoeuvres 
should be recorded. It should take place prior to measurement of lung function.  
                                    QUALITY CONTROL FOR eNO  Yes No 
Has the ATS recommendation been fulfilled?   
Is the equipment log up to date with verification and calibration records?   
 
LUNG FUNCTION TEST RESULTS 




FVC (litres) PEF (litres/min) Percentage 





Lung function test comments 
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As per the American Thoracic Society (ATS) quality criteria for spirometry, three satisfactory manoeuvres should be 
recorded with the best two FEV1  and FVC being within 150mls. The largest FEV1  and the FVC should be recorded above, 
even if they come from separate blows.  
                                    QUALITY CONTROL FOR LUNG FUNCTION Yes No 
Has the ATS criteria been fulfilled?   





















































2. Foundry participant information sheet 
 
Health Impact Assessment and Surveillance for Long-latency Diseases: Foundry Exposed Workers. 
INFORMATION FOR VOLUNTEERS 
You are invited to take part in a research study.  Before you decide if you want to take part, please read this information sheet, which will 
tell you why this study is happening. Please talk to others about this if you need to, and take time to decide if you want to take part. 
Taking part is voluntary, however, the more people who do take part the more useful the findings will be.   
 
What is the purpose of the study? 
 
This study is looking at the health of workers who work in foundries and are involved in any work where fumes, dusts and gases may be 
breathed in. This is because exposures in foundries can cause breathing problems, and we are therefore interested in your lung health. 
This study will also look at breathing test results to decide how best to monitor workers who are currently breathing in dusts, fumes and 
gases whilst working in a foundry.    
 
Your worksite has been selected as it is already participating in a separate study looking at the levels of fumes, gases and dust in foundries 
and this presents a unique opportunity to use a variety of methods to measure the health of workers and how this is affected by 
substances in the workplace. 
 
What will be involved if I agree to take part in this study? 
 
If you agree to take part, we will carry out a simple questionnaire asking about your work history, any breathing problems and other 
things that might affect your breathing such as smoking. We would also ask you to let us see any old measures of your lung function that 
your work may have and previous health questionnaires.  
 
We will ask you to carry out a simple breathing test. This is a common test that is carried out a lot in hospitals and by GPs. It is a simple 
and painless test to measure the size of your lungs and your breathing capacity using a small portable machine. We will use another 
simple blowing test to measure any inflammation in your airways.    
 
We will also ask you to provide a small sample of urine. This is to measure a substance that might help us to better understand the 
health effects of foundry exposures. This sample will only be used for this study and will not be used for any other purpose such as 
testing for drug or alcohol levels.  
 
This study will run for three years, and we would like to come back and see you a second time to repeat the questionnaire, breathing 
tests and to collect another urine sample. This will be towards then end of the three-year study period. 
 
Do I have to take part? 
 
No, the study is totally voluntary.  You can refuse to join the study, and you may withdraw from the study at any time without giving 
any reason.   
 
What are the possible benefits of taking part? 
 
The breathing tests will measure the size of your lungs and if there is any inflammation. If these tests do show any reduction in your 
breathing or show inflammation, it would be helpful for you and your family doctor (or GP), to know. We will only contact your GP with 
your agreement.  
 
The overall findings of this research will also help many other workers in foundries, as it will help us understand the best way to protect 
their health at work.  
 
What if there is a problem?  
 
If you have a concern about any aspect of this study, you should ask to speak to Dr Chris Barber who will answer your questions [01298 
218169]. 
 
In the unlikely event that something does go wrong and you are harmed during the research and this is due to someone‘s negligence, 
then you may have grounds for a legal action for compensation against HSE or the NHS but you may have to pay your legal costs. 
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Will my taking part be confidential? 
 
Yes.  No one else, other than the study team will know about this. All information will be treated with strict medical confidentiality. If 
we think information should be sent to your GP, we will only do this if you agree.   
 
What will happen to the results of the research study? 
 
The results of the study will be published in a report for the Health & Safety Executive (HSE) and in scientific journals.  Your own results 
will not be able to be identifiable from any of these publications.  
 
Who is organising and funding the research? 
 
The Health and Safety Executive (HSE) has funded this research. 
 
Who has reviewed the study? 
 
This study has been reviewed and approved by an NHS Research Ethics Committee. 
 
Contact for further information? 
 
If you require further information about any aspect of this study, general information about research, advice on participation or what 
you should do if you are in any way unhappy with the study please contact Dr Chris Barber, 01298 218169, david.fishwick@hsl.gov.uk, 





3. Foundry consent form 
 
TITLE OF PROJECT: LONG-LATENCY DISEASES IN BRITISH FOUNDRY WORKERS 
CENTRE NUMBER:  
STUDY NUMBER: 
PATIENT IDENTIFICATION NUMBER FOR THIS TRIAL:  
NAME OF RESEARCHER: _____________ 
 
1. I CONFIRM THAT I HAVE READ AND UNDERSTAND THE INFORMATION SHEET DATED 01/02/2012(VERSION 2) FOR THE 
ABOVE STUDY. I HAVE HAD THE OPPORTUNITY TO CONSIDER THE INFORMATION, ASK QUESTIONS AND HAVE HAD THESE 
ANSWERED SATISFACTORILY.  
 
2. I UNDERSTAND THAT MY PARTICIPATION IS VOLUNTARY AND THAT I AM FREE TO WITHDRAW AT ANY TIME WITHOUT 
GIVING ANY REASON, WITHOUT MY MEDICAL CARE OR LEGAL RIGHTS BEING AFFECTED.  
 
3. I AGREE TO ANY PRIOR WORKPLACE BREATHING TESTS BEING REVIEWED FOR THE PURPOSES OF THE STUDY. 
 
4. I UNDERSTAND THAT MY RESULTS WILL BE LOOKED AT BY THE STUDY TEAM, AT THE HEALTH & SAFETY LABORATORY.  
 
 
5. I UNDERSTAND THAT ANONYMISED RESULTS FROM MY WORKPLACE MAY BE INCLUDED IN A REPORT TO HSE AND MY 
EMPLOYER. 
 
6. I AGREE TO BEING CONTACTED, ALONG WITH MY GP, IN THE EVENT OF ANY IMPORTANT ABNORMALITY BEING 
DETECTED FROM MY URINE TESTS. 
7. I UNDERSTAND THAT IN THE EVENT OF ANY OTHER IMPORTANT ABNORMALITY BEING FOUND, THIS INFORMATION WILL 
ONLY BE PASSED ONTO MY GP WITH MY CONSENT 
8. I AGREE TO TAKE PART IN THE ABOVE STUDY.  
 
NAME OF PARTICIPANT   DATE     SIGNATURE  
NAME OF PERSON TAKING CONSENT   DATE    SIGNATURE 
 
One copy to be kept by the researcher; one copy to be given to the patient. 
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Appendix D: Supporting materials for SPIRAL study of laboratory animal workers 
(reproduced with kind permission of Dr Johanna Feary) 
1. SPIRAL Questionnaire 
Q1 Please enter your unique identifier code  
Q2 Please enter your gender:  Male (1)   Female (2) 
Q3 Have you been given a Participant Information Sheet for this study?   
Yes (1)   No (0) 
Q4 Please contact a member of the SPIRAL team if you have not been given a Participant Information Sheet 
Q5 Have you signed the consent form?     
Yes (1)   No (0) 
Q6 Please contact a member of the SPIRAL team if you have not signed a consent form 
Q7 Have you been given the contact telephone number and email address to get your results if you would like them?   
Yes (1)   No (0) 
Q8 Please contact a member of the SPIRAL team to get the contact details so you can get your results if you would like 
them    
 
Q9 THE FOLLOWING QUESTIONS ARE ABOUT YOUR CURRENT POST (JOB) 
 
Q10 What year did you start in your current post? (yyyy) 
Q11 Which of the following best describes your current post?    
Animal technician (1)   Scientist/research student/research assistant (2) 
Department manager/administrator/secretary (3) Maintenance/cleaning/stores/security/estates (4) 
Other (please enter details) (5) ____________________ 
Q12 Which of the following species are housed within the animal facilities where you work? (tick as many as applicable) 
Mice (1)   Rats (2) 
Q13 In your current post, is your work:   
More or less the same every week (1)   Variable from week to week (2) 
 
Q14 Do you work full-time or part-time in your current post?    
Full time (1)  Part time (2) 
Q15 If you work part-time, how many hours a week do you work?  
Q16 In the last 5 years, what is the longest single period of  time (in months) you have spent without any contact with 
mice? 
______ months (2) 
Q17 In the last 12 months, how many complete months have you spent without going into animal facilities? 
0 (0) 1 (1) 2 (2) 3 (3) 4 (4) 5 (5) 6 (6) 
7 (7) 8 (8) 9 (9) 10 (10) 11 (11) 12 (12) 
Q18 In the last 12 months, how many complete months have you spent without contact with mice? (handling mice, going 
into a room where others handle mice, or handling their cages) 
0 (0) 1 (1) 2 (2) 3 (3) 4 (4) 5 (5) 6 (6) 
7 (7) 8 (8) 9 (9) 10 (10) 11 (11) 12 (12) 
 
Q19 The NEXT SET OF QUESTIONS ARE ABOUT different TASKS YOU HAVE DONE AT WORK IN THE LAST 12 MONTHS. Some 
of them may be quite difficult to answer but please just try and give the best answer you can. it is important that we get a 
good idea about your level of exposure to mice at work. 
 
Q20 TASK 1: GOING INTO THE ANIMAL FACILITIES 
 
Q21 In the last 12 months: during those periods when you went into the animal facilities, which of the following best 
describes how often you did this? (i.e. went into the animal facilities)    
Every day (1) At least once a week but not every day (2) At least once a month but every week (3) 
Less than once a month (4)  I did not go into the animal facilities(s) (5) 
If I did not go into the anima... Is Selected, Then Skip to End of Block 
Q22 In the last 12 months: on the days you went into the animal facilities, how much time (approximately) did you spend 
there on a typical day? 
______ Hrs (1) 
Q23 In the last 12 months, what personal protective equipment did you use when you went into the animal facilities?    
None (1)      
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Gloves (2)      
Overshoes or special 
shoes (3) 
     
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
Hair net or mob cap (9)      
 
Q24 In the past 12 months, are the mice in the animal facilities which you go into housed in IVCs or open cages? 
IVC only (1) Open cages only (2) A mixture of IVCs and open cages (3) 
I don't know (88) 
 
Q25 TASK 2: DOSING/INJECTING MICE 
 
Q26 In the last 12 months, during those periods when you had contact with mice, which of the following best describes 
how often you dosed/injected mice?    
Every day (1)    At least once a week but not every day (2) 
At least once a month but not every week (3) Less than once a month (4) 
I did not dose mice (5) 
If I do not dose mice Is Selected, Then Skip to End of Block 
Q27 In the last 12 months, on the days you dosed/injected mice, how much time on a typical day did you spend doing this? 
______ Hrs (1)  ______ Mins (2) 
Q28 In the last 12 months, on the days when you dosed/injected mice, how many mice did you dose/inject on a typical 
day?   
1-10 (1)  11-20 (2)  21-50 (3)  51-100 (4) more than 100 (5) 
 
Q29 In the last 12 months, which type of personal protective equipment did you use when you dosed/injected mice? 
 Never (1) Rarely (2) Sometimes (3) Most of the Time (4) Always (5) 
None (1)      
Gloves (2)      
Overshoes or special shoes (3)      
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
Hair net or mob cap (9)      
 
Q30 In the last 12 months, when you dosed/injected mice, do you do this on an open bench or under a hood?   
Open bench only (1) Under a hood only (2) A mixture of open bench and under a hood (3) 
Q31 In the last 12 months, are the mice who you dosed/injected housed in IVCs or open cages? 
IVC only (1) Open cages only (2) A mixture of IVCs and open cages (3) 
 
Q32 TASK 3: SHAVING MICE 
Q33 In the last 12 months, during those periods when you had contact with mice, which of the following best describes 
how often you shaved mice? 
Every day (1)  At least once a week but not every day (2) 
At least once a month but not every week (3) Less than once a month   (4) I did not shave mice (5) 
If I do not shave mice Is Selected, Then Skip to End of Block 
Q34 In the last 12 months, on the days you shaved mice, how long did you spend doing this on a typical day? 
______ Hrs (1)  ______ Mins (2) 
 
Q35 In the past 12 months, on the days when you shaved mice, how many mice did you shave on a typical day? 
1-10 (1)  11-20 (2)  21-50 (3)  51-100 (4) more than 100 (5) 
Q36 In the past 12 months, what personal protective equipment did you use when you shaved mice? 
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 Never (1) Rarely (2) Sometimes (3) Most of the Time (4) Always (5) 
None (1)      
Gloves (2)      
Overshoes or special shoes (3)      
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
Hair net or mob cap (9)      
 
Q37 In the last 12 months, when you shaved mice, did you do this on an open bench or under a hood?   
Open bench only (1) Under a hood only (2) A mixture of open bench and under a hood (3) 
Q38 In last 12 months, were the mice who you shaved housed in IVCs or open cages?    
IVC only (1) Open cages only (2) A mixture of IVCs and open cages (3) 
 
Q39 TASK 4: ANAESTHETISING MICE 
Q40 In the last 12 months, during those periods when you had contact with mice, which of the following best describes 
how often you anaesthetised mice 
Every day (1)    At least once a week but not every day (2) 
At least once a month but not every week (3) Less than once a month (4) 
I did not anaesthetise mice (5) 
If I do not anaesthetise mice Is Selected, Then Skip to End of Block 
Q41 In the past 12 months, on the days when you anaesthetised mice, how much time did you spend doing this on a 
typical day? 
______ Hrs (1) ______ Mins (2) 
 
Q42 In the past 12 months, on the days when you anaesthetised mice, how many mice did you anaesthetise on a typical 
day? 
1-10 (1)  11-20 (2)  21-50 (3)  51-100 (4) more than 100 (5) 
 
Q43 In the past 12 months, what personal protective equipment did you use when you anaesthetised mice?    
 Never (1) Rarely (2) Sometimes (3) Most of the Time (4) Always (5) 
None (1)      
Gloves (2)      
Overshoes or special shoes (3)      
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
Hair net or mob cap (9)      
 
Q44 In the past 12 months, when you anaesthetised mice, did you do this on an open bench or under a hood?   
Open bench only (1) Under a hood only (2) A mixture of open bench and under a hood (3) 
Q45 In the past 12 months, are the mice who you anaesthetised housed in IVCs or open cages?    
IVC only (1) Open cages only (2) A mixture of IVCs and open cages (3) 
 
Q46 TASK 5: PERFORMING SURGERY ON MICE 
 
Q47 In the past 12 months, during those periods when you had contact with mice, which of the following best describes 
how often you performed surgery (including dissection) on mice? 
Every day (1)    At least once a week but not every day (2) 
At least once a month but not every week (3) Less than once a month (4) 
I did not perform surgery (or dissection) on mice (5) 
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If I do not anaesthetise mice Is Selected, Then Skip to End of Block 
Q48 In the past 12 months, on the days you performed surgery (including dissection) on mice, how much time did you 
spend on a typical day doing this? 
______ Hrs (1) ______ Mins (2) 
Q49 In the past 12 months, on the days when you performed surgery (including dissection) on mice, how many mice did 
you perform surgery on, on a typical day? 
1-10 (1)  11-20 (2)  21-50 (3)  51-100 (4) more than 100 (5) 
 
Q50 In the past 12 months, what personal protective equipment did you use when you performed surgery (including 
dissection) on mice? 
 
 Never (1) Rarely (2) Sometimes (3) Most of the Time (4) Always (5) 
None (1)      
Gloves (2)      
Overshoes or special shoes (3)      
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
Hair net or mob cap (9)      
 
Q51 In the past 12 months, when you performed surgery (including dissection) on mice, did you do this on an open bench 
or under a hood? 
Open bench only (1) Under a hood only (2) A mixture of open bench and under a hood (3) 
Q52 In the past 12 months, are the mice on whom you performed surgery (including dissection) housed in IVCs or open 
cages?    
IVC only (1) Open cages only (2)  A mixture of IVCs and open cages (3) 
 
Q53 TASK 6: BEHAVIOURAL TESTING 
Q54 In the past 12 months, during those periods when you had contact with mice, which of the following best describes 
how often you carried out behavioural testing on mice? 
Every day (1)    At least once a week but not every day (2) 
At least once a month but not every week (3) Less than once a month (4) 
I did not do behavioural work on mice (5) 
If I do not cull mice Is Selected, Then Skip to End of Block 
Q55 In the past 12 months, on the days you carried out behavioural testing on mice, how much time did you spend doing 
this on a typical day? 
______ Hrs (1)  ______ Mins (2) 
 
Q56 In the past 12 months, on the days when you did behavioural testing on mice, how many mice did you do this to on a 
typical day? 
1-10 (1)  11-20 (2)  21-50 (3)  51-100 (4) more than 100 (5) 
Q57 In the past 12 months, what personal protective equipment did you use when you did behavioural testing on mice? 
 Never (1) Rarely (2) Sometimes (3) Most of the Time (4) Always (5) 
None (1)      
Gloves (2)      
Overshoes or special shoes (3)      
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
Hair net or mob cap (9)      
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Q58 In the past 12 months, when you did behavioural testing on mice, did you do this on an open bench or under a hood? 
Open bench only (1) Under a hood only (2) A mixture of open bench and under a hood (3) 
Q59 In the past 12 months, are the mice on whom you did behavioural testing housed in IVCs or open cages or a mixture? 
IVC only (1)  Open cages only (2) A mixture of IVCs and open cages (3) 
Q60 TASK 7: CULLING MICE. 
Q61 In the past 12 months, during those periods when you had contact with mice, which of the following best describes 
how often you culled mice? 
Every day (1)    At least once a week but not every day (2) 
At least once a month but not every week (3) Less than once a month (4) 
I did not cull mice (5) 
If I do not cull mice Is Selected, Then Skip to End of Block 
Q62 In the past 12 months, on the days you culled mice, how much time did you spend doing this on a typical day? 
______ Hrs (1) ______ Mins (2) 
Q63 In the past 12 months, on the days when you did cull mice, how many mice did you cull on a typical day? 
1-10 (1)  11-20 (2)  21-50 (3)  51-100 (4) more than 100 (5) 
Q64 In the past 12 months, what personal protective equipment did you use when you culled mice? 
 Never (1) Rarely (2) Sometimes (3) Most of the Time (4) Always (5) 
None (1)      
Gloves (2)      
Overshoes or special shoes (3)      
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
Hair net or mob cap (9)      
 
Q65 In the past 12 months, when you culled mice, did you do this on an open bench or under a hood? 
Open bench only (1) Under a hood only (2) A mixture of open bench and under a hood (3) 
Q66 In the past 12 months, are the mice whom you culled housed in IVCs or open cages or a mixture? 
IVC only (1) Open cages only (2) A mixture of IVCs and open cages (3) 
Q67 TASK 8: CHANGING MICE CAGES 
Q68 In the past 12 months, during those periods when you had contact with mice, which of the following best describes 
how often you changed mouse cages (transferred mice from dirty to clean cage)? 
Every day (1)    At least once a week but not every day (2) 
Approximately two to three times a month (6) At least once a month but not every week (3) 
Less than once a month (4)   I didn't change mouse cages (5) 
If I don't change mouse cages Is Selected, Then Skip to End of Block 
Q69 In the past 12 months, on the days you spent transferring mice from dirty to clean cages, how much time did you 
spend doing this on a typical day? 
______ Hrs (1) ______ Mins (2) 
Q70 In the past 12 months, on the days you spent changing mouse cages (transferring mice from dirty to clean cage), how 
many cages did you change on a typical day?             
1-10 (1)  11-20 (2)  21-50 (3)  51-100 (4) more than 100 (5) 
Q71 In the past 12 months, what personal protective equipment did you use when you changed mouse cages (transferred 
mice from dirty to clean cage)?    
 Never (1) Rarely (2) Sometimes (3) Most of the Time (4) Always (5) 
None (1)      
Gloves (2)      
Overshoes or special shoes (3)      
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
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Hair net or mob cap (9)      
 
Q72 In the past 12 months, when you changed mice (transferred from dirty to clean cage), did you do this on an open 
bench or under a hood?   
Open bench only (1) Under a hood only (2) A mixture of open bench and under a hood (3) 
Q73 In the past 12 months, are the mice whose cages you changed (transferred mice from dirty to clean cage) housed in 
IVCs or open cages or a mixture?   
IVC only (1) Open cages only (2) A mixture of IVCs and open cages (3) 
 
Q74 WE REALISE THESE ARE BORING TO ANSWER BUT THE LIST OF TASKS IS NEARLY DONE! TASK 9: REMOVING DIRTY 
BEDDING FROM CAGES 
Q75 In the past 12 months, during those periods when you had contact with mice, which of the following best describes 
how often you removed dirty bedding (in preparation for cage wash) from mouse cages? 
Every day (1)    At least once a week but not every day (2) 
Approximately two to three times a month (6) At least once a month but not every week (3) 
Less than once a month (4)   I didn’t remove dirty bedding from mouse cages (5) 
If I don’t remove dirty bedding... Is Selected, Then Skip to End of Block 
Q76 In the past 12 months, on the days you spent removing dirty bedding from mouse cages, how much time on a typical 
day did you spend doing this?                                         
______ Hrs (1) ______ Mins (2) 
 
Q77 In the past 12 months, on the days you spent removing dirty bedding from mouse cages, how many cages did you do 
this to on a typical day?               
1-10 (1)  11-20 (2)  21-50 (3)  51-100 (4) more than 100 (5) 
Q78 In the past 12 months, what personal protective equipment did you use when you remove dirty bedding from mouse 
cages? 
 Never (1) Rarely (2) Sometimes (3) Most of the Time (4) Always (5) 
None (1)      
Gloves (2)      
Overshoes or special shoes (3)      
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
Hair net or mob cap (9)      
 
Q79 In the past 12 months, when you removed dirty bedding from mouse cages (before cage wash), did you do this on an 
open bench or under a hood? 
Open bench only (1) Under a hood only (2) A mixture of open bench and under a hood (3) 
Q80 In the past 12 months, did you remove dirty bedding from IVCs or open cages? 
IVC only (1) Open cages only (2) A mixture of IVCs and open cages (3) 
 
Q156 TASK 10: CAGE WASH 
Q157 In the past 12 months, during those periods when you had contact with mice, which of the following best describes 
how often you washed mouse cages? 
Every day (1)    At least once a week but not every day (2) 
Approximately two to three times a month (6) At least once a month but not every week (3) 
I didn’t wash mouse cages (5) If I didn’t wash mouse cages Is Selected, Then Skip to End of Block 
Q158 In the past 12 months, on the days you spent washing mouse cages, how much time on a typical day did you spend 
doing this?                                         
______ Hrs (1)  ______ Mins (2) 
Q159 In the past 12 months, on the days you spent washing mouse cages, how many cages did you wash on a typical 
day?               
1-10 (1)  11-20 (2)  21-50 (3)  51-100 (4) more than 100 (5) 
Q160 In the past 12 months, what personal protective equipment did you use when you washed mouse cages? 
 Never (1) Rarely (2) Sometimes (3) Most of the Time (4) Always (5) 
None (1)      
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Gloves (2)      
Overshoes or special shoes (3)      
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
Hair net or mob cap (9)      
 
Q162 In the past 12 months, did you wash mouse cages which were IVCs or open cages? 
IVC only (1) Open cages only (2) A mixture of IVCs and open cages (3) 
 
Q81 TASK 11: ENTERING ROOMS WHERE MICE HOUSED WITHOUT HANDLING THEM 
 
Q82 In the last 12 months: during those periods when you had contact with mice, which of the following best describes 
how often you went into rooms where mice are housed or handled (but did not handle them yourself)  e.g. for 
observational work, to check them, to clean the rooms or replenish stocks 
Every day (1)    At least once a week but not every day (2) 
Approximately two to three times a month (6) At least once a month but not every week (3) 
I didn't go into rooms where others handle mice (5) 
If I don't go into rooms where... Is Selected, Then Skip to End of Block 
Q83 In the past 12 months, on the days when you went into rooms where mice are housed or handled (but did not handle 
them yourself), how much time on a typical day did you spend there? e.g. For observational work, to check them, to clean 
the rooms or replenish stocks 
______ Hrs (1)  ______ Mins (2) 
Q84 In the past 12 months, what personal protective equipment did you use when you go into rooms where mice are 
housed or handled (when you were not handling them yourself)? e.g. For observational work, to check them, to clean the 
rooms or replenish stocks 
 Never (1) Rarely (2) Sometimes (3) Most of the Time (4) Always (5) 
None (1)      
Gloves (2)      
Overshoes or special shoes (3)      
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
Hair net or mob cap (9)      
 
Q85 In the past 12 months, are the mice in the rooms which you go into (when you don't touch them yourself) housed in 
IVCs or open cages? e.g. For observational work, to check them, to clean the rooms or replenish stocks 
IVC only (1) Open cages only (2) A mixture of IVCs and open cages (3) 
I don't know (88) 
Q86 In your current post do you handle pups or adult mice?                        
Pups only (1) Adult mice only (2)  Both pups and adult mice (3)  I don't handle mice (4) 
Q87 In your current post do you handle female mice or male mice?    
Female mice only (1) Male mice only (2)  Both female and male mice (3) I don't handle mice (4) 
Q88 THESE ARE THE LAST FEW QUESTIONS ABOUT YOUR WORK IN THE LAST 12 MONTHS  
Q89 Over the last 12 months, what is the greatest amount of time in any one week you have spent in the animal facilities?   
1-10 hours (1) 11-20 hours (2) 21-30 hours (3) 31-40 hours (4) 41-50 hours (5) more than 50 hours (6) 
Q90 Over the last 12 months, what is the greatest amount of time in any one week you have handled (touched) mice? 
(including, for example, doing procedures on them) 
1-10 hours (1) 11-20 hours (2) 21-30 hours (3) 31-40 hours (4) 41-50 hours (5) more than 50 hours (6) 
I did not handle(touch) mice (7) 
Q91 Over the last 12 months, what is the maximum number of mice you have handled in any one week?    If you handle 
the same mice on several occasions, count these separately e.g. 10 mice on 6 occasions each would be 60 
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1-10 (1)  11-50 (2)  51-100 (3) More than 100 (4)  I did not handle mice (5) 
Q92 Do you currently spend time in designated laboratories (rooms where mice are kept or handled outside the main 
animal facilities)?    
Yes (1)  No (2) 
Q93 Which best describes the proportion of time in your current post you spend in the designated labs     
I spend more time in designated labs than in the main animal facilities (1) 
I spend more time in the main animal facilities than in the designated labs (2) 
I spend equal amounts of time in designated labs and the main animal facilities (3) 
Q94 Which type of personal protective equipment do you use (typically) when you work (go into) in the designated labs?    
 Never (1) Rarely (2) Sometimes (3) Most of the Time (4) Always (5) 
None (1)      
Gloves (2)      
Overshoes or special shoes (3)      
Lab coat/overall (4)      
Scrubs (5)      
Face mask (6)      
Powered helmet (7)      
Safety glasses or visor (8)      
Hair net or mob cap (9)      
 
Q95 THE NEXT SET OF QUESTIONS RELATE TO ANY PREVIOUS POSTS YOU HAVE HAD WHERE YOU HAVE WORKED WITH 
MICE.    
This is my first post working with mice (1) I have had previous posts (2) 
Q96 When did you first work with mice or in animal facilities containing mice?     Do not count the occasional week or two 
in your training or studies   (mm/yyyy) 
Q97 Which type of personal protective equipment did you use in your first post when you worked with mice, mouse tissue 





























Going into animal 
facilities (1) 
          






          
Changing cages 
(move mice from 
dirty to clean 
cage) (4) 
          
Cleaning cages 
(tip sawdust out 
of dirty cage) (5) 
          




          
 
 
Q98 Which species have you worked with in previous posts?  Tick as many as applicable 
Mice (1)  Rats (2)  I have not worked with mice or rats in the past (4) 




At least once a week but 
not every day (2) 
At least once a month but 
not every week (3) 





Gone into an animal facilities 
containing mice? (2) 
     
Handled mice? (3)      
Removed dirty bedding from 
cages? (4) 
     
 
 
Q100 Which types of animal facilities have you worked in during previous posts?    
IVC only facilities (1) Open cage only facilities (2)  Both IVC and open cage facilities (3) 
I have not worked in animal facilities in the past (4) 
Q101  In your previous posts, what is the highest number of mice you have ever handled in one day?    
1-10 (1)  11-50 (2)  51-100 (3) More than 100 (4) I did not handle mice in past posts (5) 
 
Q102 THE NEXT SET OF QUESTIONS ARE ALL ABOUT YOUR HEALTH    As with the rest of the questionnaire, the results are 
entirely CONFIDENTIAL and they will not be shared with your employer or occupational health department unless you 
choose to do so.   Please answer them as accurately and honestly as you can.     
 
Q103 Have you had asthma in the last 12 months? 
Yes (1)  No (2) 
Q104 Did you have asthma as a child?                
Yes (1)  No (2) 
Q105 Have you had hay fever in the last 12 months?           
Yes (1)  No (2) 
Q106 Did you have hay fever as a child? 
Yes (1)  No (2) 
Q107 Have you ever lived in a home where any of the following animals were kept as pets? tick as many as apply  
Cat (1) Dog (2) Mouse (3) Rat (4) Gerbil (5) Hamster (6) Guinea pig (7) Rabbit (8) 
None of the above (9) 
Q108 Did you or do you ever have itchy eyes, sneezing, wheezing or chest tightness when you were near these pet 
animals?    
Yes (1)  No (2) 
Q109 Which pet animals caused these symptoms? tick as many as apply  
Cat (1) Dog (2) Mouse (3) Rat (4) Gerbil (5) Hamster (6) Guinea pig (7) Rabbit (8) 
None of the above (9) I don't know (10) 
Q110 Since starting work with laboratory animals have you had a blocked, itchy or runny nose or sneezing? (do not count 
colds or flu)     
Yes (1)  No (2) 
Q111  What year did you first notice these symptoms? (yyyy) 
Q112 What happens to these symptoms on weekends or holidays of one week or longer? 
Get better (1) Get worse (2) No change (3) 
Q113 Do you get these symptoms on contact with something at work?    
Yes (1)  No (2) 
Q114 If you get a blocked, itchy or runny nose or sneezing on contact with something at work, then in your opinion, what 
causes these symptoms?    
Q115  Since starting work with laboratory animals have you had itchy or runny eyes?    
Yes (1)  No (2) 
Q116 What year did you first notice these symptoms?  (yyyy) 
Q117 What happens to these symptoms on weekends or holidays of one week or longer?    
Get better (1) Get worse (2) No change (3) 
Q118 Do you get these symptoms on contact with something at work?    
Yes (1)  No (2) 
Q119 If you get itchy or runny eyes on contact with something at work, then, in your opinion, what causes these 
symptoms? 
Q120  Since starting work with laboratory animals have you had tightness in the chest, or difficulty in breathing or 
wheezing or whistling in the chest?    
Yes (1)  No (2) 
Q121  What year did you first notice these symptoms? (yyyy) 
Q122 What happens to these symptoms on weekends or holidays of one week or longer? 
Get better (1) Get worse (2) No change (3) 
Q123 Do you get these symptoms on contact with something at work?    
Yes (1)  No (2) 
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Q124 If you get tightness in the chest, or difficulty in breathing or wheezing or whistling in the chest more on contact with 
something at work, then, in your opinion, what causes these symptoms?    
Q125 Have you ever been scratched or bitten by a mouse? 
Yes (1)  No (2) 
Q126 Have you ever had a swollen itchy rash (like a nettle sting) around the site of the scratch or bite? 
Yes (1)  No (2) 
Q127 Has any health care professional ever told you that you are allergic to mice? 
Yes (1)  No (2) 
Q128  What year did you first notice these symptoms? (yyyy) 
Q129 Has any health care professional ever told you that you are allergic to any other laboratory animals? 
Yes (1)  No (2) 
Q130 Which ones? tick all that apply 
Rats (1)  Guinea pigs (2)  Rabbits (3) Other (4) 
Q131 What year did you first notice these symptoms? (yyyy) 
Q132 Have you had a mask fit test at work? 
Yes (1)  No (2) 
Q133 THIS IS THE LAST SET OF QUESTIONS AND ARE A FEW GENERAL QUESTIONS ABOUT YOU 
 
Q134 How many older siblings do you have? Don’t count half-siblings or step-siblings and count a twin as a younger sibling  
0 (1) 1 (2) 2 (3) 3 (4) 4 (5) 5 (6) more than 5 (7) 
Q135 How many younger siblings do you have? don’t count half-siblings or step-siblings and count a twin as a younger 
sibling        
0 (1) 1 (2) 2 (3) 3 (4) 4 (5) 5 (6) 6 (7) 7 (8) more than 7 (9) 
Q136 Do you live with any children?  
Yes (1)  No (2) 
Q137  Do you smoke cigarettes?    
Never (1)  I used to smoke (2)  I currently smoke (3) 
Q138 What year did you start smoking? (yyyy) 
Q139 What year did you stop smoking? (yyyy) 
Q140 On average, how many cigarettes a day did you used to smoke? 
Q141 On average, how many cigarettes a day do you smoke? 
Q142 Which country were you born in? 
Q143 Please choose one option that best describes your ethnic group or background? 
White (12) Mixed / multiple ethnic groups (17)  Asian / Asian British (22) 
 Black / African / Caribbean / Black British (28)  Other ethnic group (32) 
I do not wish to disclose this information (35) 
 
Q144 You have now completed the questionnaire. Thank you for taking time to participate in this study, your help is very 


























2. SPIRAL consent form 
 
 
Individually ventilated cages in laboratory animal facilities and the prevention of laboratory animal allergy: a 
proof-of-concept study. 
(SPIRAL Study: (Safe Practice In Reducing Allergy in Laboratories) 
              
 
I have read and understood the Information document (version 3, 26/08/15) and the separate ‘Genetics Information’ 
(version 1.1 18/06/14). I have had the time to consider the information and ask questions and I am happy to take part.  
 
I understand that my participation is voluntary and I am free to withdraw at any time without giving a reason. 
 
I agree to undergo the following procedures: 
 
Questionnaire 
Skin prick test 
Blood sample 
Spirometry 




I understand that my samples are being given as a ‘gift’ and some may be  
stored and used for future research into laboratory allergy.  














SPIRAL study: version 3, 26/8/15 




Name of volunteer (PRINT) Signature Date 
Name of Investigator   (PRINT) Signature Date 








List of abbreviations 
ATS – American Thoracic Society 
BTS – British Thoracic Society 
CMF – Cast Metals Federation 
CAS – Current asthma symptoms 
CASCOT - Computer Assisted Structured Coding 
Tool 
COIN - Corporate Operational Information System  
COPD – Chronic obstructive pulmonary disease 
COSHH – Control of Substances Hazardous to 
Health 
CWH – Centre for Workplace Health 
ECRHS – European Community Respiratory Health 
Survey 
ERS – European Respiratory Society 
FENO – Fractional exhaled nitric oxide 
FEV1 – Forced expiratory volume in 1 second 
FVC – Forced vital capacity 
HMW – High molecular weight 
HSE – Health and Safety Executive 
IgE – Immunoglobulin E 
LAA – Laboratory animal allergy 
LEV – Local exhaust ventilation 
LMW – Low molecular weight 





MRC – Medical Research Council 
NSBHR – Non-specific bronchial 
hyperresponsiveness 
OA – Occupational asthma 
PEF – Peak expiratory flow 
PPE – Personal protective equipment 
RPE – Respiratory protective equipment 
SIC -Specific Inhalation Challenge 
SIgE – Specific immunoglobulin E 
SIGN – Scottish Intercollegiate Guidelines Network 
SOC - Standard Occupational Classification 
SPIRAL – Safe Practice in Reducing Allergy in 
Laboratories 
SRP – Strategic Research Programme 
SWORD – Surveillance of Workplace Occupational 
Respiratory Diseases 
TWA – Time-weighted average 
WEL – Workplace exposure limit 
WRC – Western red cedar 
WRNS – Work-related nasal symptoms 
WROS – Work-related ocular symptoms 
WRRS – Work-related respiratory symptoms 
WRS – Work-related symptoms
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